

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/013636 A2

(51) International Patent Classification⁷: **G01N 33/68**

(21) International Application Number:
PCT/IB2003/003863

(22) International Filing Date: 28 July 2003 (28.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/212,628 1 August 2002 (01.08.2002) US

(71) Applicant: **SYNGENTA PARTICIPATIONS AG**
[CH/CH]; Scharzwaldallee 215, CH-4058 Basel (CH).

(72) Inventors: **HAYNES, Paul**; 902 Birchview Drive, Encinitas, CA 92024 (US). **WEI, Jing**; 8537 Donaker St., San Diego, CA 92129 (CN). **YATES, John**; 5049 Seashell Place, San Diego, CA 92130 (US). **ANDON, Nancy**; 1543 Kings Cross Drive, Cardiff-By-The-Sea, CA 92007 (US).

(74) Agent: **E. BLUM & CO.**; Vorderberg 11, CH-8044 Zürich (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIFFERENTIAL LABELING FOR QUANTITATIVE ANALYSIS OF COMPLEX PROTEIN MIXTURES

(57) Abstract: The present invention relates to a method of simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, a method for proteomic analysis, a process for preparing fusion proteins, and compounds and reagents related thereto.

WO 2004/013636 A2

DIFFERENTIAL LABELING FOR QUANTITATIVE ANALYSIS OF COMPLEX PROTEIN MIXTURES

Background of the Invention

Genomic technology has advanced to a point at which, in principle,
5 become possible to determine complete genomic sequences and to quantita
measure the mRNA levels for each gene expressed in a cell. For some speci
complete genomic sequence has now been determined, and for one strain
yeast *Saccharomyces cerevisiae*, the mRNA levels for each expressed gene
been precisely quantified under different growth conditions (Velculescu *et al*
10 88:243-251 (1997)). Comparative cDNA array analysis and related technic
have been used to determine induced changes in gene expression at the mRNA/
by concurrently monitoring the expression level of a large number of genes (in
cases all the genes) expressed by the investigated cell or tissue (Shalon
Genome Res 6:639-645 (1996)). Furthermore, biological and comput
15 techniques have been used to correlate specific function with gene sequences
interpretation of the data obtained by these techniques in the context of the str
control and mechanism of biological systems has been recognized as a consid
challenge. In particular, it has been extremely difficult to explain the mechan
biological processes by genomic analysis alone.

20 Proteins are essential for the control and execution of virtually
biological process. The rate of synthesis and the half-life of proteins and the
expression level are also controlled post-transcriptionally. Furthermore, the a
of proteins is frequently modulated by post-translational modifications, in par
protein phosphorylation, and dependent on the association of the protein with
25 molecules including DNA and proteins. Neither the level of expression nor th
of activity of proteins is therefore directly apparent from the gene sequence c
the expression level of the corresponding mRNA transcript. It is therefore es
that a complete description of a biological system include measuremen
indicate the identity, quantity and the state of activity of the proteins
30 constitute the system. The large-scale (ultimately global) analysis of p
expressed in a cell or tissue has been termed proteome analysis (Pennington
Trends Cell Bio 7:168-173 (1997)).

At present no protein analytical technology approaches the throughput and level of automation of genomic technology. The most common implementation of proteome analysis is based on the separation of complex protein samples most commonly by two-dimensional gel electrophoresis (2DE) and the subsequent sequential identification of the separated protein species (Ducret *et al.*, *Prot Sci* 7:706-719 (1998); Garrels *et al.*, *Electrophoresis* 18:1347-1360 (1997); Link *et al.*, *Electrophoresis* 18:1314-1334 (1997); Shevchenko *et al.*, *Proc Natl Acad Sci USA* 93:14440-14445 (1996); Gygi *et al.*, *Electrophoresis* 20:310-319 (1999); Boucherie *et al.*, *Electrophoresis* 17:1683-1699 (1996)). This approach has been assisted by the development of powerful mass spectrometric techniques and the development of computer algorithms which correlate protein and peptide mass spectral data with sequence databases and thus rapidly identify proteins (Eng *et al.*, *J Am Soc Mass Spectrom* 5:976-980 (1994); Mann and Wilm, *Anal Chem* 66:4390-4399 (1994); Yates *et al.*, *Anal Chem* 67:1426-1436 (1995)). This technology (two-dimensional mass spectrometry) has reached a level of sensitivity which now permits the identification of essentially any protein which is detectable by conventional protein staining methods including silver staining (Figeys and Aebersold, *Electrophoresis* 19:885-892 (1998); Figeys *et al.*, *Nature Biotech* 14:1579-1583 (1996); Figeys *et al.*, *Anal Chem* 69:3153-3160 (1997); Shevchenko *et al.*, *Anal Chem* 68:850-858 (1996)). However, the sequential manner in which samples are processed limits the sample throughput, the most sensitive methods have been difficult to automate and low abundance proteins, such as regulatory proteins, escape detection without prior enrichment, thus effectively limiting the dynamic range of the technique. In the 2DE/(MS)ⁿ method, proteins are quantified by densitometry of stained spots in the 2DE gels.

The development of methods and instrumentation for automated, data-dependent electrospray ionization (ESI) tandem mass spectrometry (MS)ⁿ in conjunction with microcapillary liquid chromatography (μ LC) and database searching has significantly increased the sensitivity and speed of the identification of gel-separated proteins. As an alternative to the 2DE/(MS)ⁿ approach to proteome analysis, the direct analysis by tandem mass spectrometry of peptide mixtures generated by the digestion of complex protein mixtures has been proposed (Dongre *et al.*, *Trends Biotechnol* 15:418-425 (1997)). μ LC-MS/MS has also been used

successfully for the large-scale identification of individual proteins directly from mixtures without gel electrophoretic separation (Link *et al.*, *Nat Biotech*, 17:676-682 (1999); Opitek *et al.*, *Anal Chem* 69:1518-1524 (1997)). While these approaches accelerate protein identification, the quantities of the analyzed proteins cannot be easily determined, and these methods have not been shown to substantially alleviate the dynamic range problem also encountered by the 2DE/(MS)ⁿ approach. Therefore, low abundance proteins in complex samples are also difficult to analyze by the μ LC/MS/MS method without their prior enrichment.

It is therefore apparent that current technologies, while suitable to identify a portion of the components of protein mixtures, are neither capable of measuring the quantity nor the state of activity of the protein in a mixture. Even improvements of the current approaches are unlikely to advance their performance sufficiently to make routine quantitative and functional proteome analysis a reality.

This invention provides methods and reagents that can be employed in proteome analysis which overcome the limitations inherent in traditional techniques. The basic approach described can be employed for the quantitative analysis of protein expression in complex samples (such as cells, tissues, and fractions thereof), the detection and quantitation of specific proteins in complex samples, and the quantitative measurement of specific enzymatic activities in complex samples.

In this regard, a multitude of analytical techniques are presently available for clinical and diagnostic assays which detect the presence, absence, deficiency or excess of a protein or protein function associable with a normal or disease state. While these techniques are quite sensitive, they do not necessarily provide chemical separation of products and may, as a result, be difficult to use for assaying several proteins or enzymes simultaneously in a single sample. Current methods may not distinguish among aberrant expression of different enzymes or their malfunctions, which lead to a common set of clinical symptoms. The methods and reagents herein can be employed in clinical and diagnostic assays for simultaneously (multiplex) monitoring of multiple proteins and protein reactions.

Complex mixtures of proteins give rise to even more complex mixtures of peptides after proteolytic digestion. One way to reduce this complexity is to label a particular amino acid and then enrich for only those peptides containing the labeled amino acid. One good example of a selective peptide label is the use of

iodoacetamido functional groups to specifically react with cysteine residues. Approximately 85-90% of all proteins contain at least one cysteine residue, which makes the labeling method applicable to almost all proteins present in a complex mixture. We have designed trifunctional synthetic peptide based reagents that can be used for reducing the complexity of peptide mixtures by labeling peptides with iodoacetamido groups and then selectively enriching only those peptides containing labeled cysteine residues.

Summary of the Invention

In the first aspect, the invention provides a compound of Formula I

(I) Immobilization Site-Cleavage Site-Link where:

Immobilization Site is selected from the group consisting of an epitope tag, a linker to a solid surface, a metal chelating site, and a magnetic site, or a combination thereof;

Cleavage Site is selected from the group consisting of a protease cleavage site, a photocleavable linker, a restriction enzyme cleavage site, a chemical cleavage site, and a thermal cleavage site, or a combination thereof;

Link is selected from the group consisting of an amino acid reactive site and a mass variance site, or a combination thereof.

In another aspect, the invention provides a compound of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula -(CH₂)_B-C(O)-NR-, an amide bond of formula -(CH₂)_B-NR-C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-\text{CH}_2-$ group;

Link is selected from the group consisting of $-(\text{CH}_2)_C-\text{I}$, $-(\text{CH}_2)_D-\text{CH}-(\text{CH}_2)_E\text{CH}_3$, $-(\text{CH}_2)_F-\text{X}-\text{I}$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme.

In another aspect, the invention provides for a method for simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, comprising:

a) preparing a first protein sample or a first peptide sample from the normal cells;

b) reacting the first protein sample or the first peptide sample with a reagent of Formula II or III:

(II) $\text{Acyl-NH-X-[Epitope Tag Site]}_A\text{-Y-[Protease Cleavage Site]-Z-Link}$

(III) $\text{Acyl-NH-X-alk-O-Ph-CH}_2\text{-Z-Link}$

where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-\text{C(O)}-\text{NR}-$, a carbonyl of formula $-\text{C(O)}-$, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-\text{C(O)}-\text{NR}-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(\text{CH}_2)_B-\text{C(O)}-\text{NR}-$, an amide bond of formula $-(\text{CH}_2)_B-\text{NR}-\text{C(O)}-$, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of -(CH₂)_C-I, -(CH₂)_D-CH(-(CH₂)_ECH₃)-(CH₂)_F-X-I, Lys-ε-iodoacetamide, Arg-δ-iodoacetamide, and Orn-δ-iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme;

c) preparing a second protein sample or a second peptide sample from the perturbed cells;

d) reacting the second protein sample or the second peptide sample of step c) with a second reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link

where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula -(CH₂)_B-C(O)-NR-, an amide bond of formula -(CH₂)_B-NR-C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-\text{CH}_2-$ group;

Link is selected from the group consisting of $-(\text{CH}_2)_C-\text{I}$, $-(\text{CH}_2)_D-\text{CH}(-(\text{CH}_2)_E\text{CH}_3)-(\text{CH}_2)_F-\text{X}-\text{I}$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme,

such that the molecular weight of the first reagent and the molecular weight of the second reagent are different by an integer multiple of 14 atomic mass units;

e) combining the reacted the first and the second protein samples or the reacted the first and the second peptide sample from steps b) and d);

f) subjecting the combined protein samples or the combined peptide samples from step e) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

g) subjecting the proteolyzed combined protein samples or the proteolyzed peptide samples from step f) to an affinity chromatography system comprising a second amino acid sequence attached to a solid, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

h) eluting the non-bound proteins from the affinity chromatography system;

i) subjecting the affinity chromatography system from step h) to a protease specific for the Protease Cleavage Site, thereby forming a cleaved protein mixture;

j) eluting the cleaved protein mixture from the affinity chromatography system of step i);

- k) isolating the eluted protein mixture obtained from step j);
- l) subjecting the eluted protein mixture from step k) to chromatographic separation, followed by mass analysis;
- m) comparing the results of step l) to:
 - (1) determining the ratio of amounts of compounds in the two samples, where the molecular weights thereof are separated by an integer multiple of 14 atomic mass units; and
 - (2) comparing the results obtained for each compound to protein databases containing chromatographic and molecular weight correlations.

In another aspect, the invention provides for a method for simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, comprising:

- a) preparing a first protein sample or a first peptide sample from the normal cells;
- b) subjecting the first protein sample or the first peptide sample from step a) to proteolysis;
- c) reacting the proteolyzed first protein sample or the proteolyzed first peptide sample with a reagent of Formula II or III:

(II) $\text{Acyl-NH-X-[Epitope Tag Site]}_A\text{-Y-[Protease Cleavage Site]-Z-Link}$

(III) $\text{Acyl-NH-X-alk-O-Ph-CH}_2\text{-Z-Link}$

where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-\text{C(O)-NR-}$, a carbonyl of formula $-\text{C(O)-}$, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-\text{C(O)-NR-}$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(\text{CH}_2)_B\text{-C(O)-NR-}$, an amide bond of formula $-(\text{CH}_2)_B\text{-NR-C(O)-}$, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-\text{CH}_2-$ group;

Link is selected from the group consisting of $-(\text{CH}_2)_C-\text{I}$, $-(\text{CH}_2)_D-\text{CH}(-(\text{CH}_2)_E\text{CH}_3)-(\text{CH}_2)_F-\text{X}-\text{I}$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme;

d) preparing a second protein sample or a second peptide sample from the perturbed cells;

e) subjecting the second protein sample or the second peptide sample from step d) to proteolysis;

f) reacting the proteolyzed second protein sample or the proteolyzed second peptide sample of step e) with a second reagent of Formula II or III:

(II) $\text{Acyl-NH-X-[Epitope Tag Site]}_A\text{-Y-[Protease Cleavage Site]-Z-Link}$

(III) $\text{Acyl-NH-X-alk-O-Ph-CH}_2\text{-Z-Link}$

where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-\text{C(O)-NR-}$, a carbonyl of formula $-\text{C(O)-}$, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-\text{C(O)-NR-}$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(\text{CH}_2)_B-\text{C(O)-NR-}$, an amide bond of formula $-(\text{CH}_2)_B\text{-NR-C(O)-}$, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of -(CH₂)_C-I, -(CH₂)_D-CH(-(CH₂)_ECH₃)-(CH₂)_F-X-I, Lys-ε-iodoacetamide, Arg-δ-iodoacetamide, and Orn-δ-iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme,

such that the molecular weight of the first reagent and the molecular weight of the second reagent are different by an integer multiple of 14 atomic mass units;

g) combining the reacted the first and the second protein samples or the reacted the first and the second peptide sample from steps c) and f);

h) subjecting the combined protein samples or the combined peptide samples from step e) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

i) subjecting the proteolyzed combined protein samples or the proteolyzed peptide samples from step f) to an affinity chromatography system comprising a second amino acid sequence attached to a solid, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

j) eluting the non-bound proteins from the affinity chromatography system;

k) subjecting the affinity chromatography system from step j) to a protease specific for the Protease Cleavage Site, thereby forming a cleaved protein mixture;

l) eluting the cleaved protein mixture from the affinity chromatography system of step k);

- m) isolating the eluted protein mixture obtained from step l);
- n) subjecting the eluted protein mixture from step m) to chromatographic separation, followed by mass analysis;
- o) comparing the results of step n) to:
 - (1) determining the ratio of amounts of compounds in the two samples, where the molecular weights thereof are separated by an integer multiple of 14 atomic mass units; and
 - (2) comparing the results obtained for each compound to protein databases containing chromatographic and molecular weight correlations.

[0014] Another aspect of the present invention relates to a method for proteomic analysis, comprising:

- a) preparing a protein sample or a peptide sample from cells;
- b) reacting the protein sample or the peptide sample with a reagent of the formula:

Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Link where:

A is an integer from 1 to 12;

X is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or X is an amino acid sequence comprising between 0 to 50 amino acids;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Z is an amino acid sequence comprising between 0 to 10 amino acids;

Link is selected from the group consisting of Lys-ε-iodoacetamide, Arg-δ-iodoacetamide, and Orn-δ-iodoacetamide;

Epitope Tag Site is a sequence of amino acids, and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme;

- c) subjecting the reacted proteins or peptides from step b) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;
- d) subjecting the proteolyzed reacted proteins or the proteolyzed reacted peptides from step c) to an affinity chromatography system comprising a second

amino acid sequence attached to a solid support, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

e) eluting the non-bound proteins from the affinity chromatography system;

f) subjecting the affinity chromatography system from step e) to a protease specific for the Protease Cleavage Site, thereby forming a cleaved protein mixture;

g) eluting the cleaved protein mixture from the affinity chromatography system of step f);

h) isolating the cleaved protein mixture obtained from step g);

i) subjecting the cleaved protein mixture from step h) to chromatographic separation, followed by mass analysis;

j) comparing the results of step i) to:

(1) determine the ratio of amounts of compounds in the sample separated by a molecular weight of 14 atomic mass units; and

(2) identify the various modified proteins by comparing the results obtained for each modified protein to protein databases containing chromatographic and molecular weight correlations.

Yet another aspect of the invention relates to a process for preparing a fusion protein of the formula:

Protein-Acyl-N-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-[Lys- δ -N-iodoacetamide] comprising,

a) preparing a fusion protein sample from cells having the formula Protein-Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Lys- δ -NHCOCH₂;

b) reacting the protein sample with an iodoacetamide,

where:

A is an integer from 1 to 12;

X is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or X is an amino acid sequence comprising between 0 to 50 amino acids;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Z is an amino acid sequence comprising between 0 to 10 amino acids;

Epitope Tag Site is a sequence of amino acids, and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme.

In another aspect, the invention relates to a process for preparing a fusion protein of the formula:

Protein-Acyl-N-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-[Orn- δ -N-iodoacetamide] comprising,

a) preparing a fusion protein sample from cells having the formula Protein-Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Orn- δ -NHCOCH₂;

b) reacting the protein sample with an iodoacetamide, where:

A is an integer from 1 to 12;

X is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or X is an amino acid sequence comprising between 0 to 50 amino acids;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Z is an amino acid sequence comprising between 0 to 10 amino acids;

Epitope Tag Site is a sequence of amino acids, and

Protease Cleavage Site is a sequence of amino acids that is a highly specific cleavage site for a protease enzyme.

Brief Description of the Drawings

Figure 1 is a chart showing the FPLC spectrum from the purification the synthesized PEPTag.

Figure 2a is a printout showing the mass spectrum of the synthesized PEPTag.

Figure 2b is a printout showing the mass spectrum from MS/MS experiment to sequence PEPTag.

Figures 3a,b show printouts of the MALDI MS analysis of PEPTag captured BSA peptides. Figure 3a is a printout wherein peaks are cysteinyl tryptic peptides from tagged BSA, which are captured by HA matrix and cleaved off by TEV. Figure 3b is a printout showing a control analysis of untagged BSA. The main peak in this spectrum is from TEV protease.

Figures 4a,b show the μ LC MS/MS analysis of PEPTag captured BSA peptides. Figure 4a is a printout showing the base peak ion current profiles of all peptides released by TEV protease. Figure 4b is a printout showing the reconstructed ion chromatograms from A (m/z 956.0-957.0) of the eluted peptide, which is doubly charged ion ($m/z=956.4$).

Figures 5a,b show the MS and MS/MS spectra of the PEPTag modified peptide. Figure 5a is a printout showing the full-scan (600-1,500 m/z) mass spectrum at time 29.49 min of μ LC-MS and μ LC-MS/MS analysis. Figure 5b is a printout showing the tandem mass spectrum (250-1925 m/z) of the $(M+2H)^{2+}$ of the eluted peptide ($m/z=957.25$).

Figure 6 is a printout showing the MALDI mass spectrum of a pair of PEPTag labeled peptides of identical sequences. The m/z difference depends on the charge state. It is either 14 or 7 for charge state one or two.

Figures 7a-c show the μ LC-MS/MS analysis of captured peptides labeled by differential PEPTags. Figure 7a is a printout showing base peak ion current profiles of all the peptides released by TEV protease from combined two protein mixtures. Figure 7b is a printout showing the reconstructed ion chromatograms (m/z 1034.0-1035.0) of a cysteinyl peptide labeled by PEPTag 1a. Figure 7c is a printout showing the reconstructed ion chromatograms (m/z 1027.0-1028.0) of the same cysteinyl peptide labeled by PEPTag 1b.

Figure 8 is a printout of the ESI mass spectrum of the pair of PEPTag labeled peptides of identical sequences. The m/z difference is 7 for doubly charged ions.

Detailed Description of the Preferred Embodiments

Embodiments of this invention provide analytical reagents and mass spectrometry-based methods using these reagents for the rapid and quantitative

analysis of proteins or protein function in mixtures of proteins. The analytical method can be used for qualitative and particularly for quantitative analysis of global protein expression profiles in cells and tissues, *i.e.*, the quantitative analysis of proteomes. The method can also be employed to screen for and identify proteins whose expression level in cells, tissue or biological fluids is affected by a stimulus (*e.g.*, administration of a drug or contact with a potentially toxic material), by a change in environment (*e.g.*, nutrient level, temperature, passage of time) or by a change in condition or cell state (*e.g.*, disease state, malignancy, site-directed mutation, gene knockouts) of the cell, tissue or organism from which the sample originated. The proteins identified in such a screen can function as markers for the changed state. For example, comparisons of protein expression profiles of normal and malignant cells can result in the identification of proteins whose presence or absence is characteristic and diagnostic of the malignancy.

In an exemplary embodiment, the methods herein can be employed to screen for changes in the expression or state of enzymatic activity of specific proteins. These changes may be induced by a variety of chemicals, including pharmaceutical agonists or antagonists, or potentially harmful or toxic materials. The knowledge of such changes may be useful for diagnosing enzyme-based diseases and for investigating complex regulatory networks in cells.

The methods herein can also be used to implement a variety of clinical and diagnostic analyses to detect the presence, absence, deficiency or excess of a given protein or protein function in a biological fluid (*e.g.*, blood), or in cells or tissue. The method is particularly useful in the analysis of complex mixtures of proteins, *i.e.*, those containing 5 or more distinct proteins or protein functions.

One method employs affinity-labeled protein reactive reagents that allow for the selective isolation of peptide fragments or the products of reaction with a given protein (*e.g.*, products of enzymatic reaction) from complex mixtures. The isolated peptide fragments or reaction products are characteristic of the presence of a protein or the presence of a protein function, *e.g.*, an enzymatic activity, respectively, in those mixtures. Isolated peptides or reaction products are characterized by mass spectrometric (MS) techniques. In particular, the sequence of isolated peptides can be determined using tandem MS (MS)ⁿ techniques, and by application of sequence

database searching techniques, the protein from which the sequenced peptide originated can be identified.

I. Reagents of the Invention

Embodiments of the present invention provide trifunctional synthetic reagents that can be used for reducing the complexity of peptide mixtures by labeling peptides at a specific amino acid residue and then selectively enriching only those peptides containing the labeled amino acid. By preparing this reagent in two forms with detectably different masses, this technique can be used to provide accurate relative quantification of peptide amounts using mass spectrometry.

The amino acids used in the reagents of the present invention may be the D isomer or the L isomer of the amino acid. Thus, the one-letter designation "A" or the three-letter designation "ala," for example, refers to both D-alanine and L-alanine. In addition, the amino acids used in the reagents of the present invention may be naturally occurring or synthetic. Thus, for example, the one-letter designation "A" or the three-letter designation "ala," refers to both the naturally occurring alanine, having the formula $^+\text{H}_3\text{N}-\text{CH}(\text{CH}_3)-\text{COO}^-$, or any chemically modified analog thereof.

In some embodiments of the invention, the peptide labeling moiety consists of a lysine residue modified with an iodoacetamide functional group on the ϵ -amino group of the side chain. The synthetic peptides contain two additional motifs: a peptide epitope tag for high affinity purification; and a highly specific protease site for releasing the affinity purified labeled peptides from the affinity matrix. In addition, these synthetic peptides can readily be prepared as isoforms of two different masses by the simple expedient of using an ornithine in place of lysine to introduce a 14 mass unit difference in the carboxyl terminal acid.

In other embodiments of the invention, the peptide labeling moiety consists of a molecule modified with an iodo-containing organic substituent, which may be an iodide on a primary carbon, an acid iodide, or an iodoacetamide functional group. In addition, the peptide labeling moiety comprises a substituted benzyl moiety, which undergoes heterolytic cleavage upon exposure to light of a certain wavelength. In addition, these molecules can readily be prepared as isoforms of two different masses by the simple expedient of using an alkylene chain that has

additional methylene groups or is missing methylene groups to introduce an integer multiple of 14 mass unit difference in the carboxyl terminal acid.

Thus, in a first aspect, the invention provides a compound of Formula I (I) Immobilization Site-Cleavage Site-Link where:

Immobilization Site is selected from the group consisting of an epitope tag, a linker to a solid surface, a metal chelating site, a magnetic site, and a specific oligonucleotide sequence, or a combination thereof;

Cleavage Site is selected from the group consisting of a protease cleavage site, a photocleavable linker, a restriction enzyme cleavage site, a chemical cleavage site, and a thermal cleavage site, or a combination thereof;

Link is selected from the group consisting of an amino acid reactive site and a mass variance site, or a combination thereof.

At some point during their use, the compounds of the present invention are immobilized on, for example, a surface, such that they do not move when washed with a fluid. The surface on which the compounds are immobilized may be a solid surface. Examples, without limitation of solid surfaces include beads (glass, plastic or other material), plastic, glass, silicon chip, multi-well plates, and membranes (such as PVDF or nylon).

There are a number of ways by which the compounds of the invention may be immobilized. For instance, the solid surface may comprise an amino acid sequence. The Immobilization Site of the compounds of the present invention will then comprise another amino acid sequence which is the epitope tag of the amino acid sequence on the surface. An epitope tag binds exclusively to its target amino acid sequence.

In other embodiments, the solid surface may comprise a metal chelating column, comprising for example nickel atoms. The Immobilization Site of the compounds of the invention may then comprise, for example, amino acid residues, such as histidines, or other residues, such as ethylenediaminetetraacetate, that will chelate to the metal atom on the column. The solid surface can be an oligonucleotide and the Immobilization Site can be the complimentary oligonucleotide. Those skilled in the art and familiar with metal affinity chromatography will know which chelating groups are best used with which metals on the column to be used.

In other embodiments of the present invention, the solid surface may comprise magnetic residues. In this case, the Immobilization Site of the compounds of the present invention will also comprise magnetic residues that are designed to bind magnetically to the magnetic residues of the solid surface.

In certain other embodiments, the Immobilization Site is a direct link between the solid surface and the compounds of the present invention. The direct link may be an acyl group or other chemical moieties that are capable of reacting with the solid surface, in some cases reversibly, so that the compounds of the present invention are immobilized on the surface.

The Cleavage Site is a part of the compound of the present invention that is capable of breaking the molecule in two different parts: One part of the molecule remains immobilized on the solid surface, while the other part of the molecule can move away from the solid surface by a wash fluid.

In certain embodiments, the Cleavage Site may be an amino acid sequence, comprising at least one amino acid residue, which is a cleavage site for a protease.

In other embodiments, the Cleavage Site may be a photocleavable linker. A photocleavable linker is a residue that breaks in two parts, either heterolytically or homolytically, when exposed to light of a certain wavelength, whether visible, infrared, or ultraviolet.

Other embodiments of the invention include a Cleavage Site which comprises a polynucleotide residue, of at least two nucleotides in length, that can be cleaved with a restriction enzyme.

In certain other embodiments, the Cleavage Site is a site that can be chemically cleaved, for example, by addition of an acid or a base.

In other embodiments, the Cleavage Site may be cleaved thermally. This embodiment may include a Cleavage Site that comprises a polynucleotide residue that can hybridize to another polynucleotide residue connected to the Immobilization Site. Heating the compounds can then result in the hybridized polynucleotides to "melt" and separate, as a DNA double helix would.

The Link comprises a residue that can react with an amino acid. The Link may react with a side-chain of an amino acid, or with the N- or C-terminus of a polypeptide. Thus, the Link residue comprises a reactive group. The reactive group may be a moiety that can undergo nucleophilic substitution with a portion of the

amino acid, or can form an amide or an ester bond with the amino acid. However, in general, the invention contemplates any reactive group that can form a bond with any part of an amino acid.

Optionally, the Link comprises a portion that allows mass variance to be introduced into a series of molecules. Thus, for example, the Link residue comprises a alkylene group, which may be a methylene in one embodiment, an ethylene in another embodiment, and a propylene in yet another embodiment, thereby introducing a mass difference of a multiple of 14 mass units between the different embodiments. The mass variance portion of the Link residue may be a series of methylene residues, or a series of -NH- residues, or a series of amide bonds, -NH-C(O)-. Any other repeating unit may work for introducing mass variance. The mass variance may be a variance that is measurable under the conditions of the experiment. Thus, mass variances in the range of 1 to 1000 mass units, or in the range of about 1 to about 500 mass units, or in the range of about 1 to about 250 mass units, or in the range of about 1 to about 100, or in the range of about 1 to about 50, or in the range of about 1 to about 30, or in the range of about 1 to about 20, or in the range of about 3 to about 20, or in the range of about 4 to about 20 are contemplated. In general, the mass variance portion of the Link affects chromatographic properties of the compound of the invention consistently.

In another aspect, the invention provides a compound of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula -(CH₂)_B-C(O)-NR-, an amide bond of formula -(CH₂)_B-NR-C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-\text{CH}_2-$ group;

Link is selected from the group consisting of $-(\text{CH}_2)_C-\text{I}$, $-(\text{CH}_2)_D-\text{CH}(-\text{CH}_2)_E\text{CH}_3$, $-(\text{CH}_2)_F-\text{X}-\text{I}$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme.

By "Acyl" it is meant a chemical substituent of the formula $\text{R}-\text{C}(\text{O})-$, where R is an organic group selected from the group consisting of straight chain, branched, or cyclic alkyl, aryl, and five-membered or six-membered heteroaryl, each being optionally substituted with one or more protected substituents, which are selected from the group consisting of hydroxyl ($-\text{OH}$), sulfhydryl ($-\text{SH}$), amino ($-\text{NH}_2$), nitro ($-\text{NO}_2$), carboxyl ($-\text{COOH}$), ester ($-\text{COOR}$), and carboxamido ($-\text{CONH}_2$). These substituents may be protected by any common organic protecting group as set forth in, for example, Greene & Wutts, *Protective Groups in Organic Chemistry*, 3rd Ed., John Wiley & Sons, New York, NY, 1999.

Electron withdrawing groups are well-known to those of skill in the art. These groups include, without limitation, $-\text{OH}$, $-\text{OR}$, $-\text{NO}_2$, $-\text{N}(\text{CH}_3)_3^+$, $-\text{CN}$, $-\text{COOH}$, $-\text{COOR}$, $-\text{SO}_3\text{H}$, $-\text{CHO}$, and $-\text{CRO}$. In general, these groups are the ones that increase the rate of nucleophilic aromatic substitution when they are located at the ortho or para position with respect to the site of attack.

One of the functional groups of the compounds is the Epitope Tag Site. Suitable Epitope Tag Sites bind selectively either covalently or non-covalently and with high affinity to a capture reagent. The "capture reagent" is an amino acid sequence bound to solid support. The solid support, with the capture reagent attached thereto, are packed into a column, preferably a column for chromatography. The amino acid sequence of the capture reagent and the amino acid sequence of the

Epitope Tag Site are designed to bind to each other with high selectivity and high affinity. The binding may be either covalently or non-covalently. Examples of non-covalent binding include ionic interactions, van der Waals interactions, and hydrophobic or hydrophilic interactions. The binding between the Epitope Tag Site and the capture reagent may be similar to the binding of an antibody to an epitope of a protein for which the antibody is specific.

The interaction or bond between the Epitope Tag Site and the capture agent preferably remains intact after extensive and multiple washings with a variety of solutions to remove non-specifically bound components. The Epitope Tag Site binds minimally or preferably not at all to components in the assay system, except the capture agent, and does not significantly bind to surfaces of reaction vessels. Any non-specific interaction of the Epitope Tag Site with other components or surfaces should be disrupted by multiple washes that leave Epitope Tag Site-capture agent interaction intact. Further, the interaction of Epitope Tag Site and the capture agent can be disrupted to release peptide, substrates or reaction products, for example, by addition of a displacing ligand or by changing the temperature or solvent conditions. Preferably, neither capture agent nor Epitope Tag Site react chemically with other components in the assay system and both groups should be chemically stable over the time period of an assay or experiment.

The Epitope Tag Site is preferably soluble in the sample liquid to be analyzed and the capture reagent should remain soluble in the sample liquid even though attached to an insoluble resin such as Agarose. In the case of the capture reagent, the term "soluble" means that the capture reagent is sufficiently hydrated or otherwise solvated such that it functions properly for binding to the Epitope Tag Site. The capture reagent or capture reagent-containing conjugates should not be present in the sample to be analyzed, except when added to capture the Epitope Tag Site.

A displacement ligand is optionally used to displace the Epitope Tag Site from the capture reagent. Suitable displacement ligands are not typically present in samples unless added. The displacement ligand should be chemically and enzymatically stable in the sample to be analyzed and should not react with or bind to components (other than the capture reagent) in samples or bind non-specifically to reaction vessel walls. The displacement ligand preferably does not undergo peptide-

like fragmentation during mass spectral analysis, and its presence in sample should not significantly suppress the ionization of tagged peptide, substrate or reaction product conjugates.

Another functional group of the compounds disclosed herein is the Protease Cleavage Site. This site is an amino acid sequence, which in some embodiments comprises between 1 and 15 amino acids, and in other embodiments comprises between 4 and 8 amino acids, while in certain other embodiments comprises at least four amino acids. In one embodiment, the Protease Cleavage Site is an amino acid sequence of formula ENLYFQG (SEQ ID NO: 1).

The Protease Cleavage Site is designed to be cleaved once it is exposed to a highly specific protease enzyme. In certain embodiments, the protease enzyme is selected from the group consisting of TEV protease, chymotrypsin, endoproteinase Arg-C, endoproteinase Asp-N, trypsin, *Staphylococcus aureus* protease, thermolysin, and pepsin. In other embodiments, the protease enzyme is TEV protease. Preferably, the Protease Cleavage Site is not cleaved by the enzyme for the initial proteolysis of the lysed cell sample, nor would the cleavage site be lysed by any contaminating proteases from the cell sample.

The third functional group of the compounds disclosed herein is the protein reactive group, designated as "Link" in the above formula. This group may selectively react with certain protein functional groups or may be a substrate of an enzyme of interest. Any selectively reactive protein reactive group should react with a functional group of interest that is present in at least a portion of the proteins in a sample. Reaction of Link with functional groups on the protein should occur under conditions that do not lead to substantial degradation of the compounds in the sample to be analyzed. Examples of selectively reactive Links suitable for use in the affinity tagged reagents include those which react with sulphydryl groups to tag proteins containing cysteine, those that react with amino groups, carboxylate groups, ester groups, phosphate reactive groups, and aldehyde and/or ketone reactive groups or, after fragmentation with CNBr, with homoserine lactone.

Thiol reactive groups include epoxides, α -haloacyl groups, nitriles, sulfonated alkyls or aryl thiols and maleimides. Amino reactive groups tag amino groups in proteins and include sulfonyl halides, isocyanates, isothiocyanates, active esters, including tetrafluorophenyl esters, and N-hydroxysuccinimidyl esters, acid

halides, and acid anhydrides. In addition, amino reactive groups include aldehydes or ketones in the presence or absence of NaBH_4 or NaCNBH_3 .

Carboxylic acid reactive groups include amines or alcohols in the presence of a coupling agent such as dicyclohexylcarbodiimide, or 2,3,5,6-tetrafluorophenyl trifluoroacetate and in the presence or absence of a coupling catalyst such as 4-dimethylaminopyridine; and transition metal-diamine complexes including Cu(II)phenanthroline.

Ester reactive groups include amines which, for example, react with homoserine lactone.

Phosphate reactive groups include chelated metal where the metal is, for example Fe(III) or Ga(III), chelated to, for example, nitrilotriacetic acid or iminodiacetic acid.


Aldehyde or ketone reactive groups include amine plus NaBH_4 or NaCNBH_3 , or these reagents after first treating a carbohydrate with periodate to generate an aldehyde or ketone.

The Link group should be soluble in the sample liquid to be analyzed and it should be stable with respect to chemical reaction, *e.g.*, substantially chemically inert, with components of the sample as well as the Epitope Tag Site, Protease Cleavage Site, and the capture reagent groups. The Link group when bound to the molecule should not interfere with the specific interaction of the Epitope Tag Site with the capture reagent or interfere with the displacement of the Epitope Tag Site from the capture reagent by a displacing ligand or by a change in temperature or solvent. The Link group should bind minimally or preferably not at all to other components in the system, to reaction vessel surfaces or to the capture reagent. Any non-specific interactions of the Link group should be broken after multiple washes which leave the Epitope Tag Site-capture reagent complex intact.

The Link group may be selected from a group of substituents that differ from one another by the presence or absence of one or more repeating units, such as methylene ($-\text{CH}_2-$) groups. Thus, groups that contain straight chain alkylene moieties within them are particularly well-suited for this purpose.

In certain embodiments, the invention contemplates using lysine, ornithine, or arginine, coupled with iodoacetamide, as the Link group. "Orn" is the three letter designation for "L-ornithine," which is (S)-(+)-2,5-diaminopentanoic acid,

$\text{H}_2\text{N}(\text{CH}_2)_3\text{CH}(\text{NH}_2)\text{COOH}$. "Iodoacetamide" is an organic substituent group with the structure $\text{I}-\text{CH}_2-\text{C}(\text{O})-\text{NH}-$. When an amino acid group of a compound is derivatized by the iodoacetamide group, the iodoacetamide group is chemically bound to the side-chain amino group of the amino acid moiety. Thus, the designation " ϵ " or " δ " following the amino acids in the above formula designate the position at which the amino acid is derivatized by the iodoacetamide group. For example, Lys- ϵ -iodoacetamide has the formula



It is also understood within the context of the invention that the incorporation of the designation " ϵ " or " δ " is optional. Therefore, Lys- ϵ -iodoacetamide and Lys-iodoacetamide (K-iodoacetamide), Arg- δ -iodoacetamide and Arg-iodoacetamide (R-iodoacetamide), and Orn- δ -iodoacetamide and Orn-iodoacetamide refer to the same compound or moiety, respectively.

Specific embodiments provided herein include, but are in no way limited to, the following compounds:

Acyl-NH-AYPYDVPDYASENLYFQGK-iodoacetamide (SEQ ID NO: 2),
 Acyl-NH-AYPYDVPDYASENLYFQGGK-iodoacetamide (SEQ ID NO: 3),
 Acyl-NH-AYPYDVPDYASENLYFQGAk-iodoacetamide (SEQ ID NO: 4),
 Acyl-NH-AYPYDVPDYASENLYFQG(GABA)K-iodoacetamide (SEQ ID NO: 5),
 Acyl-NH-AYPYDVPDYASENLYFQGVK-iodoacetamide (SEQ ID NO: 6),
 Acyl-NH-AYPYDVPDYASENLYFQGOorn-iodoacetamide (SEQ ID NO: 7),
 Acyl-NH-AYPYDVPDYASENLYFQGGOrn-iodoacetamide (SEQ ID NO: 8),
 Acyl-NH-AYPYDVPDYASENLYFQGAOrn-iodoacetamide (SEQ ID NO: 9),
 Acyl-NH-AYPYDVPDYASENLYFQG(GABA)Orn-iodoacetamide (SEQ ID NO: 10),
 Acyl-NH-AYPYDVPDYASENLYFQGVOrn-iodoacetamide (SEQ ID NO: 11),
 Acyl-NH-AYPYDVPDYASENLYFQGR-iodoacetamide (SEQ ID NO: 12),
 Acyl-NH-AYPYDVPDYASENLYFQGGR-iodoacetamide (SEQ ID NO: 13),
 Acyl-NH-AYPYDVPDYASENLYFQGAR-iodoacetamide (SEQ ID NO: 14),
 Acyl-NH-AYPYDVPDYASENLYFQG(GABA)R-iodoacetamide (SEQ ID NO: 15),
 and
 Acyl-NH-AYPYDVPDYASENLYFQGVr-iodoacetamide (SEQ ID NO: 16).


Other specific embodiments include:

Acyl-NH-CASENLYFQGK-CH₂CH₂CH₂CH₂-NH-C(O)-CH₂I (SEQ ID NO: 41),
 Acyl-NH-CASENLYFQGOm-CH₂CH₂CH₂-NH-C(O)-CH₂I (SEQ ID NO: 42),
 Acyl-NH-CASENLYFQGPK-CH₂CH₂CH₂CH₂-NH-C(O)-CH₂I (SEQ ID NO: 43),
 and
 Acyl-NH-CASENLYFQGPOm-CH₂CH₂CH₂CH₂-NH-C(O)-CH₂I (SEQ ID NO: 44).

Other embodiments of the invention include compounds in which the Link moiety is a non-amino acid organic group. In these embodiments, the Link moiety is -(CH₂)_C-I or -(CH₂)_D-CH(-(CH₂)_ECH₃)-(CH₂)_F-X-I, where C, D, E, and F are each independently an integer from 0 to 20, and X is as defined herein. In some embodiments, the Link group is iodoacetamide. In other embodiments, the Link group is selected from the group consisting of -CH(CH₂C(O)I)CH₂CH₃, -C(C(O)I)CH₂CH₂CH₃, -CH(CH₂I)CH₂CH₃, -CH₂CH(CH₂I)CH₂CH₂CH₃.

In other embodiments, the invention relates to a compound of Formula III. In some embodiments, alk is a straight or branched chain of alkylene comprising between 0 and 20, between 0 and 15, between 0 and 10, between 0 and 5, or between 0 and 3 carbon atoms carbon atoms. In some embodiments alk is a straight chain of alkylene. alk may be selected from the group consisting of methylene, ethylene, propylene, n-butylene, and n-pentylene. In certain embodiments, alk is propylene.

In some embodiments Ph is a substituted phenyl group. It may be substituted with electron withdrawing groups. The substitutions may take place at positions ortho or para to the methylene group to which Ph is connected. In certain embodiments, the substituents on Ph are methoxy or nitro. In some embodiments, Ph is the following:



The Ph groups is such that when the molecule is exposed to a light of certain wavelength, for example ultraviolet light, the bond between the CH₂ group and Z undergoes heterolytic cleavage. Therefore, the substituents on Ph are situated to stabilize the resulting benzylic free radical.

In embodiments, Z is an amino acid sequence comprising between 1 and 3 amino acids. In certain embodiments, Z is a single amino acid. It may be any of the natural or synthetic amino acids known in the art. In some embodiments, Z is selected from the group consisting of glycine, alanine, and valine. In certain other embodiments, Z may be a synthetic amino acid, where the amino group is in a position other than α to the carboxyl group. For instance, the amino group may be β , δ , ϵ , ϕ , or γ , or any other position, to the carboxyl group. In some embodiments Z is γ -aminobutyric acid.


Certain other specific embodiments of the invention include, without limitation,

Acyl-CH₂CH₂CH₂-O-Ph-CH₂-G-NH-C(O)-CH₂I,

Acyl-CH₂CH₂CH₂-O-Ph-CH₂-A-NH-C(O)-CH₂I,

Acyl-CH₂CH₂CH₂-O-Ph-CH₂- γ -aminobutyric acid-NH-C(O)-CH₂I, and

Acyl-CH₂CH₂CH₂-O-Ph-CH₂-V-NH-C(O)-CH₂I,



where Ph is

II. Determination of Levels of Expression

In another aspect, the invention provides for a method for simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, comprising:

a) preparing a first protein sample or a first peptide sample from the normal cells;

b) reacting the first protein sample or the first peptide sample with a reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-C(O)-NR-$, a carbonyl of formula $-C(O)-$, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(CH_2)_B-C(O)-NR-$, an amide bond of formula $-(CH_2)_B-NR-C(O)-$, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-CH_2-$ group;

Link is selected from the group consisting of $-(CH_2)_C-I$, $-(CH_2)_D-CH(-(CH_2)_ECH_3)-(CH_2)_F-X-I$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme;

c) preparing a second protein sample or a second peptide sample from the perturbed cells;

d) reacting the second protein sample or the second peptide sample of step c) with a second reagent of Formula II or III:

(II) $Acyl-NH-X-[Epitope\ Tag\ Site]_A-Y-[Protease\ Cleavage\ Site]-Z-Link$

(III) $Acyl-NH-X-alk-O-Ph-CH_2-Z-Link$

where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-C(O)-NR-$, a carbonyl of formula $-C(O)-$, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(CH_2)_B-C(O)-NR-$, an amide bond of formula $-(CH_2)_B-NR-C(O)-$, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-CH_2-$ group;

Link is selected from the group consisting of $-(CH_2)_C-I$, $-(CH_2)_D-CH(-(CH_2)_ECH_3)-(CH_2)_F-X-I$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme,

such that the molecular weight of the first reagent and the molecular weight of the second reagent are different by an integer multiple of 14 atomic mass units;

e) combining the reacted the first and the second protein samples or the reacted the first and the second peptide sample from steps b) and d);

f) subjecting the combined protein samples or the combined peptide samples from step e) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

g) subjecting the proteolyzed combined protein samples or the proteolyzed peptide samples from step f) to an affinity chromatography system

comprising a second amino acid sequence attached to a solid, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

h) eluting the non-bound proteins from the affinity chromatography system;

i) subjecting the affinity chromatography system from step h) to a protease specific for the Protease Cleavage Site, thereby forming a cleaved protein mixture;

j) eluting the cleaved protein mixture from the affinity chromatography system of step i);

k) isolating the eluted protein mixture obtained from step j);

l) subjecting the eluted protein mixture from step k) to chromatographic separation, followed by mass analysis;

m) comparing the results of step l) to:

(1) determining the ratio of amounts of compounds in the two samples, where the molecular weights thereof are separated by an integer multiple of 14 atomic mass units; and

(2) comparing the results obtained for each compound to protein databases containing chromatographic and molecular weight correlations.

In another aspect, the invention provides for a method for simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, comprising:

a) preparing a first protein sample or a first peptide sample from the normal cells;

b) subjecting the first protein sample or the first peptide sample from step a) to proteolysis;

c) reacting the proteolyzed first protein sample or the proteolyzed first peptide sample with a reagent of Formula II or III:

(II) $\text{Acyl-NH-X-[Epitope Tag Site]}_A\text{-Y-[Protease Cleavage Site]-Z-Link}$

(III) $\text{Acyl-NH-X-alk-O-Ph-CH}_2\text{-Z-Link}$ where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-C(O)-NR-$, a carbonyl of formula $-C(O)-$, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(CH_2)_B-C(O)-NR-$, an amide bond of formula $-(CH_2)_B-NR-C(O)-$, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-CH_2-$ group;

Link is selected from the group consisting of $-(CH_2)_C-I$, $-(CH_2)_D-CH(-(CH_2)_ECH_3)-(CH_2)_F-X-I$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme;

d) preparing a second protein sample or a second peptide sample from the perturbed cells;

e) subjecting the second protein sample or the second peptide sample from step d) to proteolysis;

f) reacting the proteolyzed second protein sample or the proteolyzed second peptide sample of step e) with a second reagent of Formula II or III:

(II) $Acyl-NH-X-[Epitope\ Tag\ Site]_A-Y-[Protease\ Cleavage\ Site]-Z-Link$

(III) $Acyl-NH-X-alk-O-Ph-CH_2-Z-Link$ where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-C(O)-NR-$, a carbonyl of formula $-C(O)-$, and an amino acid sequence comprising between 0 to 50 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(CH_2)_B-C(O)-NR-$, an amide bond of formula $-(CH_2)_B-NR-C(O)-$, and an amino acid sequence comprising between 0 to 10 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 20 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-CH_2-$ group;

Link is selected from the group consisting of $-(CH_2)_C-I$, $-(CH_2)_D-CH(-(CH_2)_E-CH_3)-(CH_2)_F-X-I$, Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide

where C, D, E, and F are each independently an integer from 0 to 20;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme,

such that the molecular weight of the first reagent and the molecular weight of the second reagent are different by an integer multiple of 14 atomic mass units;

g) combining the reacted the first and the second protein samples or the reacted the first and the second peptide sample from steps c) and f);

h) subjecting the combined protein samples or the combined peptide samples from step e) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

i) subjecting the proteolyzed combined protein samples or the proteolyzed peptide samples from step f) to an affinity chromatography system

comprising a second amino acid sequence attached to a solid, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

j) eluting the non-bound proteins from the affinity chromatography system;

k) subjecting the affinity chromatography system from step j) to a protease specific for the Protease Cleavage Site, thereby forming a cleaved protein mixture;

l) eluting the cleaved protein mixture from the affinity chromatography system of step k);

m) isolating the eluted protein mixture obtained from step l);

n) subjecting the eluted protein mixture from step m) to chromatographic separation, followed by mass analysis;

o) comparing the results of step n) to:

(1) determining the ratio of amounts of compounds in the two samples, where the molecular weights thereof are separated by an integer multiple of 14 atomic mass units; and

(2) comparing the results obtained for each compound to protein databases containing chromatographic and molecular weight correlations.

In certain embodiments, if in step c) in the above method Link is Lys- ϵ -iodoacetamide, then in step f) Link is Orn- δ -iodoacetamide. Alternatively, if in step c) Link is Orn- δ -iodoacetamide, then in step f) Link is Lys- ϵ -iodoacetamide. In another embodiment, the Z substituent in the first reagent, *i.e.*, in step c) has a molecular weight that is an integer multiple of 14 atomic mass units different than the Z substituent in the second reagent, *i.e.*, in step f). For example, and without limitation, the Z in the first reagent contains valine whereas the Z in the second reagent contains leucine instead of valine, all the other amino acids in Z, if any, remaining the same between the two reagents.

In an embodiment, the reagent of step c) is selected from the group consisting of

Acyl-NH-AYPYDVPDYASENLYFQGK-iodoacetamide (SEQ ID NO: 17),

Acyl-NH-AYPYDVPDYASENLYFQGGK-iodoacetamide (SEQ ID NO: 18),

Acyl-NH-AYPYDVPDYASENLYFQGAK-iodoacetamide (SEQ ID NO: 19),
 Acyl-NH-AYPYDVPDYASENLYFQG(GABA)K-iodoacetamide (SEQ ID NO: 20),
 Acyl-NH-AYPYDVPDYASENLYFQGVK-iodoacetamide (SEQ ID NO: 21),
 Acyl-NH-AYPYDVPDYASENLYFQGR-iodoacetamide (SEQ ID NO: 22),
 Acyl-NH-AYPYDVPDYASENLYFQGGR-iodoacetamide (SEQ ID NO: 23),
 Acyl-NH-AYPYDVPDYASENLYFQGAR-iodoacetamide (SEQ ID NO: 24),
 Acyl-NH-AYPYDVPDYASENLYFQG(GABA)R-iodoacetamide (SEQ ID NO: 25),
 Acyl-NH-AYPYDVPDYASENLYFQGVR-iodoacetamide (SEQ ID NO: 26),
 Acyl-NH-AYPYDVPDYASENLYFQGOorn-iodoacetamide (SEQ ID NO: 27),
 Acyl-NH-AYPYDVPDYASENLYFQGGorn-iodoacetamide (SEQ ID NO: 28),
 Acyl-NH-AYPYDVPDYASENLYFQGAorn-iodoacetamide (SEQ ID NO: 29),
 Acyl-NH-AYPYDVPDYASENLYFQG(GABA)orn-iodoacetamide (SEQ ID NO: 30), and
 Acyl-NH-AYPYDVPDYASENLYFQGVorn-iodoacetamide (SEQ ID NO: 31).

Therefore, by way of example only, if the reagent of step c) is Acyl-NH-AYPYDVPDYASENLYPQGK-iodoacetamide (SEQ ID NO: 32)

the reagent of step f) would be

Acyl-NH-AYPYDVPDYASENLYPQGOorn-iodoacetamide (SEQ ID NO: 33);

and if the reagent of step c) is

Acyl-NH-AYPYDVPDYASENLYPQGOorn-iodoacetamide (SEQ ID NO: 34),

the reagent of step f) would be

Acyl-NH-AYPYDVPDYASENLYPQGK-iodoacetamide (SEQ ID NO: 35).

Preferably, the reagent of step c) or of step f) reacts with the reactive side chain of one or more of the amino acid residues of the proteins in the first or second protein sample. By "reactive side chain" it is meant the amino acid side chain that is functionalized, or an amino acid side chain that is other than straight chain or branched alkyl. Therefore, the reagent reacts with the first or second protein at an amino acid residue selected from the group consisting of tyrosine, tryptophan, cysteine, methionine, proline, serine, threonine, lysine, histidine, arginine, aspartic acid, glutamic acid, asparagine, and glutamine. In certain embodiments, the reagent reacts at an amino acid residue selected from the group consisting of tyrosine, cysteine, proline, and histidine. In another embodiment, the site of reaction is a cysteine.

In some embodiments of the present invention, the chromatographic separation of step 1) is a multi-dimensional liquid chromatographic separation, which may be a two-dimensional liquid chromatographic separation or a three-dimensional liquid chromatographic separation. The dimensions of the multi-dimensional liquid chromatographic separation are selected from the group consisting of size differentiation, charge differentiation, hydrophobicity, hydrophilicity, and polarity. In some embodiments, at least one dimension of the multi-dimensional liquid chromatographic separation is separation using size differentiation. Embodiments of the invention include those in which one dimension of the multi-dimensional liquid chromatographic separation is separation using charge differentiation. In other embodiments, one dimension of the multi-dimensional liquid chromatographic separation is separation using hydrophobicity or hydrophilicity.

In another embodiment the mass analysis of step n) is a multi-dimensional mass analysis, which may be a two-dimensional mass analysis (i.e., tandem mass spectrometry).

It is well-known in the art to separate fragments of a solution using chromatography and, in tandem thereto, analyze the mass spectra of each fragment. The technique is formally known in the art as LC-MS or LC-MS/MS analysis. Multi-dimensional chromatography is also well-known in the art, where multiple columns are used in tandem, or the same column is packed with segments of different material that can separate the sample using different criteria. *See*, for example, Link *et al.*, (1999) or Opitek *et al.* (1997), above. Multi-dimensional mass analysis is a technique known to those skilled in the art as well. In this technique, following an initial ionization, an ion of interest is selected. The selected ion is fragmented and each fragment (known as "daughter ion" or "progeny ion") is now capable of being either analyzed or be subjected to further fragmentation. The technique is fully described in Siuzdak, Mass Spectrometry for Biotechnology, Academic Press, San Diego, CA, 1996, which is incorporated by reference herein in its entirety.

In certain embodiments, the preparation of proteins from step a) is subjected to orthogonal chromatography before proceeding with the labeling in step c). Orthogonal chromatography is a technique well-known in the art.

Quantitative relative amounts of proteins in one or more different samples containing protein mixtures (*e.g.*, biological fluids, cell or tissue lysates, *etc.*) can be determined using chemically similar, affinity tagged and differentially labeled reagents to affinity tag and differentially label proteins in the different samples. The label may be differentiated by having additional methylene groups, which would result in the mass of the two labels be different by an integer multiple of 14.

In this method, each sample to be compared is treated with a different labeled reagent to tag certain proteins therein with the affinity label. The treated samples are then combined, preferably in equal amounts, and the proteins in the combined sample are enzymatically digested, if necessary, to generate peptides. Some of the peptides are affinity tagged and in addition tagged peptides originating from different samples are differentially labeled. As described above, affinity labeled peptides are isolated, released from the capture reagent and analyzed by (LC/MS). Peptides characteristic of their protein origin are sequenced using (MS)ⁿ techniques allowing identification of proteins in the samples. The relative amounts of a given protein in each sample is determined by comparing relative abundance of the ions generated from any differentially labeled peptides originating from that protein. The method can be used to assess relative amounts of known proteins in different samples. The method is described in U.S. Patent No. 5,538,897, issued July 23, 1996, to Yates *et al.*, which is incorporated herein by reference in its entirety, including any drawings.

Further, since the method does not require any prior knowledge of the type of proteins that may be present in the samples, it can be used to identify proteins which are present at different levels in the samples examined. More specifically, the method can be applied to screen for and identify proteins which exhibit differential expression in cells, tissue or biological fluids. It is also possible to determine the absolute amount of specific proteins in a complex mixture. In this case, a known amount of internal standard, one for each specific protein in the mixture to be quantified, is added to the sample to be analyzed. The internal standard is an affinity tagged peptide that is identical in chemical structure to the affinity tagged peptide to be quantified except that the internal standard is differentially labeled, either in the peptide or in the affinity tagged portion, to distinguish it from the affinity tagged peptide to be quantified. The internal standard can be provided in the

sample to be analyzed in other ways. For example, a specific protein or set of proteins can be chemically tagged with a labeled affinity tagging reagent. A known amount of this material can be added to the sample to be analyzed. Alternatively, a specific protein or set of proteins may be labeled with additional methylene groups and then derivatized with an affinity tagging reagent.

Also, it is possible to quantify the levels of specific proteins in multiple samples in a single analysis (multiplexing). For example, a set of five different samples can be reacted with one of SEQ ID NO:27 - SEQ ID NO:31, then follow with subsequent steps as described herein. In this case, affinity tagging reagents used to derivatize proteins present in different affinity tagged peptides from different samples can be selectively quantified by mass spectrometry. This may be achieved by using reagents whose molecular mass varies from one sample to another by an integer multiple of 14. So, for example, the Link group in one reagent may feature ornithine whereas the Link group in another reagent may feature arginine or lysine. Similarly, the Z groups in the different reagent may vary such that the molecular mass of the reagent varies by an integer multiple of 14. It is also understood that other amino acids may also be featured. For example, the lighter reagent may have valine whereas the heavier reagent may feature leucine or isoleucine in its stead. The same would be true for having asparagine in the lighter reagent and glutamine in the heavier reagent, or aspartic acid in the lighter reagent and glutamic acid in the heavier reagent.

In this aspect of the invention, the method provides for quantitative measurement of specific proteins in biological fluids, cells or tissues and can be applied to determine global protein expression profiles in different cells and tissues. The same general strategy can be broadened to achieve the proteome-wide, qualitative and quantitative analysis of the state of modification of proteins, by employing affinity reagents with differing specificity for reaction with proteins. The method and reagents can be used to identify low abundance proteins in complex mixtures and can be used to selectively analyze specific groups or classes of proteins such as membrane or cell surface proteins, or proteins contained within organelles, sub-cellular fractions, or biochemical fractions such as immunoprecipitates. Further, these methods can be applied to analyze differences in expressed proteins in different cell states. For example, the methods and reagents herein can be employed

in diagnostic assays for the detection of the presence or the absence of one or more proteins indicative of a disease state, such as cancer.

The methods described herein can also be applied to determine the relative quantities of one or more proteins in two or more protein samples. The proteins in each sample are reacted with affinity tagging reagents which are substantially chemically identical but differentially labeled. The samples are combined and processed as one. The relative quantity of each tagged peptide which reflects the relative quantity of the protein from which the peptide originates is determined by the integration of the respective mass peaks by mass spectrometry.

The methods described herein can be applied to the analysis or comparison of multiple different samples. Samples that can be analyzed by methods of this invention include cell homogenates; cell fractions; biological fluids including urine, blood, and cerebrospinal fluid; tissue homogenates; tears; feces; saliva; lavage fluids such as lung or peritoneal lavages; mixtures of biological molecules including proteins, lipids, carbohydrates and nucleic acids generated by partial or complete fractionation of cell or tissue homogenates.


The methods described herein employ MS and (MS)ⁿ methods. While a variety of MS and (MS)ⁿ are available and may be used in these methods, Matrix Assisted Laser Desorption Ionization MS (MALDI/MS) and Electrospray ionization MS (ESI/MS) methods are preferred.

III. Proteomic Analysis

Another aspect of the present invention relates to a method for proteomic analysis, comprising:

- a) preparing a protein sample or a peptide sample from cells;
- b) reacting the protein sample or the peptide sample with a reagent of

the formula:



where:

A is an integer from 1 to 12;

X is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or X is an amino acid sequence comprising between 0 to 50 amino acids;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 50 amino acids;

Z is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Z is an amino acid sequence comprising between 0 to 10 amino acids;

Link is selected from the group consisting of Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide;

Epitope Tag Site is a sequence of amino acids, and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme;

c) subjecting the reacted proteins or peptides from step b) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

d) subjecting the proteolyzed reacted proteins or the proteolyzed reacted peptides from step c) to an affinity chromatography system comprising a second amino acid sequence attached to a solid support, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

e) eluting the non-bound proteins from the affinity chromatography system;

f) subjecting the affinity chromatography system from step e) to a protease specific for the Protease Cleavage Site, thereby forming a cleaved protein mixture;

g) eluting the cleaved protein mixture from the affinity chromatography system of step f);

h) isolating the cleaved protein mixture obtained from step g);

i) subjecting the cleaved protein mixture from step h) to chromatographic separation, followed by mass analysis;

j) comparing the results of step i) to:

(1) determine the ratio of amounts of compounds in the sample separated by a molecular weight of 14 atomic mass units; and

(2) identify the various modified proteins by comparing the results obtained for each modified protein to protein databases containing chromatographic and molecular weight correlations.

The term "proteomic analysis" refers to identifying the proteome of a cell. The "proteome" of a cell is the collection of all the proteins expressed by the cell at the time the proteomic analysis is undertaken. It is understood that, unlike the genome of a cell, which is invariable, the proteome of a cell varies depending on many factors, including the age of the cell, the environmental conditions surrounding the cell, and the position of the cell in its life cycle.

In the above methods, the reagent reacts with the reactive side chain of one or more of the amino acid residues of the first or second protein. Therefore, the reagent reacts with the protein at an amino acid residue selected from the group consisting of tyrosine, tryptophan, cysteine, methionine, proline, serine, threonine, lysine, histidine, arginine, aspartic acid, glutamic acid, asparagine, and glutamine. In certain embodiments, the reagent reacts at an amino acid residue selected from the group consisting of tyrosine, cysteine, proline, and histidine. In another preferred embodiment, the site of reaction is a cysteine.

In some embodiments of the present invention, the chromatographic separation of step i) is a multi-dimensional liquid chromatographic separation, which may be a two-dimensional liquid chromatographic separation or a three-dimensional liquid chromatographic separation. The dimensions of the multi-dimensional liquid chromatographic separation are selected from the group consisting of size differentiation, charge differentiation, hydrophobicity, hydrophilicity, and polarity. In some embodiments, at least one dimension of the multi-dimensional liquid chromatographic separation is separation using size differentiation. Embodiments of the invention include those in which one dimension of the multi-dimensional liquid chromatographic separation is separation using charge differentiation. In other embodiments, one dimension of the multi-dimensional liquid chromatographic separation is separation using hydrophobicity or hydrophilicity.

In another embodiment the mass analysis of step i) is a multi-dimensional mass analysis, which more preferably, may be a two-dimensional mass analysis.

In certain embodiments, the preparation of proteins from step a) is subjected to orthogonal chromatography before proceeding with the labeling in step b).

In one aspect, the invention provides a mass spectrometric method for identification and quantification of one or more proteins in a complex mixture which employs affinity labeled reagents in which the Link group is a group that selectively reacts with certain groups that are typically found in peptides (*e.g.*, sulfhydryl, amino, carboxy, homoserine, or lactone groups). One or more affinity labeled reagents with different Link groups are introduced into a mixture containing proteins and the reagents react with certain proteins to tag them with the affinity label. It may be necessary to pretreat the protein mixture to reduce disulfide bonds or otherwise facilitate affinity labeling. After reaction with the affinity labeled reagents, proteins in the complex mixture are cleaved, *e.g.*, enzymatically, into a number of peptides. This digestion step may not be necessary, if the proteins are relatively small. Peptides that remain tagged with the affinity label are isolated by an affinity isolation method, *e.g.*, affinity chromatography, via their selective binding to the capture reagent. Isolated peptides are released from the capture reagent by displacement of the Epitope Tag Site or cleavage of the linker, and released materials are analyzed by liquid chromatography/mass spectrometry (LC/MS). The sequence of one or more tagged peptides is then determined by (MS)ⁿ techniques. At least one peptide sequence derived from a protein will be characteristic of that protein and be indicative of its presence in the mixture. Thus, the sequences of the peptides typically provide sufficient information to identify one or more proteins present in a mixture.

IV. Quantitative Proteome Analysis

The method comprises the following steps:

Reduction. Disulfide bonds of proteins in the sample and reference mixtures are chemically reduced to free SH groups. The preferred reducing agent is tri-*n*-butylphosphine which is used under standard conditions. Alternative reducing agents include mercaptoethanol, 2-methylthioethanol, 2-methylthio-1-hexanol, and dithiothreitol. If required, this reaction can be performed in the presence of solubilizing agents including high concentrations of urea and detergents to maintain protein solubility. The reference and sample protein mixtures to be compared are processed separately, applying identical reaction conditions.

Derivatization of SH groups with an affinity tag. Free SH groups of the sample protein are derivatized with a reagent of the invention. The reagent reacts with the free SH group through the Link group.

Each sample is derivatized with a different reagent having a different mass. Derivatization of SH groups is preferably performed under slightly basic conditions (pH 8.5) for 90 min at about room temperature. For the quantitative, comparative analysis of two samples, one sample each (termed "reference sample" and "sample") are derivatized with two different reagents, whose molecular mass differs by an integer multiple of 14. For the comparative analysis of several samples one sample is designated a reference to which the other samples are related.

It is well known that cysteine residues are susceptible to the formation of disulfide bonds as the result of oxidation. These reactions potentially reduce the efficiency of the PEPTag labeling since the reagent requires that the cyteines be in a reduced state. Accordingly, in one embodiment the PEPTag labeling reaction is set-up in an essentially oxygen free environment (anaerobic conditions) or if this is not feasible then to incorporate reducing agents, such as tributylphosphine (TBP), in the reaction mixture in an amount effective to counteract or reduce the effects of oxidation, creating an environment essentially free of oxygen-dependent disulfide formation. An environment that is essentially free of oxygen contains less than about half of the oxygen concentration of the ambient air, or less than about 30%, less than about 20%, less than about 10%, less than about 5%, or less than about 1% of the oxygen concentration of the ambient air.

Anaerobic conditions are easily achieved by the use of an anaerobic chamber. An "anaerobic chamber" may be a glove box or a glove bag or a similar device, or a reaction flask that has been purged of oxygen with argon or nitrogen using Schlenk techniques or high vacuum line techniques. Any remaining trace oxygen may then be removed catalytically using palladium pellets and a reducing atmosphere (93% nitrogen, 5% carbon dioxide, 2% hydrogen), or by other similar methods. If no chamber is available then samples should be prepared using buffers that have been extensively sparged of oxygen using an inert gas such as argon or nitrogen, which in turn may be run through oxygen- or water- scrubbing materials, have an effective concentration of a reducing agent, e.g., sodium metal, sodium amalgam, potassium metal, Na/K mixture, sodium/benzophenone mixture, etc., and/or have an effective

concentration of a metal chelating agent, such as EDTA and 1,10-phenanthroline. The advantage of anaerobic sample preparation are that (1) essentially no oxidation occurs, and (2) high concentrations of additional reagents are not necessary. Since the number of competing reactions are greatly limited in the anaerobic system the labeling efficiency for low-abundance cysteine containing peptides is increased.

The above conditions have an additional benefit of minimizing other undesired oxygen-dependent reactions, such as oxidation of protein methionine.

Combination of labeled samples. After completion of the affinity tagging reaction defined aliquots of the samples labeled with different reagents are combined and all the subsequent steps are performed on the pooled samples. Combination of the differentially labeled samples at this early stage of the procedure eliminates variability due to subsequent reactions and manipulations. Preferably equal amounts of each sample are combined.

Removal of excess affinity tagged reagent. Excess reagent is adsorbed, for example, by adding an excess of SH-containing beads to the reaction mixture after protein SH groups are completely derivatized. Beads are added to the solution to achieve about a 5-fold molar excess of SH groups over the reagent added and incubated for 30 min at about room temperature. After the reaction the beads are removed by centrifugation.

Protein digestion. The proteins in the sample mixture are digested, typically with trypsin. Alternative proteases are also compatible with the procedure as in fact are chemical fragmentation procedures. In cases in which the preceding steps were performed in the presence of high concentrations of denaturing solubilizing agents, the sample mixture is diluted until the denaturant concentration is compatible with the activity of the proteases used. This step may be omitted in the analysis of small proteins.

Affinity isolation of the affinity tagged peptides by interaction with a capture reagent. The tagged peptides are isolated on anti-HA antibodies-agarose. After digestion the pH of the peptide samples is lowered to 6.5 and the tagged peptides are immobilized on beads coated with anti-HA. The beads are extensively washed. The last washing solvent includes 10% methanol to remove residual SDS.

Release of the captured peptides with specific protease. A solution of TEV in TRIS at pH 7.5 is added to the column and digestion is allowed to proceed. The bound peptides are cleaved from the column by incubation at 30 °C for 6 hours.

Analysis of the isolated, derivatized peptides by μ LC-(MS)ⁿ or CE-(MS)ⁿ with data dependent fragmentation. Methods and instrument control protocols well-known in the art and described, for example, in Ducret *et al.* (1998); Figeys and Aebersold (1998); Figeys *et al.* (1996); or Haynes *et al.* (*Electrophoresis* 19:939-945 (1998)) are used.

In this last step, both the quantity and sequence identity of the proteins from which the tagged peptides originated can be determined by automated multistage MS. This is achieved by the operation of the mass spectrometer in a dual mode in which it alternates in successive scans between measuring the relative quantities of peptides eluting from the capillary column and recording the sequence information of selected peptides. Peptides are quantified by measuring in the MS mode the relative signal intensities for pairs of peptide ions of identical sequence that are tagged with the lighter or heavier forms of the reagent, respectively, and which therefore differ in mass by the mass differential encoded within the affinity tagged reagent. Peptide sequence information is automatically generated by selecting peptide ions of a particular mass-to-charge (m/z) ratio for collision-induced dissociation (CID) in the mass spectrometer operating in the (MS)ⁿ mode. (Link *et al.* *Electrophoresis* 18:1314-1334 (1997); Gygi *et al.* *Nature Biotechnol* 17:994-999 (1999); Gygi *et al.*, *Cell Biol* 19:1720-1730 (1999)). The resulting CID spectra are then automatically correlated with sequence databases to identify the protein from which the sequenced peptide originated. Combination of the results generated by MS and (MS)ⁿ analyses of affinity tagged and differentially labeled peptide samples therefore determines the relative quantities as well as the sequence identifies of the components of protein mixtures in a single, automated operation.

This method can also be practiced using other affinity tags and other protein reactive groups, including amino reactive groups, carboxyl reactive groups, or groups that react with homoserine lactones.

The approach employed herein for quantitative proteome analysis is based on two principles. First, a short sequence of contiguous amino acids from a protein contains sufficient information to uniquely identify that protein. Protein


identification by (MS)ⁿ is accomplished by correlating the sequence information contained in the CID mass spectrum with sequence databases, using sophisticated computer searching algorithms (Yates, III *et al.* U.S. Patent 5,538,897). Second, pairs of peptides tagged with lighter and heavier Link groups or Z groups, respectively, are chemically similar and therefore serve as mutual internal standards for accurate quantification. The MS measurement readily differentiates between peptides originating from different samples, representing for example different cell states, because of the difference between the distinct reagents attached to the peptides. The ratios between the intensities of the differing weight components of these pairs or sets of peaks provide an accurate measure of the relative abundance of the peptides (and hence the proteins) in the original cell pools.

Specifically, the peptide labeling moiety consists of a lysine residue modified with an iodoacetamido functional group on the ϵ -amino side chain. The synthetic chemistry necessary for this modification reaction is readily available in the literature. The synthetic peptides contain two additional motifs: a peptide epitope tag for high affinity purification; and a highly specific protease site for releasing the affinity purified labeled peptides from the affinity matrix. In addition, these synthetic peptides can readily be prepared as isoforms of two different masses by the simple expedient of using an ornithine in place of lysine to introduce a 14 mass unit difference in the carboxyl terminal acid.

Examples of the reagents (SEQ ID NO: 36 and SEQ ID NO: 37) are thus:

Ala-[Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala]-Ser-(Glu-Asn-Leu-Tyr-Phe-Gln-Gly)-Lys---

Iodoacetamide



Ala-[Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala]-Ser-(Glu-Asn-Leu-Tyr-Phe-Gln-Gly)-Orn---

Iodoacetamide

The peptide sequence in the square brackets is an Epitope Tag Site and the sequence in parentheses is a Protease Cleavage Site. In the case shown here, the peptide sequence YPYDVPDYA (SEQ ID NO: 38) is an influenza hemagglutinin (HA) epitope tag. This part of the reagent could be replaced by any other epitope tag, or multiple copies of a single tag for higher efficiency purification, or parallel copies of different tags for higher specificity purification. Examples of other Epitope Tag Sites include Flag, His-6, and c-myc.

The protease cleavage site shown here is that of TEV protease, which is commercially available. This enzyme has been shown to cleave at only one protein site in the entire yeast genome, thus indicating that the enzyme is highly specific for an extremely rare sequence. This part of the reagent could be replaced by any other highly specific protease cleavage site, either commercially available, such as Factor Xa, or Pharmacia Prescission Enzyme, or one that is newly discovered. The amino acid indicated in bold is used to provide a site of attachment for the iodoacetamide group, hence we have used lysine which contains an ϵ -amino side chain that is suitable for the purpose. This amino acid is also used to introduce a differential mass between the two reagents, and this can be readily accomplished by using ornithine in place of lysine. Ornithine is commercially available and differs from lysine only by the presence of one additional methyl group, which makes it 14 amu (atomic mass unit) heavier than lysine. Arginine is also commercially available and its molecular weight is 28 amu (*i.e.*, 2 x 14) heavier than lysine. This part of the reagent could be replaced with any other amino acid or similar molecule that provided an attachment site for the iodoacetamide group. Finally, the integral difference of 14 amu could be further enhanced by the choice of two amino acids

differing by 14 amu (*e.g.*, valine and leucine) in the Z portion of the peptide labeling moiety.

V. Qualitative Proteome Analysis



In addition to the above methods, the methods of the invention may be used to determine the proteomic differences in an organism or cell based on the change in the cell's environmental condition. Thus, for example, one may compare the proteome of the cells of two plants of the same species, one having encountered high salt concentrations and the other low salt concentrations, thereby determining the effect of salt concentration on the plant's proteome.

It is also within the scope of the present invention that the two modes of analysis discussed herein, *i.e.*, the qualitative and quantitative proteome analyses, are exercised in conjunction with each other. Thus, by way of example only, one may compare the proteome of the cells of two plants of the same species, one having encountered higher temperatures than the other, thereby not only determining the effect of heat on the proteome in terms of which proteins are expressed, but also determining the effect of heat on the level of expression of each protein of interest.

In practicing the present invention to achieve the above end, one may use a number of different compounds of the present invention, having different masses (yet all within an integer multiple of 14 from each other), and mark different proteins of the cells with the different reagents. By applying the multidimensional LC/MS techniques described herein, one is able to determine which proteins, and to what extent, are expressed in the cells.

IV. Fusion Proteins

Another aspect of the invention relates to a process for preparing a fusion protein of Formula IV or V:



where A, X, Y, Z, alk, Ph, Link, Epitope Tag Site, and Protease Cleavage Site are as defined herein

comprising,

a) preparing a fusion protein sample of Formula II or III from cells

(II) Protein-Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Orn-δ-

NHCOCH₂

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-NHCOCH₂

b) reacting the protein sample with a Link or with iodoacetamide.

In another aspect, the invention relates to a process for preparing a fusion protein of Formula VI:

(VI) Protein-Acyl-N-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-[Lys-δ-N-iodoacetamide]

where A, X, Y, Z, alk, Ph, Link, Epitope Tag Site, and Protease Cleavage Site are as defined herein

comprising,

a) preparing a fusion protein sample of Formula VII from cells

(VII) Protein-Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Lys-δ-NHCOCH₂

b) reacting the protein sample with iodoacetamide.

Markers that are useful in plant breeding, genetics, and diagnostics are disclosed in U.S. Provisional Patent Application No. 60/264,226, entitled "Cereal Simple Sequence Repeat Markers," filed on January 26, 2001 (Attorney Docket No. NADII.026PR), which is hereby incorporated by reference in its entirety.

VI. Databases

Aspects of the invention not only include the chemical compounds and MS data described above, but also include data files (e.g.: databases) corresponding to these compounds and data. For example, the amino acid sequences of the labeled compounds can be created and manipulated *in silico*. These data files can be stored in a conventional computer system on any type of temporary or permanent storage. Examples of such storage include Read Only Memory, Random Access Memory, Hard Disk, Floppy Disk, CD-ROM and the like.

In addition to data relating to the modified amino acid sequences, aspects of the invention include data files of the MS data itself. A data file of, for example, a

cell that has been subjected to high salt conditions, can be stored to a database and thereafter compared to other data files of cells having different treatments. Thus, aspects of the invention contemplate analyzing the differences between organisms or cells by comparing MS data gathered from the methods described above.

Examples

Examples are provided below to illustrate different aspects and embodiments of the present invention. These examples are not intended in any way to limit the disclosed invention. Rather, they illustrate the compounds and the methodology by which the protein analysis of the invention may be practiced.

The following proteins and reagents were purchased from Sigma, St. Louis, MO, USA: rabbit glyceraldehydes-3-phosphate dehydrogenase, E.Coli β -galactosidase, rabbit phosphorylase b, chicken ovalbumin, bovine β -lactoglobulin, bovine α -lactalbumin, bovine serum albumin, dimethylformamide (DMF), Iodoacetic anhydride, Urea, tris-hydrochloride, acid washed glass beads, and diisopropylethylamine (DIEA). Tributyl phosphine was purchased from BioRad (Hercules, CA). Synthetic peptides were custom made by QCB/Biosource International (Hopkinton, MA). HA affinity matrix and Lys-C were from Roche Diagnostics (Indianapolis, IN), and PreScission protease was from Amersham Pharmacia Biotech (Uppsala, Sweden). HPLC grade acetonitrile (ACN) and HPLC grade methanol was purchased from Fischer Scientific (Fair Lawn, NJ). Yeast extract were products of BD Biosciences (Sparks, MD). Heptafluorobutyric acid (HFBA) was obtained from Pierce (Rockford, IL). SPEC Plus PT C18 solid phase extraction pipette tips were purchased from Ansys Diagnostics (Lake Forest, CA). Glacial acetic acid was purchased from Malinckrodt Baker Inc. (Paris, KY).

Example 1: Synthesis of peptide labeling moiety (or peptide encoded tags, "PEPTags")

A pair of PEPTags, described generally above, was synthesized from peptides with following sequences: Ac-AYPYDVPDYASENLYFQGK (SEQ ID NO: 39) and AYPYDVPDYASENLYFQGO^{rn} (SEQ ID NO: 40). In dry DMF containing excess (2-3 molar equivalents) DIEA, each of the peptides was mixed with two molar equivalents of iodoacetic anhydride for 10 min at room temperature under N₂ gas, to give Lys-PEPTag and Orn-PEPTag, respectively. The reaction was terminated by adding acetic acid. Solvent was removed by vacuum centrifugation, and the product was purified by reverse-phase FPLC, and analyzed by MALDI MS (TofSpec 2E, Micromass, Beverly, MA) and ESI MS/MS (API 3, PE Sciex, Foster City, CA).

In order to demonstrate that the mass spectrometric ionization efficiency of the two synthesized peptide tags was essentially equal, the two products were mixed in different ratios and analysed by LC-MS. The ratio of the measured peak areas gave the data shown in the following table.

Amount of tag1 (pmol)	Amount of tag2 (pmol)	Calculated ratio	Measured ratio
30	3	10:1	11.95:1
15	3	5:1	5.19:1
7.5	3	2.5:1	2.70:1
3.75	3	1.25:1	0.97:1
1.875	3	0.625:1	0.64:1
0.375	3	0.125:1	0.11:1

Example 2: PEPTag qualitative protein analysis: simplification of complex mixtures

We tested the PEPTag method, described generally herein, on Bovine Serum Albumin (BSA). 200 µL BSA (0.25 mg/mL) was denatured and reduced in a solution containing 0.1% SDS, 5 mM tributyl phosphine and 50 mM Tris buffer (pH 8.5) for 3 min at 100 °C and for 1 hour at 37 °C. The side chains of cysteinyl residues were derivatized with a tenfold molar excess of Lys- PEPTag. Tagged

protein was digested by trypsin overnight at 37 °C. Trypsin activity was quenched with trypsin inhibitor and the peptide mixture bound to anti-HA affinity matrix for 2 hours at 4 °C. The anti-HA resin with bound peptides was washed in equilibration - buffer (20mM Tris, pH 7.5; 0.1 M NaCl; 0.1mM EDTA), 3 X 10 min. at 4 °C. The bound peptides were cleaved from the matrix by incubation with TEV protease for 6 hours at 30 °C. The cleaved peptides were analyzed by either Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS), or separated and analyzed by μ LC-MS/MS. Using the Sequest database searching algorithm (Yates, III *et al.* U.S. Patent 5,538,897), the resulting MS/MS spectra were correlated with the sequence database.

The sequence of bovine serum albumin is shown below:

```
SW:ALBU_BOVIN P02769 bos taurus (bovine). serum albumin precursor.
12/1998 [MASS=69293]
MKWVTFISLL LLFSSAYSRG VFRDTHKSE IAHRFKDLGE EHFKGLVLIA FSQYLQQCPF
DEHVKLVNEL TEFKTCVAD ESHAGCEKSL HTLFGDELCK VASLRETYGD MADCCEKQEP
ERNECFLSHK DDSPDLPKLK PDPNTLCDEF KADEKKFWGK YLYEIARRHP YFYAPELLYY
ANKYNGVFQE CCQAEDKGAC LLPKIETMRE KVLASSARQR LRCASIQKFG ERALKAWSVA
RLSQKFPKAE FVEVTKLVTD LTKVHKECCH GDLLECADDR ADLAKYICDN QDTISSKLKE
CCDKPLLEKS HCIAEVEKDA IPENLPPLTA DFAEDKDVCK NYQEAKDAFL GSFLYEYSRR
HPEYAVSVLL RLAKEYEATL EECCAEDDPH ACYSTVFDKL KHLVDEPQNL IKQNCDOFEK
LGEYGFQNAL IVRYTRKVPQ VSTPTLVEVS RSLGKVGTRC CTKPESERMP CTEDYLSLIL
NRLCVLHEKT PVSEKVTKCC TESLVNRRPC FSALTPDETY VPKAFDEKLF TFHADICTLP
DTEKQIKKQT ALVELLKHKP KATEEQLKTV MENFVAFVDK CCAADDKEAC FAVEGPKLVV
STQTALA
```

(SEQ ID NO: 45)

>average mass = 69294, pI = 5.82

Cysteine-containing peptides indicated in bold-underline are those detected in the experiment described in example 2. The protein is successfully identified from each peptide tandem MS spectra, and the complex total tryptic mixture of peptides is considerably simplified. The peptides are shown in more detail in the table below, with C# indicating a peptag-modified cysteine residue.

Position	Mass (MH+)	Peptide sequence
89-100	1363.57	SLHTLFGDELC#K (SEQ ID NO: 46)
286-297	1387.50	YIC#DNQDTISSK (SEQ ID NO: 47)

139-151	1520.74	LKPDNTLC#DEFK (SEQ ID NO: 48)
510-523	1571.78	C#FSALTPDETYVPK (SEQ ID NO: 49)
469-482	1668.96	MPC#TEDYLSLILNR (SEQ ID NO: 50)
508-523	1825.08	RPC# FSALTPDETYVPK (SEQ ID NO: 51)
123-138	1846.02	NEC#FLSHKDDSPDLPK (SEQ ID NO: 52)
529-544	1852.11	LFTFHADIC#TLPDTEK (SEQ ID NO: 53)
118-138	2485.68	QEPERNEC#FLSHKDDSPDLPK (SEQ ID NO: 54)
461-482	2599.99	CTKPESERMPC#TEDYLSLILNR (SEQ ID NO: 55)

Example 3: PEPTag quantitative protein analysis: differential labeling

We tested the PEPTag quantitative strategy on two mixtures containing the same two proteins at different concentrations. Mixture 1 had 500 pmol BSA (0.1 mg/mL) and 400 pmol β -lactoglobulin (0.1 mg/mL) and was reacted with 9 nmol Lys-PEPTag. Mixture 2 had 250 pmol BSA (0.05 mg/mL) and 800 pmol β -lactoglobulin (0.2mg/mL) and was reacted with 9 nmol Orn-PEPTag. Protein denaturation, reduction, tagging, and digestion were the same as described above. The two samples were combined after tryptic digestions, and bound to anti-HA matrix. TEV digestion and MS analysis were as described in Example 2. Peptides were quantified by measuring, in the MS mode, the relative signal intensities for pairs of peptide ions of identical sequence, tagged with Lys or Orn-PEPTags, respectively. The results are shown in Figures 6, 7, and 8 and the following table.

Protein	Peptide sequence identified	Observed ratio	Mean \pm S.D.	Expected ratio
---------	-----------------------------	----------------	-----------------	----------------

Bovine serum albumin	SLHTLFGDELC#K (SEQ ID NO: 56)	2.19	2.05±0.10	2.00
	GLVLIAFSQYLQQC#PFDEHVK (SEQ ID NO: 57)	1.96		
	GLVLIAFSQYLQQC#PFDEHVKLVNELTEFAK (SEQ ID NO: 58)	1.99		
Beta-lactoglobulin	VYVEELKPTPEGDGLLEILLQKWENDEC#AQKK (SEQ ID NO: 59)	0.40	0.46±0.05	0.50
	LSFNPTQLEEQC#HI (SEQ ID NO: 60)	0.51		

Example 4: Proteome analysis

A. Perturbed cell sample versus normal cell sample

A biological sample of interest is subjected to a treatment expected to cause physiological changes, such as treating tissue culture cells with a drug sample. Protein samples are prepared from the normal and perturbed cells. The normal cell protein sample is labeled at all cysteine residues using the first (lysine-based) reagent shown above, and the perturbed cell protein sample is labeled at all cysteine residues using the heavier (ornithine-based) version of the reagent as shown above. The two labeled samples are then combined and protease digested, typically with trypsin, to produce a very complex peptide mixture. This complex mixture is then passed over an anti-HA tag affinity tag column that retains only those tryptic fragments containing labeled cysteine residues, allowing all other material to be washed away. The peptides are then released from the column by addition of TEV protease, producing a mixture of peptides labeled with either lysine or ornithine attached via an acetamido group.

This complex mixture is then analyzed using microscale high-performance liquid chromatography-tandem mass spectrometry. Two distinct classes of information are then obtained during the course of a single experiment. Firstly, the relative amounts of each peptide that were produced from the initial normal and perturbed samples are accurately quantified by measuring the ratio of peak areas for a given peak pair differing by 14 amu. Since the two samples have been mixed together very early in the experimental process, variation in sampling handling

between the two samples is essentially eliminated as for each pair there is a mutual internal standard present in the same sample. Secondly, the identity of each peptide is determined by tandem mass spectrometric fragmentation and database searching using established methods.

The result of this experiment is simultaneous peptide identification and relative quantification. Thus, for any experimental perturbation that can be applied to cells, it would be possible to identify which proteins were up and down regulated, and quantify the amount of any change detected.

B. Whole cell analysis

Another type of experiment is performed using just one of the reagents described above, where massively parallel protein identification is required such as characterizing the proteome of a whole organism or cell type. Using the technique outlined above for enrichment of labeled cysteine containing peptides, the number of proteins that can be identified from a very complex mixture is dramatically increased. This is due to the fact the number of peptides analyzed from each protein, even those of high abundance, is reduced, thus allowing greater coverage of the range of proteins present. This coverage is increased still further by using two-dimensional liquid chromatography prior to tandem mass spectrometry in order to maximize the number of peptides analyzed. It is also possible to perform a further orthogonal chromatography step prior to labeling, thus increasing the number of peptides identified even more. Using such a system, it is possible to describe the entire proteome of a simple organism in a single experiment.

The applications of this method are almost limitless. Any biological sample containing proteins benefits from either a complete description of all the proteins present, or a complete description and quantification of changes that occur in response to a physiological stimulus, or both.

The complete cataloging type of experiment, set forth in Subsection B, above, is best limited to organisms with complete sequences available, although it should be noted that the list now includes humans.

Example 5: Synthesis of affinity peptide encoded tags (APEPTags)

A pair of APEPTags was synthesized from peptides with following sequences: Ac-AYPYDVPDYASLEVLFGQPK-NH₂ (SEQ ID NO: 61) and Ac-AYPYDVPDYASLEVLFGQP^{Orn}-NH₂ (SEQ ID NO: 62). In dry DMF containing excess (2-3 molar equivalents) DIEA, each of the peptides was mixed with two molar equivalents of iodoacetic anhydride for 10 min at room temperature under N₂ gas. The reaction was terminated by adding acetic acid. Solvent was removed by vacuum centrifugation, and the product was purified on a Sephasil_Peptide_C18_5 μ _ST_4.6/100 column connected to AKTA purifier Amersham Pharmacia Biotech FPLC system (Uppsala, Sweden). Solvent A was 0.01% v/v TFA/H₂O, and solvent B was 0.01 % v/v TFA/ H₂O/90% acetonitrile. A flow rate of 0.8 ml/min was used, with the UV monitored at 280 nm. The gradient was from 0 to 50% B over 35 column volume. The fraction-collected peak was analyzed by MALDI MS (TofSpec 2E, Micromass) with α -cyano-4-hydroxy-cinnamic acid as matrix and by ESI MS/MS (API 3, PE Sciex).

Example 6: Synthesis of immobilized peptide encoded tags (IPEPTags)

A pair of IPEPTags was synthesized from peptides with following sequences: Sepharose gel-CASASLEVLFGQPK-NH₂ (SEQ ID NO: 63) and Sepharose gel-CASASLEVLFGQP^{Orn}-NH₂ (SEQ ID NO: 64). Pack two 10 ml empty columns with 2 ml of each gel-coupled peptide. Drain the storage buffer completely. Rinse the gel bed three times with 5 ml DMF. Add 2 ml DMF with 2 μ mol iodoacetic anhydride and 1 μ l DIEA into each column. Mix and react at room temperature for 15 min. Drain reagents completely and rinse the gel with 10 X volume of buffer 50 mM tris (pH 8.5) and then store in the same buffer.

Example 7: Growth and Lysis of *S. cerevisiae*

Strain BJ5460 was grown to mid log phase (O.D. 0.6) in YPD, centrifuged and washed 1X with buffer (1 M sorbitol, 10 mM KH₂PO₄, pH 7.5, 50 mM NaCl, 1 mM EDTA). Resuspended cells in buffer, added zymolase (3 mg per 100 OD), and incubate at 30 °C for 45 min. Cells were harvested by centrifugation, wash once and then solubilized in 8 M Urea, 50 mM Tris-HCl pH 8.5 and disrupted in the presence

of glass beads on a mixer. The protein concentration was determined by the Bradford assay.

Example 8. APEPTag analysis of protein mixtures

Protein mixtures were denatured and reduced in a buffer containing 8 M Urea, 10 mM tributyl phosphine and 50 mM Tris buffer (pH 8.5) for 30 min at 50°C. The side chains of cysteinyl residues were derivatized with about 5 fold molar excess of APEPTag. Tagged proteins were dialysis against 50 mM Tris buffer (pH 8.5) for 5 hours and then digested by trypsin overnight at 37 °C. Trypsin activity was quenched with trypsin inhibitor and the peptide mixture bound to anti-HA affinity matrix for 2 hours at 4 °C. The anti-HA resin with bound peptides was washed with 10 volume of equilibration buffer (20mM Tris, pH 7.5; 0.1m NaCl; 0.1mM EDTA), 3 X 10 min. at 4 °C. The bound peptides were cleaved from the matrix by incubation with PreScission protease overnight at 4 °C.

For APEPTag quantitative strategy, two protein mixtures were denatured, reduced and then labeled differentially with either Lys-APEPTag or Orn-APEPTag. The two mixtures were combined after their dialysis. Protein denaturation, reduction, tagging, dialysis, digestion, affinity binding and were the same as described above.

Example 9. IPEPTag analysis of protein mixtures

Protein mixtures were denatured and reduced in a buffer containing 8 M Urea, 10 mM tributyl phosphine and 50 mM Tris buffer (pH 8.5) for 30 min at 50 °C. The side chains of cysteinyl residues were derivatized with about 10 fold molar excess of IPEPTag beads. Tagged proteins were digested first by Lys-C in 8M urea for 6 hours and then by trypsin in 2 M urea overnight at 37 °C. The beads with bound peptides were washed with 10 volume of equilibration buffer (20mM Tris, pH 7.5; 0.1m NaCl; 0.1mM EDTA), 3 X 10 min. at 4 °C. The bound peptides were cleaved from the matrix by incubation with PreScission protease overnight at 4 °C.

For IPEPTag quantitative strategy, two protein mixtures were denatured, reduced and then labeled differentially with either Lys-IPEPTag or Orn-IPEPTag beads. Protein denaturation, reduction, tagging, and digestion were the same as

described above. Two batches of beads with bound peptides were combined after digestion, followed by wash and preScission cleavage as described above.

Example 10. Chromatography and Mass Spectrometry

Each sample was subjected to MudPIT analysis with modifications to the method described by Link et al. A quaternary HP 1100 HPLC pump (Hewlett-Packard, Palo Alto, CA) was interfaced with a Finnigan LCQ ion trap mass spectrometer (Finnigan MAT, San Jose, CA). The tip at the end of the 100 x 365 μm fused silica capillary (J & W Scientific, Folsom, CA) was pulled with a P-2000 laser (Sutter Instruments Co., Novato, CA). The fritless capillary was first packed with 10 cm of 5 μm Zorbax Eclipse XDB-C18 (Hewlett Packard, Palo Alto, CA) and then with 4 cm of 5 μm Partisphere SCX (Whatman, Clifton, New Jersey). The column, was connected to a PEEK micro-cross as described elsewhere, in order to split the flow of the HPLC pump to an effective flow rate of 0.15 -0.25 $\mu\text{L}/\text{min}$ and supply a spray voltage of 1.8 W. The Zorbax 4.6 x 30 mm Eclipse XDB C18 column for the off-line fractionation was manufactured by Hewlett Packard, Palo Alto, CA.

Each sample mixture was loaded onto separate microcolumn for the analysis. After loading the microcapillary column, the column was placed in-line with the system. A fully automated 7-step chromatography run was carried out on each sample. The four buffer solutions used for the chromatography were 5% ACN/0.5% acetic acid/0.02% HFBA (buffer A), 80% ACN//0.5% acetic acid/0.02% HFBA (buffer B), 250 mM ammonium acetate/5% ACN/0.5% acetic acid/0.02% HFBA (buffer C), and 1.5 M ammonium acetate/5% ACN/0.5% acetic acid/ 0.02% HFBA (buffer D). The first step of 80 min consisted of a 70 min gradient from 0 to 80% buffer B and a 10 min hold at 80% buffer B. The next 5 steps were 110 min each with the following profile: 5 min of 100% buffer A, 2 min of x% buffer C, 3 min of 100% buffer A, a 10 min gradient from 0 to 10% buffer B, and a 90 min gradient from 10 to 50% buffer B. The 2 min buffer C percentages (x) in steps 2-13 were as follows: 10, 30, 50, 70 and 100%. Step 7 is 5 min of 100% buffer A, 2 min of 100% buffer D, 3 min of 100% buffer A, a 10 min gradient from 0 to 10% buffer B, and a 90 min gradient from 10 to 100% buffer B, and a 10 min hold at 100% buffer B.

The mass spectrometer was operated in a four step cycle, where the 3 most intense ions were scanned in a MS/MS mode (3 μ scans per scan). The scan range for the MS experiment was set to m/z 400-2000.

Example 11. Analysis of SEQUEST data

A singly charged peptide must be tryptic and the cross-correlation score has to be higher than 1.9. Tryptic or partially tryptic peptides with a charge state +2 must have a cross-correlation score of at least 2.2. Peptides with cross-correlation scores (XCorr) above 3 were accepted regardless of their tryptic nature. Triply charged tryptic or partially tryptic peptides were accepted if their XCorr was above 3.75. If proteins were identified by less than 4 different peptide spectra, the existence of the protein was manually checked by at least one good spectrum. Proteins identified by more than 4 peptides were considered as valid identification. Spectra of good quality need to meet the following criteria. MS/MS spectra have to show fragment ions clearly above the noise level with continuity in the b and y ion series. Y-ions of a protein sequence should be intense. The highest and second best scoring amino acid sequence should differ in their cross-correlation score by 0.1 or more.

Results:

The following data were generated from the application of affinity peptide encoded tags (APEPTags) method on a mixture of six model proteins.

Qualitative analysis: 35 modified cysteine containing peptides were extracted.

In the following sequence, "C#" indicates a modified cysteine, and "M@" indicates an oxidized methionine.

ALBU_BOVIN - 35 69293

1	K.CC#TESLVNR.R	(SEQ ID NO: 65)
2	K.DAIPENLPPLTADFAEDKDVC#K.M	(SEQ ID NO: 66)
3	K.EYEATLEECC#AK.D	(SEQ ID NO: 67)
4	K.EYEATLEECC#AKDDPHACYSTVFDK.L	(SEQ ID NO: 68)
5	K.LFTFHADIC#TLPDTEK.Q	(SEQ ID NO: 69)
6	K.LKEC#CDKPLLEK.S	(SEQ ID NO: 70)
7	K.LKPDPTLC#DEFK.A	(SEQ ID NO: 71)
8	R.M@PC#TEDYLSLILNR.L	(SEQ ID NO: 72)
9	R.MPC#TEDYLSLILNR.L	(SEQ ID NO: 73)

10	R.NEC#FLSHKDDSPDLPK.L	(SEQ ID NO: 74)
11	R.RPC#FSALTPDETYVPK.A	(SEQ ID NO: 75)
12	K.SCH#IAEVEK.D	(SEQ ID NO: 76)
13	K.SLHTLFGDELC#K.V	(SEQ ID NO: 77)
14	K.YIC#DNQDTISSK.L	(SEQ ID NO: 78)
15	K.YNGVFQECC#QAEDK.G	(SEQ ID NO: 79)

BGAL_ECOLI -

1	R.AVELHTADGTLIEAEAC#DVGFR.E	(SEQ ID NO: 80)
2	R.IGLNC#QLAQVAER.V	(SEQ ID NO: 81)
3	D.PSRPVQYEGGGADTTATDIIC#PM@YAR.V	(SEQ ID NO: 82)
4	D.PSRPVQYEGGGADTTATDIIC#PMYAR.V	(SEQ ID NO: 83)
5	R.PVQYEGGGADTTATDIIC#PMYAR.V	(SEQ ID NO: 84)
6	K.SVDPSRPVQYEGGGADTTATDIIC#PM@YAR.V	(SEQ ID NO: 85)
7	K.SVDPSRPVQYEGGGADTTATDIIC#PMYAR.V	(SEQ ID NO: 86)

G3P_RABIT -

1	K.IVSNASC#TTNCLAPLAK.V	(SEQ ID NO: 87)
2	K.IVSNASC#TTNC#LAPLAK.V	(SEQ ID NO: 88)
3	R.VPTPNVSVVDLTC#R.L	(SEQ ID NO: 89)

LACB_BOVIN -

1	R.LSFNPTQLEEQC#HI.-	(SEQ ID NO: 90)
---	---------------------	-----------------

LCA_BOVIN -

1	K.DDQNPSSNIC#NISCDK.F	(SEQ ID NO: 91)
2	K.DDQNPSSNIC#NISCDK.F	(SEQ ID NO: 92)
3	K.FLDDDLTDDIM@C#VK.K	(SEQ ID NO: 93)
4	K.FLDDDLTDDIMC#VK.K	(SEQ ID NO: 94)
5	K.LDQWLC#EK.L	(SEQ ID NO: 95)
6	S.NICNISCDKFLDDDLTDDIMC#VK.K	(SEQ ID NO: 96)
7	H.SSNIC#NISCDK.F	(SEQ ID NO: 97)

OVAL_CHICK - 3 42750

1	R.ADHPFLFC#IK.H	(SEQ ID NO: 98)
2	R.YPILPEYLQC#VK.E	(SEQ ID NO: 99)

The following data were generated from immobilized peptide encoded tags method, applied to a whole cell extract from yeast. 142 unique proteins were identified.

[0189] Yeast protein extracts:

YAL003W EFB1 1 22627 0.00

1	N.C#VVEDDKVSLDDLQQSIEEDEDHVQSTDAAMQK.L	(SEQ ID NO: 100)
---	--	------------------

YAL005C SSA1 9 69767 0.00

1	K.AVGIDLGTTYSC#VAH.F	(SEQ ID NO: 101)
2	K.AVGIDLGTTYSC#VAHFANDR.V	(SEQ ID NO: 102)

3 R.FEELC#ADLFR.S (SEQ ID NO: 103)

YAL038W CDC19 20 54545 0.00

1 R.AEVSDVGNAILDGADC#VMLSGETAK.G (SEQ ID NO: 104)

2 V.GNAILDGADC#VMLSGETAK.G (SEQ ID NO: 105)

3 R.NC#TPKPTSTTETVAASAVAAVFEQK.A (SEQ ID NO: 106)

4 K.PVIC#ATQMLESM@TYNPR.P (SEQ ID NO: 107)

5 K.SNLAGKPVIC#ATQMLESM@TYNPR.P (SEQ ID NO: 108)

6 K.SNLAGKPVIC#ATQMLESM@TYNPR.P (SEQ ID NO: 109)

7 K.YRPNC#PIILVTR.C (SEQ ID NO: 110)

YBL024W - 1 77879 0.00

1 R.LVYSTC#SLNPIENEAVVAEALR.K (SEQ ID NO: 111)

YBL047C - 1 150783 0.00

1 R.LPNQTLGEIWALC#DR.D (SEQ ID NO: 112)

YBL072C RPS8A 2 22490 0.00

1 R.C#DGYILEGEEELAFYLR.R (SEQ ID NO: 113)

YBL075C SSA3 2 70547 0.00

1 R.AVGIDLGTYS#VAHFSNDR.V (SEQ ID NO: 114)

YBL087C RPL23A 4 14473 0.00

1 R.ISLGLPVGAIM@NC#ADNSGAR.N (SEQ ID NO: 115)

2 R.ISLGLPVGAIMNC#ADNSGAR.N (SEQ ID NO: 116)

3 L.PVGAIMNC#ADNSGAR.N (SEQ ID NO: 117)

YBR025C - 4 44174 0.00

1 R.C#PLGNPANYPFATIDPEEAR.V (SEQ ID NO: 118)

2 K.LDLISFFTC#GPDEV.R (SEQ ID NO: 119)

3 K.PC#IYLIINLSER.D (SEQ ID NO: 120)

4 R.SVDSIYQVVR.C (SEQ ID NO: 121)

YBR031W RPL4A 5 39092 0.00

1 R.SGQGAFGNMC#R.G (SEQ ID NO: 122)

YBR048W RPS11B 4 17749 0.00

1 K.C#PFTGLVSIR.G (SEQ ID NO: 123)

3 R.VQVGDIVTVGQC#R.P (SEQ ID NO: 124)

4 R.VQVGDIVTVGQC#RPISK.T (SEQ ID NO: 125)

YBR118W TEF2 17 50033 0.00

1 N.ATVIVLNHPGQISAGYSPVLDL#HTAH.I (SEQ ID NO: 126)

2 M.C#VEAFSEYPPLGR.F (SEQ ID NO: 127)

3 F.NATVIVLNHPGQISAGYSPVLDL#HTAH.I (SEQ ID NO: 128)

4 K.NM@ITGTSQADC#AILIIAGGVGEFEAGISK. (SEQ ID NO: 129)

5 K.NMITGTSQADC#AILIIAGGVGEFEAGISK.D (SEQ ID NO: 130)

6 K.PMC#VEAFSEYPPLGR.F (SEQ ID NO: 131)

7 V.PSKPMC#VEAFSEYPPLGR.F (SEQ ID NO: 132)

YBR127C VMA2 4 57749 0.00

1 K.IPIFSASGLPHNEIAAQIC#R.Q (SEQ ID NO: 133)

YBR169C SSE2 1 77621 0.00

1 K.GAAFIC#AIHSPTLR.V (SEQ ID NO: 134)

YBR249C ARO4 6 39749 0.00

1 K.GNEHC#FVILR.G (SEQ ID NO: 135)

2 K.NGTDGTLNVAVDAC#QAAAHSHHFM@GVTK.H (SEQ ID NO: 136)

3 K.NGTDGTLNVAVDAC#QAAAHSHHFMGVTK.H (SEQ ID NO: 137)

4 R.VLVIVGPC#SIHDLEAAQEYALR.L (SEQ ID NO: 138)

5 K.VNDVVC#EQIANGENAITGVMIESNINEGNQGIPAEGK.A (SEQ ID NO: 139)

6 K.YGVSITDAC#IGWETTEDVLR.K (SEQ ID NO: 140)

YBR263W SHM1 1 62862 0.00

1 K.EISQGC#GAYLMSDMAH.I (SEQ ID NO: 141)

YCL009C ILV6 1 33987 0.00

1 K.LVEPFGVLEC#AR.S (SEQ ID NO: 142)

YCL030C HIS4 1 87790 0.00

1 K.FHAAQLPTETLEVETQPGVLC#SR.F (SEQ ID NO: 143)

YDL014W NOP1 2 34465 0.00

1 R.DHC#IVVGR.Y (SEQ ID NO: 144)

2 R.MLIGMVDC#VFADVAQPDQAR.I (SEQ ID NO: 145)

YDL055C PSA1 3 39566 0.00

1 K.DNSPFFVLNSDVIC#EYPFK.E (SEQ ID NO: 146)

2 K.STIVGWNSTVGQWC#R.L (SEQ ID NO: 147)

3 R.SVVLC#NSTIK.N (SEQ ID NO: 148)

YDL061C RPS29B 1 6728 0.00

1 R.VC#SSHTGLVR.K (SEQ ID NO: 149)

YDL066W IDP1 1 48190 0.00

1 K.C#ATITPDEAR.V (SEQ ID NO: 150)

YDL097C RPN6 1 49774 0.00

1 R.SHFNALYDTLLESNLC#K.I (SEQ ID NO: 151)

YDL126C CDC48 2 91996 0.00

1 K.DTVLIVLIDDELEDGAC#R.I (SEQ ID NO: 152)

2 R.LGDLVTIHPC#PDIK.Y (SEQ ID NO: 153)

YDL131W LYS21 3 48594 0.00

1 R.DIENLVADAVEVNIPFNNPITGFC#AF.T (SEQ ID NO: 154)

2 R.VGIADTVGC#ANPR.Q (SEQ ID NO: 155)

YDL136W RPL35B 1 13910 0.00

1 K.SIAC#VLTVINEQQR.E (SEQ ID NO: 156)

YDL229W SSB1 10 66602 0.00

1 G.ERVNC#KENTLLGEFDLKNIPMMPAGEP.V (SEQ ID NO: 157)

2 R.TFTTC#ADNQTTVQFPVYQGER.V (SEQ ID NO: 158)

YDR002W - 1 22953 0.00

1 K.IC#ANHIIAPEYTLKPNVGS DR.S (SEQ ID NO: 159)

YDR035W ARO3 2 41070 0.00

1 R.IMIDC#SHGNSNK.D (SEQ ID NO: 160)

2 K.LPIAGEMLDTISPQFLSDC#FSLGAIGAR.T (SEQ ID NO: 161)

YDR037W KRS1 2 67959 0.00

1 K.LEC#PPPLTNAR.M (SEQ ID NO: 162)

YDR061W - 1 61191 0.00

1 K.YDSIEVSGGC#PIVIGLR.Y (SEQ ID NO: 163)

YDR091C - 1 68340 0.00

1 R.APESLLTGC#NR.F (SEQ ID NO: 164)

YDR127W ARO1 1 174755 0.00

1 R.ALILAALGEGQC#K.I (SEQ ID NO: 165)

YDR155C CPH1 5 17391 0.00

1 N.AGPNTNGSQFFITTVPC#PWLDGK.H (SEQ ID NO: 166)

2 M.ANAGPNTNGSQFFITTVPC#PWLDGK. (SEQ ID NO: 167)

3 R.PGLLSM@ANAGPNTNGSQFFITTVPC#PWLDGK.H (SEQ ID NO: 168)

YDR158W HOM2 1 39544 0.00

1 R.VAVSDGHTC#ISLR.F (SEQ ID NO: 169)

YDR188W CCT6 2 59924 0.00

1 R.AAAAQDEITGDGTTTVVC#LVGELLR.Q (SEQ ID NO: 170)

2 R.NAITGATGIASNLLLC#DELLR.A (SEQ ID NO: 171)

YDR190C - 2 50453 0.00

1 K.VPFC#PLVGSELYSVEVK.K (SEQ ID NO: 172)

2 R.YALQLLAPC#GILAQTSNR.K (SEQ ID NO: 173)

YDR226W ADK1 1 24255 0.00

1 K.DELTNNPAC#K.N (SEQ ID NO: 174)

YDR321W ASP1 1 41395 0.00

1 K.SQNAAVNGSGIAC#QQR.S (SEQ ID NO: 175)

YDR353W TRR1 1 34238 0.00
1 R.NKPLAVIGGDSAC#EEAQFLTK.Y (SEQ ID NO: 176)

YDR385W EFT2 10 93289 0.00
1 R.AEQLYEGPADDANC#IAIK.N (SEQ ID NO: 177)
2 K.IWC#FGPDGNGPNLVIDQTK.A (SEQ ID NO: 178)
3 R.VTDGALVVVDTIEGVC#VQTETVLR.Q (SEQ ID NO: 179)

YDR418W RPL12B 1 17823 0.00
1 K.EILGTAQSVGC#R.V (SEQ ID NO: 180)

YDR447C RPS17B 4 15803 0.00
1 R.LC#DEIATIQSK.R (SEQ ID NO: 181)

YDR487C RIB3 1 22568 0.00
1 R.GHTEAGVDLC#K.L (SEQ ID NO: 182)

YDR502C SAM2 2 42256 0.00
1 K.SLVAAGLC#K.R (SEQ ID NO: 183)
2 K.TC#NVLVAIEQQSPDIAQGLHYEK.S (SEQ ID NO: 184)

YEL046C GLY1 1 42815 0.00
1 R.THLMQPPYSILC#DYS.A (SEQ ID NO: 185)

YEL047C - 2 50844 0.00
1 R.LGGSSLLEC#VVFGFR.T (SEQ ID NO: 186)

YER007C-A 1 20278 0.00
1 K.FVLSGANIMC#PGLTSAGADLPPAPGYEK.G (SEQ ID NO: 187)
1 K.HYSKPDGPNNNVAVVC#SAR.S (SEQ ID NO: 188)

YER055C HIS1 1 32266 0.00
1 K.C#DLGITGVDQVR.E (SEQ ID NO: 189)

YER091C MET6 2 85860 0.00
1 K.GMLTGPITC#LR.W (SEQ ID NO: 190)

YER107C GLE2 1 40523 0.00
1 R.AQHESSPVLC#TR.W (SEQ ID NO: 191)

YER133W GLC7 2 35907 0.00
1 K.IC#GDIHQYYDLLR.L (SEQ ID NO: 192)
2 K.IFC#MHGGLSPDLNSMEQIR.R (SEQ ID NO: 193)

YER177W RPL23B 2 30091 0.00
1 K.SHQVELIC#SYR.S (SEQ ID NO: 194)

YFL018C LPD1 1 54010 0.00

- 1 K.AAQLGFNTAC#VEK.R (SEQ ID NO: 195)
- YFL039C ACT1 4 41690 0.00
- 1 K.LC#YVALDFEQEMQTAAQSSSIEK.S (SEQ ID NO: 196)
- YFL045C SEC53 4 29063 0.00
- 1 K.TYC#LQHVEK.D (SEQ ID NO: 197)
- YGL009C LEU1 4 85794 0.00
- 1 R.EAEILVVTGDNFGC#GSSR.E (SEQ ID NO: 198)
- 2 K.HC#LVNGLDDIGITLQK.E (SEQ ID NO: 199)
- 3 R.VDC#TLATVDHNIPTESR.K (SEQ ID NO: 200)
- 4 K.VFIGSC#TNGR.I (SEQ ID NO: 201)
- YGL026C TRP5 3 76626 0.00
- 1 R.FGDFGGQYVPEALHAC#LR.E (SEQ ID NO: 202)
- 2 K.LPDAVVAC#VGGGSNSTGMFSPFEHDTSVK.L (SEQ ID NO: 203)
- 3 R.LTEHC#QGAQIWLK.R (SEQ ID NO: 204)
- YGL087C MMS2 1 15545 0.00
- 1 K.INLPC#VNPTTGEVQTDFTLR.D (SEQ ID NO: 205)
- YGL105W ARC1 1 42084 0.00
- 1 K.STAMVLC#GSNDDKVEFVEPPKDSK.A (SEQ ID NO: 206)
- YGL135W RPL1B 2 24486 0.00
- 1 K.SC#GVDAMSVDLKK.K (SEQ ID NO: 207)
- 2 K.SC#GVDAMSVDLKK.L (SEQ ID NO: 208)
- YGL147C RPL9A 4 21569 0.00
- 1 K.DEIVLSGNSVEDVSNAAADLQQIC#R.V (SEQ ID NO: 209)
- 2 N.VKDEIVLSGNSVEDVSNAAADLQQIC#R.V (SEQ ID NO: 210)
- YGL148W ARO2 3 40838 0.00
- 1 R.C#PDASVAGLMVK.E (SEQ ID NO: 211)
- 2 K.DSIGGVVTC#VVR.N (SEQ ID NO: 212)
- YGL157W - 1 38083 0.00
- 1 K.DC#IVDTAAQMLEVQNEA.- (SEQ ID NO: 213)
- YGL202W ARO8 1 56178 0.00
- 1 K.DYFPWDNLSVDSPPKPPFPQGIGAPIDEQNC#IK.Y (SEQ ID NO: 214)
- 1 K.C#VHFQNSYYR.K (SEQ ID NO: 215)
- YGL245W - 1 82663 0.00
- 1 K.YSAADVAC#WGALR.S (SEQ ID NO: 216)
- YGR192C TDH3 19 35747 0.00
- 1 K.IVSNASCTTNC#LAPLAK.V (SEQ ID NO: 217)

YGR204W ADE3 2 102205 0.00
1 K.NGHPFFLPC#TPK.G (SEQ ID NO: 218)
2 R.SPVTVEDVGC#TGALTALLR.D (SEQ ID NO: 219)

YGR234W YHB1 1 44646 0.00
1 K.C#NPNRPIYWIQSSYDEK.T (SEQ ID NO: 220)

YGR240C PFK1 2 107970 0.00
1 R.QAAGNLISQGIDALVVC#GGDGSLTGADLFR.H (SEQ ID NO: 221)

YGR254W ENO1 7 46816 0.00
2 K.IGLDC#ASSEFFK.D (SEQ ID NO: 222)

YGR285C ZUO1 3 49020 0.00
1 R.AQYDSC#DFVADVPPPK.K (SEQ ID NO: 223)

YHR019C DED81 2 62207 0.00
2 K.YGTC#PHGGYGIGTER.I (SEQ ID NO: 224)

YHR025W THR1 1 38712 0.00
1 K.C#IAIIPQFELSTADSR.G (SEQ ID NO: 225)

YHR030C SLT2 1 55636 0.00
1 R.ITVDEALEHPYLSIWHDPADVPVC#SEK.F (SEQ ID NO: 226)

YHR064C PDR13 1 62186 0.00
1 K.C#ANGAPAVEVDGK.V (SEQ ID NO: 227)

YHR208W BAT1 3 43596 0.00
1 K.EIGWNNEDIHVPLLPGEQC#GALTK.Q (SEQ ID NO: 228)
2 R.IC#LPTFESEELIK.L (SEQ ID NO: 229)
3 K.LGANYAPC#ILPQLQAAK.R (SEQ ID NO: 230)

YHR216W - 1 56530 0.00
1 L.LGGIGFIHNC#TPEDQADMVR.R (SEQ ID NO: 231)

YIL022W TIM44 1 48854 0.00
1 K.LLAPQDIPVLVVGCR.A (SEQ ID NO: 232)

YIL041W - 1 36670 0.00
1 K.VALNSSEC#LNK.M (SEQ ID NO: 233)

YIL094C LYS12 1 40069 0.00
1 K.EQC#QGALFGAVQSPTTK.V (SEQ ID NO: 234)

YIR006C PAN1 1 160267 0.00
1 R.SIVTNGSNTVSGANC#R.K (SEQ ID NO: 235)

YJR034C LYS1 1 41465 0.00
1 R.GGPFDEIPQADIFINC#IYLSK.P (SEQ ID NO: 236)

YJL045W - 1 69382 0.00
1 K.YRNVIAHTLDENEC#APVPPAVR.S (SEQ ID NO: 237)

YJL130C URA2 1 245126 0.00
1 R.GHNIPC#TSTISGR.C (SEQ ID NO: 238)

YJL138C TIF2 2 44697 0.00
1 K.VHAC#IGGTSFVEDAEGLER.D (SEQ ID NO: 239)

YJL200C - 2 86583 0.00
1 K.DLPSSIATNQEVDFLESC#AK.R (SEQ ID NO: 240)

YJR016C ILV3 2 62861 0.00
1 R.EIIADSFETIMMAQHYDANIAIPSC#DK.N (SEQ ID NO: 241)
2 K.LVSNASNGC#VLDA.- (SEQ ID NO: 242)

YJR109C CPA2 1 123915 0.00
1 R.HLGVIGEC#NVQYALQPDGLDYR.V (SEQ ID NO: 243)

YJR148W BAT2 2 41625 0.00
1 R.IC#LPTFDPEELITLIGK.L (SEQ ID NO: 244)
2 K.LGANYAPC#VLPQLQAASR.G (SEQ ID NO: 245)

YKL006W RPL14A 1 15167 0.00
1 K.WAAAVC#EK.W (SEQ ID NO: 246)

YKL060C FBA1 6 39621 0.00
1 H.MLDLSEETDEENISTC#VK.Y (SEQ ID NO: 247)
2 R.SIAPAYGIPVVLHSDHC#AK.K (SEQ ID NO: 248)
3 K.VNLDTDC#QYAYLTGIR.D (SEQ ID NO: 249)

YKL182W FAS1 2 228691 0.00
1 R.GYTC#QFVDMVLPNTALK.T (SEQ ID NO: 250)
2 R.TC#ILHGPVAAQFTK.V (SEQ ID NO: 251)

YKL216W URA1 2 34801 0.00
1 K.DAFEHLLC#GASMLQIGTELQK.E (SEQ ID NO: 252)
2 K.IQDSEFNGITELNLSC#PNVPGKPQVAYDFDLTK.E (SEQ ID NO: 253)

YLL026W HSP104 1 102035 0.00
1 R.LPDSALDLVDISC#AGVAVAR.D (SEQ ID NO: 254)

YLR027C AAT2 1 47793 0.00
1 K.LSTVSPVFVC#QSFAK.N (SEQ ID NO: 255)
2 K.NPVILADACC#SR.H (SEQ ID NO: 256)

YLR058C SHM2 1 52218 0.00
1 R.M@EILC#QQR.A (SEQ ID NO: 257)

YLR075W RPL10 3 25361 0.00
1 K.MLSC#AGADR.L (SEQ ID NO: 258)

YLR109W - 2 19115 0.00
1 K.FQYIAISQSDADSESC#K.M (SEQ ID NO: 259)

YLR153C ACS2 1 75492 0.00
1 R.TYLPVSC#DAEDPLFLLYTSGSTGSPK.G (SEQ ID NO: 260)

YLR249W YEF3 13 115945 0.00
1 R.AIANGQVDGFPTQEEC#R.T (SEQ ID NO: 261)
2 R.FIPSLIQC#IADPTEVPETVHLLGATTF.V (SEQ ID NO: 262)
3 H.IANQSNLSPSVEPYIVQLVPAIC#TNAGNK.D (SEQ ID NO: 263)
5 R.KEIEHC#SMLGLDPEIVSHSR.I (SEQ ID NO: 264)
6 K.NTYEYEC#SFLGENIGMK.S (SEQ ID NO: 265)
8 K.PQITDINFQC#SLSSR.I (SEQ ID NO: 266)
10 K.STLINVLTGELLPTSGEVYTHENC#R.I (SEQ ID NO: 267)
13 K.VTNMEFQYPGTSKPQITDINFQC#SLSSR.I (SEQ ID NO: 268)

YLR259C HSP60 3 60752 0.00
1 K.NVAAGC#NPM@DLR.R (SEQ ID NO: 269)
2 K.NVAAGC#NPMDLR.R (SEQ ID NO: 270)

YLR304C ACO1 1 85368 0.00
1 R.VGLIGSC#TNSSYEDMSR.S (SEQ ID NO: 271)

YLR355C ILV5 5 44368 0.00
1 K.YGMDYMYDAC#STTAR.R (SEQ ID NO: 272)

YLR441C RPS1A 3 28743 0.00
1 R.VVEVC#LADLQSEDHSFR.K (SEQ ID NO: 273)

YLR447C VMA6 1 39791 0.00
1 R.NITWIAEC#IAQNQR.E (SEQ ID NO: 274)

YML007W YAP1 1 72533 0.00
1 S.EFC#SKMNQVCGTRQCPIPKKPISALDK.E (SEQ ID NO: 275)

YML008C ERG6 2 43431 0.00
1 R.GDLVLDVGC#GVGGPAR.E (SEQ ID NO: 276)
2 K.VYAIEATC#HAPK.L (SEQ ID NO: 277)

YML028W TSA1 3 21590 0.00
1 R.LVEAFQWTDKNGTVLPC#NWTPGAATIKPTVEDSK.E (SEQ ID NO: 278)
2 K.NGTVLPC#NWTPGAATIKPTVEDSK.E (SEQ ID NO: 279)

YML085C TUB1 1 49800 0.00
1 K.IGIC#YEPPTATPNSQLATVDR.A (SEQ ID NO: 280)

YML126C HMGS 2 55014 0.00
1 R.VGLFSYGSGLAASLYSC#K.I (SEQ ID NO: 281)

YMR079W SEC14 1 34901 0.00
1 R.AAGHLVETSC#TIMDLK.G (SEQ ID NO: 282)

YMR116C BEL1 4 34805 0.00
1 Q.C#LATLLGHNDWVSQVR.V (SEQ ID NO: 283)
2 K.GQC#LATLLGHNDWVSQVR.V (SEQ ID NO: 284)

YMR120C ADE17 1 65263 0.00
1 K.YTQSNSVC#YAR.N (SEQ ID NO: 285)

YMR173W-A - 1 43890 0.00
1 K.C#PHLEIVNLSDNAFLR.T (SEQ ID NO: 286)

YMR260C TIF11 1 17435 0.00
1 R.VEASC#FDGNKR.M (SEQ ID NO: 287)

YMR315W - 1 38216 0.00
1 K.IAESTPLPVGVAENWLYLPC#IK.I (SEQ ID NO: 288)

YNL104C LEU4 1 68409 0.00
1 R.GC#GVAATELGMLAGADR.V (SEQ ID NO: 289)

YNL134C - 1 41164 0.00
1 K.IGPQGALLGC#DAAGQIVK.L (SEQ ID NO: 290)

YNL178W RPS3 3 26503 0.00
2 K.GC#EVVVSGLK.L (SEQ ID NO: 291)

YNL220W ADE12 2 48279 0.00
1 R.C#AGGNNAGHTIVVDGVK.Y (SEQ ID NO: 292)
2 R.C#GWLDLVVLK.Y (SEQ ID NO: 293)

YNL244C SUI1 1 12312 0.00
1 K.VC#EFMISQLGLQK.K (SEQ ID NO: 294)

YNL301C RPL18B 6 20563 0.00
1 K.AGSEC#ITLDQLAVR.A (SEQ ID NO: 295)

YNR050C LYS9 6 48918 0.00
1 Y.C#GGLPAPEDSDNPLGYK.F (SEQ ID NO: 296)
2 R.GNALDTLC#AR.L (SEQ ID NO: 297)
3 F.LSYC#GGLPAPEDSDNPLGYK.F (SEQ ID NO: 298)
4 K.SFLSYC#GGLPAPEDSDNPLGYK.F (SEQ ID NO: 299)

YOL086C ADH1 5 36849 0.00
2 Y.ATADAVQAAHIPQGTDLAQVAPILC#AGITVYK.A (SEQ ID NO: 300)

YOL143C RIB4 1 18556 0.00
1 K.VDMPVIFGLLTC#MTEEQALAR.A (SEQ ID NO: 301)

YOR007C SGT2 1 37218 0.00
1 K.EISEDGADSLNVAMDC#ISEAFGFER.E (SEQ ID NO: 302)

YOR122C PFY1 1
1 R.HDAEGVVC#VR.T (SEQ ID NO: 303)

YOR187W - 1
1 R.ELLNEYGFDGDNAPIIMGSALC#ALEGR.Q (SEQ ID NO: 304)

YOR204W DED1 2
1 R.DLMAC#AQTGSGK.T (SEQ ID NO: 305)

YOR229W WTM2 1
1 R.FFNNHLFASC#SDDNILR.F (SEQ ID NO: 306)

YOR261C RPN8 1
1 R.C#VGVILGDANSSTIR.V (SEQ ID NO: 307)

YPL028W ERG10 2
1 K.VNVYGGAVALGHPLGC#SGAR.V (SEQ ID NO: 308)

YPL061W ALD6 6
1 K.IAPALAMGNVC#ILK.P (SEQ ID NO: 309)
2 K.PAAVTPLNALYFASLC#K.K (SEQ ID NO: 310)

YPL117C IDI1 1
1 K.IIC#ENYLFNWWEQLDDLSEVENDR.Q (SEQ ID NO: 311)

Totals: # Unique Proteins = 142
Unique Peptides = 218

CONCLUSION

Thus, it will be appreciated that the compounds and methods described herein are used to identify proteins using mass spectrometry.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, molecules, and specific compounds described herein are presently representative of preferred embodiments and are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that the use of such terms and expressions indicates the exclusion of equivalents of the features shown and described or portions thereof. It is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in

the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.

WHAT IS CLAIMED IS:

1. A compound of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]_A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is selected from the group consisting of an amide bond of formula -(CH₂)B-C(O)-NR-, an amide bond of formula -(CH₂)B-NR-C(O)-, and an amino acid sequence comprising between 0 to 3 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 5 carbon atoms;

Ph is a phenyl group optionally substituted with one or more methoxy or nitro groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of Lys-ε-iodoacetamide, Arg-δ-iodoacetamide, and Orn-δ-iodoacetamide;


Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and


Protease Cleavage Site is an amino acid sequence of SEQ ID NO: 1 that is a cleavage site for TEV protease.

2. The compound of Claim 1, wherein said compound is selected from the group consisting of Acyl-NH-CASENLYFQGK-CH₂CH₂CH₂CH₂-NH-C(O)-CH₂I, Acyl-NH-CASENLYFQGO_{rn}-CH₂CH₂CH₂-NH-C(O)-CH₂I, Acyl-NH-CASENLYFQGPK-CH₂CH₂CH₂CH₂-NH-C(O)-CH₂I, and Acyl-NH-CASENLYFQGPO_{rn}-CH₂CH₂CH₂CH₂-NH-C(O)-CH₂I.

3. The compound of Claim 1, wherein said alk is a straight chain alkylene selected from the group consisting of methylene, ethylene, propylene, n-butylene, and n-pentylene.



4. The compound of Claim 1, wherein said Ph is
5. The compound of Claim 1, wherein said Z is a single amino acid.
6. The compound of Claim 5, wherein said Z is selected from the group consisting of glycine, alanine, and valine.
7. The compound of Claim 1, wherein said Z is a synthetic amino acid.
8. The compound of Claim 7, wherein said synthetic amino acid contains an amino group in a position selected from the group consisting of β , δ , ϵ , ϕ , or γ to the carboxyl group.
9. The compound of Claim 7, wherein said Z is γ -aminobutyric acid.
10. The compound of Claim 1, wherein said compound is selected from the group consisting of: Acyl-CH₂CH₂CH₂-O-Ph-CH₂-G-NH-C(O)-CH₂I, Acyl-CH₂CH₂CH₂-O-Ph-CH₂-A-NH-C(O)-CH₂I, Acyl-CH₂CH₂CH₂-O-Ph-CH₂- γ -aminobutyric acid-NH-C(O)-CH₂I, and Acyl-CH₂CH₂CH₂-O-Ph-CH₂-V-NH-C(O)-CH₂I,



where Ph is

11. A method for simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, comprising:

- a) preparing a first protein sample or a first peptide sample from the normal cells;
- b) reacting the first protein sample or the first peptide sample with a reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link

where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is selected from the group consisting of an amide bond of formula -(CH₂)B-C(O)-NR-, an amide bond of formula -(CH₂)B-NR-C(O)-, and an amino acid sequence comprising between 0 to 3 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 10 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of Lys-ε-iodoacetamide, Arg-δ-iodoacetamide, and Orn-δ-iodoacetamide;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is an amino acid sequence of SEQ ID NO: 1 that is a cleavage site for TEV protease;

c) preparing a second protein sample or a second peptide sample from the perturbed cells;

d) reacting the second protein sample or the second peptide sample of step c) with a second reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula $-C(O)-NR-$, a carbonyl of formula $-C(O)-$, and an amino acid sequence comprising between 0 to 10 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula $-C(O)-NR-$, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is selected from the group consisting of an amide bond of formula $-(CH_2)_B-C(O)-NR-$, an amide bond of formula $-(CH_2)_B-NR-C(O)-$, and an amino acid sequence comprising between 0 to 3 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 10 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the $-CH_2-$ group;

Link is selected from the group consisting of Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is an amino acid sequence of SEQ ID NO: 1 that is a cleavage site for TEV protease,

such that the molecular weight of the first reagent and the molecular weight of the second reagent are different by an integer multiple of 14 atomic mass units;

e) combining the reacted the first and the second protein samples or the reacted the first and the second peptide sample from steps b) and d);

f) subjecting the combined protein samples or the combined peptide samples from step e) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

g) subjecting the proteolyzed combined protein samples or the proteolyzed peptide samples from step f) to an affinity chromatography system comprising a second amino acid sequence attached to a solid, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

h) eluting the non-bound proteins from the affinity chromatography system;

i) subjecting the affinity chromatography system from step h) to a TEV protease, thereby forming a cleaved protein mixture;

j) eluting the cleaved protein mixture from the affinity chromatography system of step i);

k) isolating the eluted protein mixture obtained from step j);

l) subjecting the eluted protein mixture from step k) to chromatographic separation, followed by mass analysis;

m) comparing the results of step l) to:

(1) determining the ratio of amounts of compounds in the two samples, where the molecular weights thereof are separated by an integer multiple of 14 atomic mass units; and

(2) comparing the results obtained for each compound to protein databases containing chromatographic and molecular weight correlations.

12. A method for simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, comprising:

a) preparing a first protein sample or a first peptide sample from the normal cells;

b) reacting¹ the first protein sample or the first peptide sample with a reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link

where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is selected from the group consisting of an amide bond of formula -
(CH₂)_B-C(O)-NR-, an amide bond of formula -(CH₂)_B-NR-C(O)-, and an amino
acid sequence comprising between 0 to 3 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 10
carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron
withdrawing groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of Lys-ε-iodoacetamide, Arg-δ-
iodoacetamide, and Orn-δ-iodoacetamide;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag
Site can be the same or different; and

Protease Cleavage Site is an amino acid sequence of SEQ ID NO: 1 that is a
cleavage site for TEV protease;

c) preparing a second protein sample or a second peptide sample from
the perturbed cells;

d) reacting the second protein sample or the second peptide sample of
step c) with a second reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-
NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between
0 to 10 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower
alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is selected from the group consisting of an amide bond of formula -
(CH₂)_B-C(O)-NR-, an amide bond of formula -(CH₂)_B-NR-C(O)-, and an amino
acid sequence comprising between 0 to 3 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 10 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of Lys-ε-iodoacetamide, Arg-δ-iodoacetamide, and Orn-δ-iodoacetamide;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is an amino acid sequence of SEQ ID NO: 1 that is a cleavage site for TEV protease,

such that the molecular weight of the first reagent and the molecular weight of the second reagent are different by an integer multiple of 14 atomic mass units;

e) combining the reacted the first and the second protein samples or the reacted the first and the second peptide sample from steps b) and d);

f) subjecting the combined protein samples or the combined peptide samples from step e) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

g) subjecting the proteolyzed combined protein samples or the proteolyzed peptide samples from step f) to an affinity chromatography system comprising a second amino acid sequence attached to a solid, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

h) eluting the non-bound proteins from the affinity chromatography system;

i) subjecting the affinity chromatography system from step h) to TEV protease, thereby forming a cleaved protein mixture;

j) eluting the cleaved protein mixture from the affinity chromatography system of step i);

k) isolating the eluted protein mixture obtained from step j);

l) subjecting the eluted protein mixture from step k) to chromatographic separation, followed by mass analysis;

m) comparing the results of step l) to:

(1) determining the ratio of amounts of compounds in the two samples, where the molecular weights thereof are separated by an integer multiple of 14 atomic mass units; and

(2) comparing the results obtained for each compound to protein databases containing chromatographic and molecular weight correlations.

13. A method for simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, comprising:

a) preparing a first protein sample or a first peptide sample from the normal cells;

b) subjecting the first protein sample or the first peptide sample from step a) to proteolysis;

c) reacting the proteolyzed first protein sample or the proteolyzed first peptide sample with a reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is selected from the group consisting of an amide bond of formula -(CH₂)B-C(O)-NR-, an amide bond of formula -(CH₂)B-NR-C(O)-, and an amino acid sequence comprising between 0 to 3 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 10 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is an amino acid sequence of SEQ ID NO: 1 that is a cleavage site for TEV protease;

d) preparing a second protein sample or a second peptide sample from the perturbed cells;

e) subjecting the second protein sample or the second peptide sample from step d) to proteolysis;

f) reacting the proteolyzed second protein sample or the proteolyzed second peptide sample of step e) with a second reagent of Formula II or III:

(II) Acyl-NH-X-[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Link

(III) Acyl-NH-X-alk-O-Ph-CH₂-Z-Link where:

A is an integer from 0 to 12;

X is selected from the group consisting of an amide bond of formula -C(O)-NR-, a carbonyl of formula -C(O)-, and an amino acid sequence comprising between 0 to 10 amino acids, where R is hydrogen or lower alkyl;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is selected from the group consisting of an amide bond of formula -(CH₂)B-C(O)NR-, an amide bond of formula -(CH₂)B-NR-C(O)-, and an amino acid sequence comprising between 0 to 3 amino acids,

where R is hydrogen or lower alkyl, and

where B is an integer from 0 to 20;

alk is straight or branched chain of alkylene comprising between 0 and 10 carbon atoms;

Ph is a phenyl group optionally substituted with one or more electron withdrawing groups ortho or para to the -CH₂- group;

Link is selected from the group consisting of Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide;

Epitope Tag Site is a sequence of amino acids,

where when A is two or more, the amino acid sequence of each Epitope Tag Site can be the same or different; and

Protease Cleavage Site is an amino acid sequence of SEQ ID NO: 1 that is a cleavage site for TEV protease,

such that the molecular weight of the first reagent and the molecular weight of the second reagent are different by an integer multiple of 14 atomic mass units;

g) combining the reacted first and second protein samples or the reacted first and second peptide sample from steps c) and f);

h) subjecting the combined protein samples or the combined peptide samples from step e) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

i) subjecting the proteolyzed combined protein samples or the proteolyzed peptide samples from step f) to an affinity chromatography system comprising a second amino acid sequence attached to a solid, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

j) eluting the non-bound proteins from the affinity chromatography system;

k) subjecting the affinity chromatography system from step j) to TEV protease, thereby forming a cleaved protein mixture;

l) eluting the cleaved protein mixture from the affinity chromatography system of step k);

m) isolating the eluted protein mixture obtained from step l);

n) subjecting the eluted protein mixture from step m) to a two-dimensional liquid chromatographic separation, wherein said dimensions are selected from the group consisting of size differentiation, charge differentiation, hydrophobicity, hydrophilicity, and polarity, followed by a two-dimensional mass analysis;

o) comparing the results of step n) to:

(1) determining the ratio of amounts of compounds in the two samples, where the molecular weights thereof are separated by an integer multiple of 14 atomic mass units; and

(2) comparing the results obtained for each compound to protein databases containing chromatographic and molecular weight correlations;

wherein said Z substituent in the first reagent has a molecular weight that is an integer multiple of 14 atomic mass units different than the Z substituent in the second reagent.

14. The method of Claim 13, wherein said Link in step c) is Lys- ϵ -iodoacetamide, and said Link in step f) is Orn- δ -iodoacetamide.

15. The method of Claim 13, wherein said Link in step c) is Orn- δ -iodoacetamide, and said Link in step f) is Lys- ϵ -iodoacetamide.


16. The method of Claim 13, wherein said reagent of step c) or step f) reacts with the reactive side chain of one or more amino acid residues of a protein in the first or second protein sample;

wherein said amino acid residue is selected from the group consisting of tyrosine, cysteine, proline, and histidine.

17. The method of Claim 16 wherein said amino acid residue is a cysteine.

18. A method for proteomic analysis, comprising:

- a) preparing a protein sample or a peptide sample from cells;
- b) reacting the protein sample or the peptide sample with a reagent of the formula:



where:

A is an integer from 1 to 12;

X is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or X is an amino acid sequence comprising between 0 to 10 amino acids;

Y is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Y is an amino acid sequence comprising between 0 to 10 amino acids;

Z is an amide bond of formula -C(O)-NR-, where R is hydrogen or lower alkyl, or Z is an amino acid sequence comprising between 0 to 10 amino acids;

Link is selected from the group consisting of Lys- ϵ -iodoacetamide, Arg- δ -iodoacetamide, and Orn- δ -iodoacetamide;

Epitope Tag Site is a sequence of amino acids, and

Protease Cleavage Site is a sequence of amino acids that is a cleavage site for a highly specific protease enzyme;

c) subjecting the reacted proteins or peptides from step b) to proteolysis at a site on the protein samples or at a site on the peptide samples, the site being other than the Protease Cleavage Site;

d) subjecting the proteolyzed reacted proteins or the proteolyzed reacted peptides from step c) to an affinity chromatography system comprising a second amino acid sequence attached to a solid support, thereby forming bound proteins and non-bound proteins,

where the Epitope Tag Site of the reagent and the second amino acid sequence bind with high specificity to each other;

e) eluting the non-bound proteins from the affinity chromatography system;

f) subjecting the affinity chromatography system from step e) to TEV protease specific for the Protease Cleavage Site, thereby forming a cleaved protein mixture;

g) eluting the cleaved protein mixture from the affinity chromatography system of step f);

h) isolating the cleaved protein mixture obtained from step g);

i) subjecting the cleaved protein mixture from step h) to a two-dimensional chromatographic separation, wherein said dimensions of the multi-dimensional liquid chromatographic separation are selected from the group consisting of size differentiation, charge differentiation, hydrophobicity, hydrophilicity, and polarity, followed by a twodimensional mass analysis;

j) comparing the results of step i) to:

(1) determine the ratio of amounts of compounds in the sample separated by a molecular weight of 14 atomic mass units; and

(2) identify the various modified proteins by comparing the results obtained for each modified protein to protein databases containing chromatographic and molecular weight correlations.

19. The method of Claim 18, wherein said reagent reacts with the reactive side chain of one or more of the amino acid residues of the first or second protein;

wherein said amino acid residue is selected from the group consisting of tyrosine, cysteine, proline, and histidine.

20. The method of Claim 19, wherein said amino acid residue is a cysteine.

21. The method of any one of Claims 11-13, wherein said reacting steps are carried out in a condition that is essentially free of oxygen-dependent disulfide bond formation.

22. The method of Claims 21, wherein said reacting steps are carried out in an essentially oxygen free environment.

23. The method of Claims 21, wherein said reacting steps are carried out with a reagent that reduces oxygen-dependent disulfide formation.

1/9




FIG. 1

2/9

Mass Spectrum of PETag




FIG. 2A

3/9

PETag Sequencing by MS/MS







FIG. 2B



5/9




FIG. 4A




FIG. 4B

6/9

jw_1012bsa2282#698
RT: 29.49 AV. 1 NL:
2.19E8 T: + cESI Full
ms (600.00-2000.00)




FIG. 5A

jw_1012bsa2282#696
RT: 29.46 AV. 1 NL:
7.10E6 T: + c d Full
ms2 957.25@35.00
{250.00-1925.00}

FIG. 5B






FIG. 6


NL:
1.11E9
Base Peak
m/z =
155.0-
2000.0 MS
jw_1012bsa
mix



NL:
1.11E9
m/z =
1034.0-
1035.0 MS
jw_1012bsa
mix



NL:
9.75E8
m/z =
1027.0-
1028.0 MS
jw_1012bsa
mix



w_1012bsamlx#595 RT: 28.00 AV 1 NL 1.11E9
T: + c ESI Full ms (600.00-2000.00)




FIG. 8

SEQUENCE LISTING

<110> Paul Haynes
 Jing Wei
 John Yates
 Nancy Andon

<120> DIFFERENTIAL LABELING FOR QUANTITATIVE
 ANALYSIS OF COMPLEX PROTEIN MIXTURES

<130> NADII.022CP1

<140> Unassigned
 <141> 2002-08-01

<150> US 60/264,576
 <151> 2001-01-26

<150> US 60/305,232
 <151> 2001-07-13

<150> US 10/057,789
 <151> 2002-01-25

<160> 311

<170> FastSEQ for Windows Version 4.0

<210> 1
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 1
 Glu Asn Leu Tyr Phe Gln Gly
 1 5

<210> 2
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 2
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Lys

<210> 3
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 3
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Gly Lys
 20

<210> 4
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 4
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Ala Lys
 20

<210> 5
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 5
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Lys

<210> 6
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 6
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15

Gln Gly Val Lys
20

<210> 7
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<400> 7
Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
1 5 10 15
Gln Gly

<210> 8
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<400> 8
Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
1 5 10 15
Gln Gly Gly

<210> 9
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<400> 9
Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
1 5 10 15
Gln Gly Ala

<210> 10
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<400> 10
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Ala

<210> 11
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 11
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Val

<210> 12
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 12
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Arg

<210> 13
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 13
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Gly Arg
 20

<210> 14
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 14

Ala	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Glu	Asn	Leu	Tyr	Phe
1				5					10					15	
Gln	Gly	Ala	Arg												
			20												

<210> 15

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 15

Ala	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Glu	Asn	Leu	Tyr	Phe
1				5					10					15	
Gln	Gly	Arg													

<210> 16

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 16

Ala	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Glu	Asn	Leu	Tyr	Phe
1				5					10					15	
Gln	Gly	Val	Arg												
			20												

<210> 17

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 17

Ala	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Glu	Asn	Leu	Tyr	Phe
1				5					10					15	
Gln	Gly	Lys													

<210> 18

<211> 20

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 18
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Gly Lys
 20

<210> 19
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 19
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Ala Lys
 20

<210> 20
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 20
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Lys

<210> 21
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 21
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Val Lys
 20

<210> 22
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 22
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Arg

<210> 23
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 23
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Gly Arg
 20

<210> 24
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 24
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Ala Arg
 20

<210> 25
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 25
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15

Gln Gly Arg

<210> 26
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 26
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Val Arg
 20

<210> 27
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 27
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly

<210> 28
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 28
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Gly

<210> 29
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 29

Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Ala

<210> 30

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 30

Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly

<210> 31

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 31

Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Val

<210> 32

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 32

Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Pro
 1 5 10 15
 Gln Gly Lys

<210> 33

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 33

Ala	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Glu	Asn	Leu	Tyr	Pro
1				5					10					15	
Gln	Gly														

<210> 34

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 34

Ala	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Glu	Asn	Leu	Tyr	Pro
1				5					10					15	
Gln	Gly														

<210> 35

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 35

Ala	Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Ser	Glu	Asn	Leu	Tyr	Pro
1				5					10					15	
Gln	Gly	Lys													

<210> 36

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 36

Tyr	Pro	Tyr	Asp	Val	Pro	Asp	Tyr	Ala	Glu	Asn	Leu	Tyr	Phe	Gln	Gly
1				5					10					15	

<210> 37

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 37

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Glu Asn Leu Tyr Phe Gln Gly
 1 5 10 15

<210> 38

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 38

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 1 5

<210> 39

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<400> 39

Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Lys

<210> 40

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> VARIANT

<222> 19

<223> Xaa = Ornithine

<223> Synthesized Peptide

<400> 40

Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Glu Asn Leu Tyr Phe
 1 5 10 15
 Gln Gly Xaa

<210> 41

<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<400> 41
Cys Ala Ser Glu Asn Leu Tyr Phe Gln Gly Lys
1 5 10

<210> 42
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<221> VARIANT
<222> 11
<223> Xaa = Ornithine

<400> 42
Cys Ala Ser Glu Asn Leu Tyr Phe Gln Gly Xaa
1 5 10

<210> 43
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<400> 43
Cys Ala Ser Glu Asn Leu Tyr Phe Gln Gly Pro Lys
1 5 10

<210> 44
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized Peptide

<221> VARIANT
<222> 12
<223> Xaa = Ornithine

<400> 44
Cys Ala Ser Glu Asn Leu Tyr Phe Gln Gly Pro Xaa
1 5 10

<210> 45
 <211> 607
 <212> PRT
 <213> bovine serum albumin

<400> 45
 Met Lys Trp Val Thr Phe Ile Ser Leu Leu Leu Leu Phe Ser Ser Ala
 1 5 10 15
 Tyr Ser Arg Gly Val Phe Arg Arg Asp Thr His Lys Ser Glu Ile Ala
 20 25 30
 His Arg Phe Lys Asp Leu Gly Glu Glu His Phe Lys Gly Leu Val Leu
 35 40 45
 Ile Ala Phe Ser Gln Tyr Leu Gln Gln Cys Pro Phe Asp Glu His Val
 50 55 60
 Lys Leu Val Asn Glu Leu Thr Glu Phe Ala Lys Thr Cys Val Ala Asp
 65 70 75 80
 Glu Ser His Ala Gly Cys Glu Lys Ser Leu His Thr Leu Phe Gly Asp
 85 90 95
 Glu Leu Cys Lys Val Ala Ser Leu Arg Glu Thr Tyr Gly Asp Met Ala
 100 105 110
 Asp Cys Cys Glu Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Ser
 115 120 125
 His Lys Asp Asp Ser Pro Asp Leu Pro Lys Leu Lys Pro Asp Pro Asn
 130 135 140
 Thr Leu Cys Asp Glu Phe Lys Ala Asp Glu Lys Lys Phe Trp Gly Lys
 145 150 155 160
 Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu
 165 170 175
 Leu Leu Tyr Tyr Ala Asn Lys Tyr Asn Gly Val Phe Gln Glu Cys Cys
 180 185 190
 Gln Ala Glu Asp Lys Gly Ala Cys Leu Leu Pro Lys Ile Glu Thr Met
 195 200 205
 Arg Glu Lys Val Leu Ala Ser Ser Ala Arg Gln Arg Leu Arg Cys Ala
 210 215 220
 Ser Ile Gln Lys Phe Gly Glu Arg Ala Leu Lys Ala Trp Ser Val Ala
 225 230 235 240
 Arg Leu Ser Gln Lys Phe Pro Lys Ala Glu Phe Val Glu Val Thr Lys
 245 250 255
 Leu Val Thr Asp Leu Thr Lys Val His Lys Glu Cys Cys His Gly Asp
 260 265 270
 Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys
 275 280 285
 Asp Asn Gln Asp Thr Ile Ser Ser Lys Leu Lys Glu Cys Cys Asp Lys
 290 295 300
 Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Lys Asp Ala
 305 310 315 320
 Ile Pro Glu Asn Leu Pro Pro Leu Thr Ala Asp Phe Ala Glu Asp Lys
 325 330 335
 Asp Val Cys Lys Asn Tyr Gln Glu Ala Lys Asp Ala Phe Leu Gly Ser
 340 345 350
 Phe Leu Tyr Glu Tyr Ser Arg Arg His Pro Glu Tyr Ala Val Ser Val
 355 360 365
 Leu Leu Arg Leu Ala Lys Glu Tyr Glu Ala Thr Leu Glu Glu Cys Cys
 370 375 380
 Ala Lys Asp Asp Pro His Ala Cys Tyr Ser Thr Val Phe Asp Lys Leu

```

385          390          395          400
Lys His Leu Val Asp Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Asp
          405          410          415
Gln Phe Glu Lys Leu Gly Glu Tyr Gly Phe Gln Asn Ala Leu Ile Val
          420          425          430
Arg Tyr Thr Arg Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu
          435          440          445
Val Ser Arg Ser Leu Gly Lys Val Gly Thr Arg Cys Cys Thr Lys Pro
          450          455          460
Glu Ser Glu Arg Met Pro Cys Thr Glu Asp Tyr Leu Ser Leu Ile Leu
465          470          475          480
Asn Arg Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Glu Lys Val
          485          490          495
Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser
          500          505          510
Ala Leu Thr Pro Asp Glu Thr Tyr Val Pro Lys Ala Phe Asp Glu Lys
          515          520          525
Leu Phe Thr Phe His Ala Asp Ile Cys Thr Leu Pro Asp Thr Glu Lys
530          535          540
Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Leu Lys His Lys Pro
545          550          555          560
Lys Ala Thr Glu Glu Gln Leu Lys Thr Val Met Glu Asn Phe Val Ala
          565          570          575
Phe Val Asp Lys Cys Cys Ala Ala Asp Asp Lys Glu Ala Cys Phe Ala
          580          585          590
Val Glu Gly Pro Lys Leu Val Val Ser Thr Gln Thr Ala Leu Ala
595          600          605

```

```

<210> 46
<211> 12
<212> PRT
<213> Artificial Sequence

```

```

<220>
<221> VARIANT
<222> 11
<223> Xaa = Peptag-modified Cysteine Residue

<223> Synthesized Peptide

```

```

<400> 46
Ser Leu His Thr Leu Phe Gly Asp Glu Leu Xaa Lys
 1              5              10

```

```

<210> 47
<211> 12
<212> PRT
<213> Artificial Sequence

```

```

<220>
<221> VARIANT
<222> 3
<223> Xaa = Peptag-modified Cysteine Residue

<223> Synthesized Peptide

```

<400> 47

Tyr Ile Xaa Asp Asn Gln Asp Thr Ile Ser Ser Lys
 1 5 10

<210> 48

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<221> VARIANT

<222> 9

<223> Xaa = Peptag-modified Cysteine Residue

<400> 48

Leu Lys Pro Asp Pro Asn Thr Leu Xaa Asp Glu Phe Lys
 1 5 10

<210> 49

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<221> VARIANT

<222> 1

<223> Xaa = Peptag-modified Cysteine Residue

<400> 49

Xaa Phe Ser Ala Leu Thr Pro Asp Glu Thr Tyr Val Pro Lys
 1 5 10

<210> 50

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<221> VARIANT

<222> 3

<223> Xaa = Peptag-modified Cysteine Residue

<400> 50

Met Pro Xaa Thr Glu Asp Tyr Leu Ser Leu Ile Leu Asn Arg
 1 5 10

<210> 51
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<221> VARIANT
 <222> 3
 <223> Xaa = Peptag-modified Cysteine Residue

<400> 51
 Arg Pro Xaa Phe Ser Ala Leu Thr Pro Asp Glu Thr Tyr Val Pro Lys
 1 5 10 15

<210> 52
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<221> VARIANT
 <222> 3
 <223> Xaa = Peptag-modified Cysteine Residue.

<400> 52
 Asn Glu Xaa Phe Leu Ser His Lys Asp Asp Ser Pro Asp Leu Pro Lys
 1 5 10 15

<210> 53
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<221> VARIANT
 <222> 9
 <223> Xaa = Peptag-modified Cysteine Residue

<400> 53
 Leu Phe Thr Phe His Ala Asp Ile Xaa Thr Leu Pro Asp Thr Glu Lys
 1 5 10 15

<210> 54
 <211> 21
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthesized Peptide

<221> VARIANT

<222> 8

<223> Xaa = Peptag-modified Cysteine Residue

<400> 54

Gln Glu Pro Glu Arg Asn Glu Xaa Phe Leu Ser His Lys Asp Asp Ser
 1 5 10 15
 Pro Asp Leu Pro Lys
 20

<210> 55

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized Peptide

<221> VARIANT

<222> 11

<223> Xaa = Peptag-modified Cysteine Residue

<400> 55

Cys Thr Lys Pro Glu Ser Glu Arg Met Pro Xaa Thr Glu Asp Tyr Leu
 1 5 10 15
 Ser Leu Ile Leu Asn Arg
 20

<210> 56

<211> 12

<212> PRT

<213> Bovine serum albumin

<220>

<221> VARIANT

<222> 11

<223> Xaa = Peptag-modified Cysteine Residue

<400> 56

Ser Leu His Thr Leu Phe Gly Asp Glu Leu Xaa Lys
 1 5 10

<210> 57

<211> 21

<212> PRT

<213> Bovine serum albumin

<220>

<221> VARIANT

<222> 14

<223> Xaa = Peptag-modified Cysteine Residue

<400> 57

Gly Leu Val Leu Ile Ala Phe Ser Gln Tyr Leu Gln Gln Xaa Pro Phe
 1 5 10 15
 Asp Glu His Val Lys
 20

<210> 58

<211> 31

<212> PRT

<213> Bovine serum albumin

<220>

<221> VARIANT

<222> 14

<223> Xaa = Peptag-modified Cysteine Residue

<400> 58

Gly Leu Val Leu Ile Ala Phe Ser Gln Tyr Leu Gln Gln Xaa Pro Phe
 1 5 10 15
 Asp Glu His Val Lys Leu Val Asn Glu Leu Thr Glu Phe Ala Lys
 20 25 30

<210> 59

<211> 31

<212> PRT

<213> Beta-lactoglobulin

<220>

<221> VARIANT

<222> 27

<223> Xaa = Peptag-modified Cysteine Residue

<400> 59

Val Tyr Val Glu Glu Leu Lys Pro Thr Pro Glu Gly Asp Gly Leu Glu
 1 5 10 15
 Ile Leu Leu Gln Lys Trp Glu Asn Asp Glu Xaa Ala Gln Lys Lys
 20 25 30

<210> 60

<211> 14

<212> PRT

<213> Beta-lactoglobulin

<220>

<221> VARIANT

<222> 12

<223> Xaa = Peptag-modified Cysteine Residue

<400> 60

Leu Ser Phe Asn Pro Thr Gln Leu Glu Glu Gln Xaa His Ile
 1 5 10

<210> 61

<211> 20
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Synthesized Peptide

 <400> 61
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Glu Val Leu Phe
 1 5 10 15
 Gln Gly Pro Lys
 20

<210> 62
 <211> 20
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Synthesized Peptide

 <221> VARIANT
 <222> 20
 <223> Xaa = Ornithine

<400> 62
 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Glu Val Leu Phe
 1 5 10 15
 Gln Gly Pro Xaa
 20

<210> 63
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<400> 63
 Cys Ala Ser Ala Ser Leu Glu Val Leu Phe Gln Gly Pro Lys
 1 5 10

<210> 64
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized Peptide

<221> VARIANT
 <222> 14
 <223> Xaa = Ornithine

<400> 64

Cys Ala Ser Ala Ser Leu Glu Val Leu Phe Gln Gly Pro Xaa
 1 5 10

<210> 65

<211> 9

<212> PRT

<213> Borus torus

<220>

<221> VARIANT

<222> 2

<223> Xaa = Modified Cysteine

<400> 65

Cys Xaa Thr Glu Ser Leu Val Asn Arg
 1 5

<210> 66

<211> 22

<212> PRT

<213> Borus torus

<220>

<221> VARIANT

<222> 21

<223> Xaa = Modified Cysteine

<400> 66

Asp Ala Ile Pro Glu Asn Leu Pro Pro Leu Thr Ala Asp Phe Ala Glu
 1 5 10 15
 Asp Lys Asp Val Xaa Lys
 20

<210> 67

<211> 12

<212> PRT

<213> Borus torus

<220>

<221> VARIANT

<222> 10

<223> Xaa = Modified Cysteine

<400> 67

Glu Tyr Glu Ala Thr Leu Glu Glu Cys Xaa Ala Lys
 1 5 10

<210> 68

<211> 25

<212> PRT

<213> Borus torus

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

 <400> 68
 Glu Tyr Glu Ala Thr Leu Glu Glu Cys Xaa Ala Lys Asp Asp Pro His
 1 5 10 15
 Ala Cys Tyr Ser Thr Val Phe Asp Lys
 20 25

<210> 69
 <211> 16
 <212> PRT
 <213> Borus torus

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

 <400> 69
 Leu Phe Thr Phe His Ala Asp Ile Xaa Thr Leu Pro Asp Thr Glu Lys
 1 5 10 15

<210> 70
 <211> 12
 <212> PRT
 <213> Borus torus

<220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Modified Cysteine

 <400> 70
 Leu Lys Glu Xaa Cys Asp Lys Pro Leu Leu Glu Lys
 1 5 10

<210> 71
 <211> 13
 <212> PRT
 <213> Borus torus

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

 <400> 71
 Leu Lys Pro Asp Pro Asn Thr Leu Xaa Asp Glu Phe Lys
 1 5 10

<210> 72
 <211> 14
 <212> PRT
 <213> Borus torus

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Oxidized Methionine

<221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 72
 Xaa Pro Xaa Thr Glu Asp Tyr Leu Ser Leu Ile Leu Asn Arg
 1 5 10

<210> 73
 <211> 14
 <212> PRT
 <213> Borus torus

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 73
 Met Pro Xaa Thr Glu Asp Tyr Leu Ser Leu Ile Leu Asn Arg
 1 5 10

<210> 74
 <211> 16
 <212> PRT
 <213> Borus torus

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 74
 Asn Glu Xaa Phe Leu Ser His Lys Asp Asp Ser Pro Asp Leu Pro Lys
 1 5 10 15

<210> 75
 <211> 16
 <212> PRT
 <213> Borus torus

<220>
 <221> VARIANT

<222> 3

<223> Xaa = Modified Cysteine

<400> 75

Arg Pro Xaa Phe Ser Ala Leu Thr Pro Asp Glu Thr Tyr Val Pro Lys
1 5 10 15

<210> 76

<211> 9

<212> PRT

<213> Borus torus

<220>

<221> VARIANT

<222> 3

<223> Xaa = Modified Cysteine

<400> 76

Ser His Xaa Ile Ala Glu Val Glu Lys
1 5

<210> 77

<211> 12

<212> PRT

<213> Borus torus

<220>

<221> VARIANT

<222> 11

<223> Xaa = Modified Cysteine

<400> 77

Ser Leu His Thr Leu Phe Gly Asp Glu Leu Xaa Lys
1 5 10

<210> 78

<211> 12

<212> PRT

<213> Borus torus

<220>

<221> VARIANT

<222> 3

<223> Xaa = Modified Cysteine

<400> 78

Tyr Ile Xaa Asp Asn Gln Asp Thr Ile Ser Ser Lys
1 5 10

<210> 79

<211> 14

<212> PRT

<213> Borus torus

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 79
 Tyr Asn Gly Val Phe Gln Glu Cys Xaa Gln Ala Glu Asp Lys
 1 5 10

<210> 80
 <211> 23
 <212> PRT
 <213> Eschericia coli

<220>
 <221> VARIANT
 <222> 18
 <223> Xaa = Modified Cysteine

<400> 80
 Ala Val Val Glu Leu His Thr Ala Asp Gly Thr Leu Ile Glu Ala Glu
 1 5 10 15
 Ala Xaa Asp Val Gly Phe Arg
 20

<210> 81
 <211> 13
 <212> PRT
 <213> Eschericia coli

<220>
 <221> VARIANT
 <222> 5
 <223> Xaa = Modified Cysteine

<400> 81
 Ile Gly Leu Asn Xaa Gln Leu Ala Gln Val Ala Glu Arg
 1 5 10

<210> 82
 <211> 26
 <212> PRT
 <213> Eschericia coli

<220>
 <221> VARIANT
 <222> 21
 <223> Xaa = Modified Cysteine

<221> VARIANT
 <222> 23
 <223> Xaa = Oxidized Methionine

<400> 82
 Pro Ser Arg Pro Val Gln Tyr Glu Gly Gly Gly Ala Asp Thr Thr Ala
 1 5 10 15
 Thr Asp Ile Ile Xaa Pro Xaa Tyr Ala Arg
 20 25

<210> 83
 <211> 26
 <212> PRT
 <213> Eschericia coli

<220>
 <221> VARIANT
 <222> 21
 <223> Xaa = Modified Cysteine

<400> 83
 Pro Ser Arg Pro Val Gln Tyr Glu Gly Gly Gly Ala Asp Thr Thr Ala
 1 5 10 15
 Thr Asp Ile Ile Xaa Pro Met Tyr Ala Arg
 20 25

<210> 84
 <211> 23
 <212> PRT
 <213> Eschericia coli

<220>
 <221> VARIANT
 <222> 18
 <223> Xaa = Modified Cysteine

<400> 84
 Pro Val Gln Tyr Glu Gly Gly Gly Ala Asp Thr Thr Ala Thr Asp Ile
 1 5 10 15
 Ile Xaa Pro Met Tyr Ala Arg
 20

<210> 85
 <211> 29
 <212> PRT
 <213> Eschericia coli

<220>
 <221> VARIANT
 <222> 24
 <223> Xaa = Modified Cysteine

<221> VARIANT
 <222> 26
 <223> Xaa = Oxidized Methionine

<400> 85
 Ser Val Asp Pro Ser Arg Pro Val Gln Tyr Glu Gly Gly Gly Ala Asp

1 5 10 15
 Thr Thr Ala Thr Asp Ile Ile Xaa Pro Xaa Tyr Ala Arg
 20 25

<210> 86
 <211> 29
 <212> PRT
 <213> Eschericia coli

<220>
 <221> VARIANT
 <222> 24
 <223> Xaa = Modified Cysteine

<400> 86
 Ser Val Asp Pro Ser Arg Pro Val Gln Tyr Glu Gly Gly Gly Ala Asp
 1 5 10 15
 Thr Thr Ala Thr Asp Ile Ile Xaa Pro Met Tyr Ala Arg
 20 25

<210> 87
 <211> 17
 <212> PRT
 <213> Oryctolagus cuniculus

<220>
 <221> VARIANT
 <222> 7
 <223> Xaa = Modified Cysteine

<400> 87
 Ile Val Ser Asn Ala Ser Xaa Thr Thr Asn Cys Leu Ala Pro Leu Ala
 1 5 10 15
 Lys

<210> 88
 <211> 17
 <212> PRT
 <213> Oryctolagus cuniculus

<220>
 <221> VARIANT
 <222> 11
 <223> Xaa = Modified Cysteine

<400> 88
 Ile Val Ser Asn Ala Ser Cys Thr Thr Asn Xaa Leu Ala Pro Leu Ala
 1 5 10 15
 Lys

<210> 89

<211> 14
 <212> PRT
 <213> *Oryctolagus cuniculus*

<220>
 <221> VARIANT
 <222> 13
 <223> Xaa = Modified Cysteine

<400> 89
 Val Pro Thr Pro Asn Val Ser Val Val Asp Leu Thr Xaa Arg
 1 5 10

<210> 90
 <211> 14
 <212> PRT
 <213> *Bos torus*

<220>
 <221> VARIANT
 <222> 12
 <223> Xaa = Modified Cysteine

<400> 90
 Leu Ser Phe Asn Pro Thr Gln Leu Glu Glu Gln Xaa His Ile
 1 5 10

<210> 91
 <211> 17
 <212> PRT
 <213> *Bos torus*

<220>
 <221> VARIANT
 <222> 11
 <223> Xaa = Modified Cysteine

<400> 91
 Asp Asp Gln Asn Pro His Ser Ser Asn Ile Xaa Asn Ile Ser Cys Asp
 1 5 10 15
 Lys

<210> 92
 <211> 17
 <212> PRT
 <213> *Bos torus*

<220>
 <221> VARIANT
 <222> 15
 <223> Xaa = Modified Cysteine

<400> 92

Asp Asp Gln Asn Pro His Ser Ser Asn Ile Cys Asn Ile Ser Xaa Asp
 1 5 10 15
 Lys

<210> 93
 <211> 14
 <212> PRT
 <213> Bos torus

<220>
 <221> VARIANT
 <222> 11
 <223> Xaa = Oxidized Methionine

<221> VARIANT
 <222> 12
 <223> Xaa = Modified Cysteine

<400> 93
 Phe Leu Asp Asp Leu Thr Asp Asp Ile Xaa Xaa Val Lys
 1 5 10

<210> 94
 <211> 14
 <212> PRT
 <213> Bos torus

<220>
 <221> VARIANT
 <222> 12
 <223> Xaa = Modified Cysteine

<400> 94
 Phe Leu Asp Asp Leu Thr Asp Asp Ile Met Xaa Val Lys
 1 5 10

<210> 95
 <211> 8
 <212> PRT
 <213> Bos torus

<220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

<400> 95
 Leu Asp Gln Trp Leu Xaa Glu Lys
 1 5

<210> 96
 <211> 23

```

<212> PRT
<213> Bos torus

<220>
<221> VARIANT
<222> 21
<223> Xaa = Modified Cysteine

<400> 96
Asn Ile Cys Asn Ile Ser Cys Asp Lys Phe Leu Asp Asp Asp Leu Thr
 1           5           10           15
Asp Asp Ile Met Xaa Val Lys
          20

<210> 97
<211> 11
<212> PRT
<213> Bos torus

<220>
<221> VARIANT
<222> 5
<223> Xaa = Modified Cysteine

<400> 97
Ser Ser Asn Ile Xaa Asn Ile Ser Cys Asp Lys
 1           5           10

<210> 98
<211> 10
<212> PRT
<213> Gallus gallus

<220>
<221> VARIANT
<222> 8
<223> Xaa = Modified Cysteine

<400> 98
Ala Asp His Pro Phe Leu Phe Xaa Ile Lys
 1           5           10

<210> 99
<211> 12
<212> PRT
<213> Gallus gallus

<220>
<221> VARIANT
<222> 10
<223> Xaa = Modified Cysteine

<400> 99
Tyr Pro Ile Leu Pro Glu Tyr Leu Gln Xaa Val Lys

```

1 5 10

```
<210> 100
<211> 34
<212> PRT
<213> Saccharomyces cerevisiae
```

```
<220>
<221> VARIANT
<222> 1
<223> Xaa = Modified Cysteine
```

```

<400> 100
Xaa Val Val Glu Asp Asp Lys Val Ser Leu Asp Asp Leu Gln Gln Ser
  1          5          10          15
Ile Glu Glu Asp Glu Asp His Val Gln Ser Thr Asp Ile Ala Ala Met
          20          25          30
Gln Lys

```

```
<210> 101
<211> 15
<212> PRT
<213> Saccharomyces cerevisiae
```

```
<220>
<221> VARIANT
<222> 12
<223> Xaa = Modified Cysteine
```

```
<400> 101
Ala Val Gly Ile Asp Leu Gly Thr Thr Tyr Ser Xaa Val Ala His
  1                      5                      10                     15
```

```
<210> 102
<211> 20
<212> PRT
<213> Saccharomyces cerevisiae
```

```
<220>
<221> VARIANT
<222> 12
<223> Xaa = Modified Cysteine
```

```

<400> 102
Ala Val Gly Ile Asp Leu Gly Thr Thr Tyr Ser Xaa Val Ala His Phe
 1             5             10             15
Ala Asn Asp Arg
      20

```

```
<210> 103
<211> 10
<212> PRT
```

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine

<400> 103

Phe Glu Glu Leu Xaa Ala Asp Leu Phe Arg
1 5 10

<210> 104

<211> 25

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 16

<223> Xaa = Modified Cysteine

<400> 104

Ala Glu Val Ser Asp Val Gly Asn Ala Ile Leu Asp Gly Ala Asp Xaa
1 5 10 15
Val Met Leu Ser Gly Glu Thr Ala Lys
20 25

<210> 105

<211> 19

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 10

<223> Xaa = Modified Cysteine

<400> 105

Gly Asn Ala Ile Leu Asp Gly Ala Asp Xaa Val Met Leu Ser Gly Glu
1 5 10 15
Thr Ala Lys

<210> 106

<211> 25

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 2

<223> Xaa = Modified Cysteine

<400> 106

Asn Xaa Thr Pro Lys Pro Thr Ser Thr Thr Glu Thr Val Ala Ala Ser
 1 5 10 15
 Ala Val Ala Ala Val Phe Glu Gln Lys
 20 25

<210> 107
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> A
 <223> Xaa = Modified Cysteine

<400> 107
 Pro Val Ile Xaa Ala Thr Gln Met Leu Glu Ser Met Thr Tyr Asn Pro
 1 5 10 15
 Arg

<210> 108
 <211> 23
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<221> VARIANT
 <222> 18
 <223> Xaa = Oxidized Methionine

<400> 108
 Ser Asn Leu Ala Gly Lys Pro Val Ile Xaa Ala Thr Gln Met Leu Glu
 1 5 10 15
 Ser Xaa Thr Tyr Asn Pro Arg
 20

<210> 109
 <211> 23
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 109
 Ser Asn Leu Ala Gly Lys Pro Val Ile Xaa Ala Thr Gln Met Leu Glu
 1 5 10 15

Ser Met Thr Tyr Asn Pro Arg
20

<210> 110
<211> 12
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> VARIANT
<222> 5
<223> Xaa = Modified Cysteine

<400> 110
Tyr Arg Pro Asn Xaa Pro Ile Ile Leu Val Thr Arg
1 5 10

<210> 111
<211> 22
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> VARIANT
<222> 6
<223> Xaa = Modified Cysteine

<400> 111
Leu Val Tyr Ser Thr Xaa Ser Leu Asn Pro Ile Glu Asn Glu Ala Val
1 5 10 15
Val Ala Glu Ala Leu Arg
20

<210> 112
<211> 15
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> VARIANT
<222> 13
<223> Xaa = Modified Cysteine

<400> 112
Leu Pro Asn Gln Thr Leu Gly Glu Ile Trp Ala Leu Xaa Asp Arg
1 5 10 15

<210> 113
<211> 16
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 1

<223> Xaa = Modified Cysteine

<400> 113

Xaa Asp Gly Tyr Ile Leu Glu Gly Glu Glu Leu Ala Phe Tyr Ileu Arg
1 5 10 15

<210> 114

<211> 20

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 12

<223> Xaa = Modified Cysteine

<400> 114

Ala Val Gly Ile Asp Leu Gly Thr Thr Tyr Ser Xaa Val Ala His Phe
1 5 10 15
Ser Asn Asp Arg
20

<210> 115

<211> 20

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 11

<223> Xaa = Oxidized Methionine

<221> VARIANT

<222> 13

<223> Xaa = Modified Cysteine

<400> 115

Ile Ser Leu Gly Leu Pro Val Gly Ala Ile Xaa Asn Xaa Ala Asp Asn
1 5 10 15
Ser Gly Ala Arg
20

<210> 116

<211> 20

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 13

<223> Xaa = Modified Cysteine

<400> 116
 Ile Ser Leu Gly Leu Pro Val Gly Ala Ile Met Asn Xaa Ala Asp Asn
 1 5 10 15
 Ser Gly Ala Arg
 20

<210> 117
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 117
 Pro Val Gly Ala Ile Met Asn Xaa Ala Asp Asn Ser Gly Ala Arg
 1 5 10 15

<210> 118
 <211> 20
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 118
 Xaa Pro Leu Gly Asn Pro Ala Asn Tyr Pro Phe Ala Thr Ile Asp Pro
 1 5 10 15
 Glu Glu Ala Arg
 20

<210> 119
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 119
 Leu Asp Leu Ile Ser Phe Phe Thr Xaa Gly Pro Asp Glu Val Arg
 1 5 10 15

<210> 120
 <211> 11
 <212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 2

<223> Xaa = Modified Cysteine

<400> 120

Pro Xaa Ile Tyr Leu Ile Asn Leu Ser Glu Arg
1 5 10

<210> 121

<211> 10

<212> PRT

<213> *Saccharomyces cerevisiae*

<400> 121

Ser Val Asp Ser Ile Tyr Gln Val Val Arg
1 5 10

<210> 122

<211> 11

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 10

<223> Xaa = Modified Cysteine

<400> 122

Ser Gly Gln Gly Ala Phe Gly Asn Met Xaa Arg
1 5 10

<210> 123

<211> 10

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 1

<223> Xaa = Modified Cysteine

<400> 123

Xaa Pro Phe Thr Gly Leu Val Ser Ile Arg
1 5 10

<210> 124

<211> 13

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 12
 <223> Xaa = Modified Cysteine

 <400> 124
 Val Gln Val Gly Asp Ile Val Thr Val Gly Gln Xaa Arg
 1 5 10

 <210> 125
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 12
 <223> Xaa = Modified Cysteine

 <400> 125
 Val Gln Val Gly Asp Ile Val Thr Val Gly Gln Xaa Arg Pro Ile Ser
 1 5 10 15
 Lys

 <210> 126
 <211> 26
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 22
 <223> Xaa = Modified Cysteine

 <400> 126
 Ala Thr Val Ile Val Leu Asn His Pro Gly Gln Ile Ser Ala Gly Tyr
 1 5 10 15
 Ser Pro Val Leu Asp Xaa His Thr Ala His
 20 25

 <210> 127
 <211> 13
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

 <400> 127
 Xaa Val Glu Ala Phe Ser Glu Tyr Pro Pro Leu Gly Arg
 1 5 10

<210> 128
 <211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 23
 <223> Xaa = Modified Cysteine

<400> 128
 Asn Ala Thr Val Ile Val Leu Asn His Pro Gly Gln Ile Ser Ala Gly
 1 5 10 15
 Tyr Ser Pro Val Leu Asp Xaa His Thr Ala His
 20 25

<210> 129
 <211> 29
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Oxidized Methionine

<221> VARIANT
 <222> 11
 <223> Xaa = Modified Cysteine

<400> 129
 Asn Xaa Ile Thr Gly Thr Ser Gln Ala Asp Xaa Ala Ile Leu Ile Ile
 1 5 10 15
 Ala Gly Gly Val Gly Glu Phe Glu Ala Gly Ile Ser Lys
 20 25

<210> 130
 <211> 29
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 11
 <223> Xaa = Modified Cysteine

<400> 130
 Asn Met Ile Thr Gly Thr Ser Gln Ala Asp Xaa Ala Ile Leu Ile Ile
 1 5 10 15
 Ala Gly Gly Val Gly Glu Phe Glu Ala Gly Ile Ser Lys
 20 25

<210> 131
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 131
 Pro Met Xaa Val Glu Ala Phe Ser Glu Tyr Pro Pro Leu Gly Arg
 1 5 10 15

<210> 132
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

<400> 132
 Pro Ser Lys Pro Met Xaa Val Glu Ala Phe Ser Glu Tyr Pro Pro Leu
 1 5 10 15
 Gly Arg

<210> 133
 <211> 20
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 19
 <223> Xaa = Modified Cysteine

<400> 133
 Ile Pro Ile Phe Ser Ala Ser Gly Leu Pro His Asn Glu Ile Ala Ala
 1 5 10 15
 Gln Ile Xaa Arg
 20

<210> 134
 <211> 14
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 6

<223> Xaa = Modified Cysteine

<400> 134

Gly Ala Ala Phe Ile Xaa Ala Ile His Ser Pro Thr Leu Arg
1 5 10

<210> 135

<211> 10

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine

<400> 135

Gly Asn Glu His Xaa Phe Val Ile Leu Arg
1 5 10

<210> 136

<211> 28

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 14

<223> Xaa = Modified Cysteine

<221> VARIANT

<222> 24

<223> Xaa = Oxidized Methionine

<400> 136

Asn Gly Thr Asp Gly Thr Leu Asn Val Ala Val Asp Ala Xaa Gln Ala
1 5 10 15
Ala Ala His Ser His His Phe Xaa Gly Val Thr Lys
20 25

<210> 137

<211> 28

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 14

<223> Xaa = Modified Cysteine

<400> 137

Asn Gly Thr Asp Gly Thr Leu Asn Val Ala Val Asp Ala Xaa Gln Ala
1 5 10 15
Ala Ala His Ser His His Phe Met Gly Val Thr Lys

20

25

<210> 138
 <211> 22
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 138
 Val Leu Val Ile Val Gly Pro Xaa Ser Ile His Asp Leu Glu Ala Ala
 1 5 10 15
 Gln Glu Tyr Ala Leu Arg
 20

<210> 139
 <211> 37
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

<400> 139
 Val Asn Asp Val Val Xaa Glu Gln Ile Ala Asn Gly Glu Asn Ala Ile
 1 5 10 15
 Thr Gly Val Met Ile Glu Ser Asn Ile Asn Glu Gly Asn Gln Gly Ile
 20 25 30
 Pro Ala Glu Gly Lys
 35

<210> 140
 <211> 20
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 140
 Tyr Gly Val Ser Ile Thr Asp Ala Xaa Ile Gly Trp Glu Thr Thr Glu
 1 5 10 15
 Asp Val Leu Arg
 20

<210> 141

<211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

 <400> 141
 Glu Ile Ser Gln Gly Xaa Gly Ala Tyr Leu Met Ser Asp Met Ala His
 1 5 10 15

 <210> 142
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Any Amino Acid

 <400> 142
 Leu Val Glu Pro Phe Gly Val Leu Glu Xaa Ala Arg
 1 5 10

 <210> 143
 <211> 23
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 21
 <223> Xaa = Modified Cysteine

 <400> 143
 Phe His Ala Ala Gln Leu Pro Thr Glu Thr Leu Glu Val Glu Thr Gln
 1 5 10 15
 Pro Gly Val Leu Xaa Ser Arg
 20

 <210> 144
 <211> 8
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Any Amino AcidXaa = Modified Cysteine

 <400> 144

Asp His Xaa Ile Val Val Gly Arg
1 5

<210> 145
<211> 20
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> VARIANT
<222> 8
<223> Xaa = Modified Cysteine

<400> 145
Met Leu Ile Gly Met Val Asp Xaa Val Phe Ala Asp Val Ala Gln Pro
1 5 10 15
Asp Gln Ala Arg
20

<210> 146
<211> 19
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> VARIANT
<222> 14
<223> Xaa = Modified Cysteine

<400> 146
Asp Asn Ser Pro Phe Phe Val Leu Asn Ser Asp Val Ile Xaa Glu Tyr
1 5 10 15
Pro Phe Lys

<210> 147
<211> 15
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
<221> VARIANT
<222> 14
<223> Xaa = Modified Cysteine

<400> 147
Ser Thr Ile Val Gly Trp Asn Ser Thr Val Gly Gln Trp Xaa Arg
1 5 10 15

<210> 148
<211> 10
<212> PRT
<213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 5
 <223> Xaa = Modified Cysteine

 <400> 148
 Ser Val Val Leu Xaa Asn Ser Thr Ile Lys
 1 5 10

<210> 149
 <211> 10
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 149
 Val Xaa Ser Ser His Thr Gly Leu Val Arg
 1 5 10

<210> 150
 <211> 10
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 150
 Xaa Ala Thr Ile Thr Pro Asp Glu Ala Arg
 1 5 10

<210> 151
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 151
 Ser His Phe Asn Ala Leu Tyr Asp Thr Leu Leu Glu Ser Asn Leu Xaa
 1 5 10 15
 Lys

<210> 152
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 17
 <223> Xaa = Modified Cysteine

<400> 152
 Asp Thr Val Leu Ile Val Leu Ile Asp Asp Glu Leu Glu Asp Gly Ala
 1 5 10 15
 Xaa Arg

<210> 153
 <211> 14
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 153
 Leu Gly Asp Leu Val Thr Ile His Pro Xaa Pro Asp Ile Lys
 1 5 10

<210> 154
 <211> 26
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 24
 <223> Xaa = Modified Cysteine

<400> 154
 Asp Ile Glu Asn Leu Val Ala Asp Ala Val Glu Val Asn Ile Pro Phe
 1 5 10 15
 Asn Asn Pro Ile Thr Gly Phe Xaa Ala Phe
 20 25

<210> 155
 <211> 13
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT

<222> 9

<223> Xaa = Modified Cysteine

<400> 155

Val Gly Ile Ala Asp Thr Val Gly Xaa Ala Asn Pro Arg
 1 5 10

<210> 156

<211> 14

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 4

<223> Xaa = Modified Cysteine

<400> 156

Ser Ile Ala Xaa Val Leu Thr Val Ile Asn Glu Gln Gln Arg
 1 5 10

<210> 157

<211> 27

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine

<400> 157

Glu Arg Val Asn Xaa Lys Glu Asn Thr Leu Leu Gly Glu Phe Asp Leu
 1 5 10 15
 Lys Asn Ile Pro Met Met Pro Ala Gly Glu Pro
 20 25

<210> 158

<211> 21

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine

<400> 158

Thr Phe Thr Thr Xaa Ala Asp Asn Gln Thr Thr Val Gln Phe Pro Val
 1 5 10 15
 Tyr Gln Gly Glu Arg
 20

<210> 159
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 159
 Ile Xaa Ala Asn His Ile Ile Ala Pro Glu Tyr Thr Leu Lys Pro Asn
 1 5 10 15
 Val Gly Ser Asp Arg
 20

<210> 160
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 5
 <223> Xaa = Modified Cysteine

<400> 160
 Ile Met Ile Asp Xaa Ser His Gly Asn Ser Asn Lys
 1 5 10

<210> 161
 <211> 28
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 19
 <223> Xaa = Modified Cysteine

<400> 161
 Leu Pro Ile Ala Gly Glu Met Leu Asp Thr Ile Ser Pro Gln Phe Leu
 1 5 10 15
 Ser Asp Xaa Phe Ser Leu Gly Ala Ile Gly Ala Arg
 20 25

<210> 162
 <211> 11
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 3

<223> Xaa = Modified Cysteine

<400> 162

Leu Glu Xaa Pro Pro Pro Leu Thr Asn Ala Arg
1 5 10

<210> 163

<211> 17

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 10

<223> Xaa = Modified Cysteine

<400> 163

Tyr Asp Ser Ile Glu Val Ser Gly Gly Xaa Pro Ile Val Ile Gly Leu
1 5 10 15
Arg

<210> 164

<211> 11

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 9

<223> Xaa = Modified Cysteine

<400> 164

Ala Pro Glu Ser Leu Leu Thr Gly Xaa Asn Arg
1 5 10

<210> 165

<211> 13

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 12

<223> Xaa = Modified Cysteine

<400> 165

Ala Leu Ile Leu Ala Ala Leu Gly Glu Gly Gln Xaa Lys
1 5 10

<210> 166

<211> 23

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 17

<223> Xaa = Modified Cysteine

<400> 166

Ala	Gly	Pro	Asn	Thr	Asn	Gly	Ser	Gln	Phe	Phe	Ile	Thr	Thr	Val	Pro
1				5					10					15	
Xaa	Pro	Trp	Leu	Asp	Gly	Lys									
															20

<210> 167

<211> 25

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 19

<223> Xaa = Modified Cysteine

<400> 167

Ala	Asn	Ala	Gly	Pro	Asn	Thr	Asn	Gly	Ser	Gln	Phe	Phe	Ile	Thr	Thr
1				5					10					15	
Val	Pro	Xaa	Pro	Trp	Leu	Asp	Gly	Lys							
															20
															25

<210> 168

<211> 31

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 6

<223> Xaa = Oxidized Methionine

<221> VARIANT

<222> 25

<223> Xaa = Modified Cysteine

<400> 168

Pro	Gly	Leu	Leu	Ser	Xaa	Ala	Asn	Ala	Gly	Pro	Asn	Thr	Asn	Gly	Ser
1				5					10					15	
Gln	Phe	Phe	Ile	Thr	Thr	Val	Pro	Xaa	Pro	Trp	Leu	Asp	Gly	Lys	
															20
															25
															30

<210> 169

<211> 14

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

 <400> 169
 Val Ala Val Ser Asp Gly His Thr Glu Xaa Ile Ser Leu Arg
 1 5 10

 <210> 170
 <211> 25
 <212> PRT
 <213> Saccharomyces cerevisiae

 <220>
 <221> VARIANT
 <222> 18
 <223> Xaa = Modified Cysteine

 <400> 170
 Ala Ala Ala Ala Gln Asp Glu Ile Thr Gly Asp Gly Thr Thr Thr Val
 1 5 10 15
 Val Xaa Leu Val Gly Glu Leu Leu Arg
 20 25

 <210> 171
 <211> 21
 <212> PRT
 <213> Saccharomyces cerevisiae

 <220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

 <400> 171
 Asn Ala Ile Thr Gly Ala Thr Gly Ile Ala Ser Asn Leu Leu Leu Xaa
 1 5 10 15
 Asp Glu Leu Leu Arg
 20

 <210> 172
 <211> 17
 <212> PRT
 <213> Saccharomyces cerevisiae

 <220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Modified Cysteine

 <400> 172
 Val Pro Phe Xaa Pro Leu Val Gly Ser Glu Leu Tyr Ser Val Glu Val
 1 5 10 15

Lys

<210> 173
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 173
 Tyr Ala Leu Gln Leu Leu Ala Pro Xaa Gly Ile Leu Ala Gln Thr Ser
 1 5 10 15
 Asn Arg

<210> 174
 <211> 10
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 174
 Asp Glu Leu Thr Asn Asn Pro Ala Xaa Lys
 1 5 10

<210> 175
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 13
 <223> Xaa = Modified Cysteine

<400> 175
 Ser Gln Asn Ala Ala Val Asn Gly Ser Gly Ile Ala Xaa Gln Gln Arg
 1 5 10 15

<210> 176
 <211> 22
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 14

<223> Xaa = Modified Cysteine

<400> 176

Asn Lys Pro Leu Ala Val Ile Gly Gly Gly Asp Ser Ala Xaa Glu Glu
 1 5 10 15
 Ala Gln Phe Leu Thr Lys
 20

<210> 177

<211> 18

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 14

<223> Xaa = Modified Cysteine

<400> 177

Ala Glu Gln Leu Tyr Glu Gly Pro Ala Asp Asp Ala Asn Xaa Ile Ala
 1 5 10 15
 Ile Lys

<210> 178

<211> 19

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 3

<223> Xaa = Modified Cysteine

<400> 178

Ile Trp Xaa Phe Gly Pro Asp Gly Asn Gly Pro Asn Leu Val Ile Asp
 1 5 10 15
 Gln Thr Lys

<210> 179

<211> 24

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 16

<223> Xaa = Modified Cysteine

<400> 179

Val Thr Asp Gly Ala Leu Val Val Val Asp Thr Ile Glu Gly Val Xaa

1 5 10 15
Val Gln Thr Glu Thr Val Leu Arg
20

```
<210> 180
<211> 12
<212> PRT
<213> Saccharomyces cerevisiae
```

```
<220>
<221> VARIANT
<222> 11
<223> Xaa = Modified Cysteine
```

<400> 180
Glu Ile Leu Gly Thr Ala Gln Ser Val Gly Xaa Arg
1 5 10

```
<210> 181
<211> 11
<212> PRT
<213> Saccharomyces cerevisiae.
```

```
<220>  
<221> VARIANT  
<222> 2  
<223> Xaa = Modified Cysteine
```

<400> 181
Leu Xaa Asp Glu Ile Ala Thr Ile Gln Ser Lys
1 5 10

```
<210> 182
<211> 11
<212> PRT
<213> Saccharomyces cerevisiae
```

```
<220>
<221> VARIANT
<222> 10
<223> Xaa = Modified Cysteine
```

<400> 182
Gly His Thr Glu Ala Gly Val Asp Leu Xaa Lys
1 5 10

```
<210> 183
<211> 9
<212> PRT
<213> Saccharomyces cerevisiae
```

<220>
<221> VARIANT

<222> 8

<223> Xaa = Modified Cysteine

<400> 183

Ser Leu Val Ala Ala Gly Leu Xaa Lys

1

5

<210> 184

<211> 23

<212> PRT

<213> Saccharomyces cerevisiae

<220>

<221> VARIANT

<222> 2

<223> Xaa = Modified Cysteine

<400> 184

Thr Xaa Asn Val Leu Val Ala Ile Glu Gln Gln Ser Pro Asp Ile Ala

1

5

10

15

Gln Gly Leu His Tyr Glu Lys

20

<210> 185

<211> 15

<212> PRT

<213> Saccharomyces cerevisiae

<220>

<221> VARIANT

<222> 12

<223> Xaa = Modified Cysteine

<400> 185

Thr His Leu Met Gln Pro Pro Tyr Ser Ile Leu Xaa Asp Tyr Arg

1

5

10

15

<210> 186

<211> 14

<212> PRT

<213> Saccharomyces cerevisiae

<220>

<221> VARIANT

<222> 9

<223> Xaa = Modified Cysteine

<400> 186

Leu Gly Gly Ser Ser Leu Leu Glu Xaa Val Val Phe Gly Arg

1

5

10

<210> 187

<211> 28

<212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 187
 Phe Val Leu Ser Gly Ala Asn Ile Met Xaa Pro Gly Leu Thr Ser Ala
 1 5 10 15
 Gly Ala Asp Leu Pro Pro Ala Pro Gly Tyr Glu Lys
 20 25

<210> 188
 <211> 19
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 188
 His Tyr Ser Lys Pro Asp Gly Pro Asn Asn Asn Val Ala Val Val Xaa
 1 5 10 15
 Ser Ala Arg

<210> 189
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 189
 Xaa Asp Leu Gly Ile Thr Gly Val Asp Gln Val Arg
 1 5 10

<210> 190
 <211> 11
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 190

Gly Met Leu Thr Gly Pro Ile Thr Xaa Leu Arg
 1 5 10

<210> 191

<211> 13

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 11

<223> Xaa = Modified Cysteine

<400> 191

Ala Gln His Glu Ser Ser Ser Pro Val Leu Xaa Thr Arg
 1 5 10

<210> 192

<211> 14

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 2

<223> Xaa = Modified Cysteine

<400> 192

Ile Xaa Gly Asp Ile His Gly Gln Tyr Tyr Asp Leu Leu Arg
 1 5 10

<210> 193

<211> 19

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 3

<223> Xaa = Modified Cysteine

<400> 193

Ile Phe Xaa Met His Gly Gly Leu Ser Pro Asp Leu Asn Ser Met Glu
 1 5 10 15
 Gln Ile Arg

<210> 194

<211> 12

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine
 <400> 194
 Ser Glu His Gln Val Glu Leu Ile Xaa Ser Tyr Arg
 1 5 10

<210> 195
 <211> 13
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 195
 Ala Ala Gln Leu Gly Phe Asn Thr Ala Xaa Val Glu Lys
 1 5 10

<210> 196
 <211> 23
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 196
 Leu Xaa Tyr Val Ala Leu Asp Phe Glu Gln Glu Met Gln Thr Ala Ala
 1 5 10 15
 Gln Ser Ser Ser Ile Glu Lys
 20

<210> 197
 <211> 9
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 197
 Thr Tyr Xaa Leu Gln His Val Glu Lys
 1 5

<210> 198
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 14
 <223> Xaa = Modified Cysteine

<400> 198
 Glu Ala Glu Ile Leu Val Val Thr Gly Asp Asn Phe Gly Xaa Gly Ser
 1 5 10 15
 Ser Arg

<210> 199
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 199
 His Xaa Leu Val Asn Gly Leu Asp Asp Ile Gly Ile Thr Leu Gln Lys
 1 5 10 15

<210> 200
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 200
 Val Asp Xaa Thr Leu Ala Thr Val Asp His Asn Ile Pro Thr Glu Ser
 1 5 10 15
 Arg

<210> 201
 <211> 10
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 6

<223> Xaa = Modified Cysteine

<400> 201

Val Phe Ile Gly Ser Xaa Thr Asn Gly Arg
1 5 10

<210> 202

<211> 18

<212> PRT

<213> Saccharomyces cerevisiae

<220>

<221> VARIANT

<222> 16

<223> Xaa = Modified Cysteine

<400> 202

Phe Gly Asp Phe Gly Gly Gln Tyr Val Pro Glu Ala Leu His Ala Xaa
1 5 10 15
Leu Arg

<210> 203

<211> 29

<212> PRT

<213> Saccharomyces cerevisiae

<220>

<221> VARIANT

<222> 8

<223> Xaa = Modified Cysteine

<400> 203

Leu Pro Asp Ala Val Val Ala Xaa Val Gly Gly Gly Ser Asn Ser Thr
1 5 10 15
Gly Met Phe Ser Pro Phe Glu His Asp Thr Ser Val Lys
20 25

<210> 204

<211> 13

<212> PRT

<213> Saccharomyces cerevisiae

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine.

<400> 204

Leu Thr Glu His Xaa Gln Gly Ala Gln Ile Trp Leu Lys
1 5 10

<210> 205

<211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 5
 <223> Xaa = Modified Cysteine

<400> 205
 Ile Asn Leu Pro Xaa Val Asn Pro Thr Thr Gly Glu Val Gln Thr Asp
 1 5 10 15
 Phe His Thr Leu Arg
 20

<210> 206
 <211> 24
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 7
 <223> Xaa = Modified Cysteine

<400> 206
 Ser Thr Ala Met Val Leu Xaa Gly Ser Asn Asp Asp Lys Val Glu Phe
 1 5 10 15
 Val Glu Pro Pro Lys Asp Ser Lys
 20

<210> 207
 <211> 13
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 207
 Ser Xaa Gly Val Asp Ala Met Ser Val Asp Asp Leu Lys
 1 5 10

<210> 208
 <211> 14
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 208
 Ser Xaa Gly Val Asp Ala Met Ser Val Asp Asp Leu Lys Lys
 1 5 10

<210> 209
 <211> 25
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 24
 <223> Xaa = Modified Cysteine

<400> 209
 Asp Glu Ile Val Leu Ser Gly Asn Ser Val Glu Asp Val Ser Gln Asn
 1 5 10 15
 Ala Ala Asp Leu Gln Gln Ile Xaa Arg
 20 25

<210> 210
 <211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 26
 <223> Xaa = Modified Cysteine

<400> 210
 Val Lys Asp Glu Ile Val Leu Ser Gly Asn Ser Val Glu Asp Val Ser
 1 5 10 15
 Gln Asn Ala Ala Asp Leu Gln Gln Ile Xaa Arg
 20 25

<210> 211
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 211
 Xaa Pro Asp Ala Ser Val Ala Gly Leu Met Val Lys
 1 5 10

<210> 212
 <211> 12

<212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 212
 Asp Ser Ile Gly Gly Val Val Thr Xaa Val Val Arg
 1 5 10

<210> 213
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 213
 Asp Xaa Ile Val Asp Thr Ala Ala Gln Met Leu Glu Val Gln Asn Glu
 1 5 10 15
 Ala

<210> 214
 <211> 32
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 30
 <223> Xaa = Modified Cysteine

<400> 214
 Asp Tyr Phe Pro Trp Asp Asn Leu Ser Val Asp Ser Pro Lys Pro Pro
 1 5 10 15
 Phe Pro Gln Gly Ile Gly Ala Pro Ile Asp Glu Gln Asn Xaa Ile Lys
 20 25 30

<210> 215
 <211> 10
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 215

Xaa Val His Phe Gln Asn Ser Tyr Tyr Arg
 1 5 10

<210> 216

<211> 13

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 8

<223> Xaa = Modified Cysteine

<400> 216

Tyr Ser Ala Ala Asp Val Ala Xaa Trp Gly Ala Leu Arg
 1 5 10

<210> 217

<211> 17

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 11

<223> Xaa = Modified Cysteine

<400> 217

Ile Val Ser Asn Ala Ser Cys Thr Thr Asn Xaa Leu Ala Pro Leu Ala
 1 5 10 15
 Lys

<210> 218

<211> 12

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 9

<223> Xaa = Modified Cysteine

<400> 218

Asn Gly His Pro Phe Phe Leu Pro Xaa Thr Pro Lys
 1 5 10

<210> 219

<211> 19

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 219
 Ser Pro Val Thr Val Glu Asp Val Gly Xaa Thr Gly Ala Leu Thr Ala
 1 5 10 15
 Leu Leu Arg

<210> 220
 <211> 17
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 220
 Xaa Asn Pro Asn Arg Pro Ile Tyr Trp Ile Gln Ser Ser Tyr Asp Glu
 1 5 10 15
 Lys

<210> 221
 <211> 30
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 17
 <223> Xaa = Modified Cysteine

<400> 221
 Gln Ala Ala Gly Asn Leu Ile Ser Gln Gly Ile Asp Ala Leu Val Val
 1 5 10 15
 Xaa Gly Gly Asp Gly Ser Leu Thr Gly Ala Asp Leu Phe Arg
 20 25 30

<210> 222
 <211> 12
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 5
 <223> Xaa = Modified Cysteine

<400> 222

Ile Gly Leu Asp Xaa Ala Ser Ser Glu Phe Phe Lys
 1 5 10

<210> 223
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

<400> 223
 Ala Gln Tyr Asp Ser Xaa Asp Phe Val Ala Asp Val Pro Pro Pro Lys
 1 5 10 15

<210> 224
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Modified Cysteine

<400> 224
 Tyr Gly Thr Xaa Pro His Gly Gly Tyr Gly Ile Gly Thr Glu Arg
 1 5 10 15

<210> 225
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 225
 Xaa Ile Ala Ile Ile Pro Gln Phe Glu Leu Ser Thr Ala Asp Ser Arg
 1 5 10 15

<210> 226
 <211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 24

<223> Xaa = Modified Cysteine

<400> 226

Ile Thr Val Asp Glu Ala Leu Glu His Pro Tyr Leu Ser Ile Trp His
 1 5 10 15
 Asp Pro Ala Asp Glu Pro Val Xaa Ser Glu Lys
 20 25

<210> 227

<211> 13

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 1

<223> Xaa = Modified Cysteine

<400> 227

Xaa Ala Asn Gly Ala Pro Ala Val Glu Val Asp Gly Lys
 1 5 10

<210> 228

<211> 24

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 19

<223> Xaa = Modified Cysteine

<400> 228

Glu Ile Gly Trp Asn Asn Glu Asp Ile His Val Pro Leu Leu Pro Gly
 1 5 10 15
 Glu Gln Xaa Gly Ala Leu Thr Lys
 20

<210> 229

<211> 13

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 2

<223> Xaa = Modified Cysteine

<400> 229

Ile Xaa Leu Pro Thr Phe Glu Ser Glu Glu Leu Ile Lys
 1 5 10

<210> 230

<211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 230
 Leu Gly Ala Asn Tyr Ala Pro Xaa Ile Leu Pro Gln Leu Gln Ala Ala
 1 5 10 15
 Lys

<210> 231
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 11
 <223> Xaa = Modified Cysteine

<400> 231
 Leu Gly Gly Ile Gly Phe Ile His His Asn Xaa Thr Pro Glu Asp Gln
 1 5 10 15
 Ala Asp Met Val Arg
 20

<210> 232
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 14
 <223> Xaa = Modified Cysteine

<400> 232
 Leu Leu Ala Pro Gln Asp Ile Pro Val Leu Val Val Gly Xaa Arg
 1 5 10 15

<210> 233
 <211> 11
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 233
 Val Ala Leu Asn Ser Ser Glu Xaa Leu Asn Lys
 1 5 10

<210> 234
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 234
 Glu Gln Xaa Gln Gly Ala Leu Phe Gly Ala Val Gln Ser Pro Thr Thr
 1 5 10 15
 Lys

<210> 235
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 15
 <223> Xaa = Modified Cysteine

<400> 235
 Ser Ile Val Thr Asn Gly Ser Asn Thr Val Ser Gly Ala Asn Xaa Arg
 1 5 10 15

<210> 236
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 236
 Gly Gly Pro Phe Asp Glu Ile Pro Gln Ala Asp Ile Phe Ile Asn Xaa
 1 5 10 15
 Ile Tyr Leu Ser Lys
 20

<210> 237
 <211> 22

<212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 14
 <223> Xaa = Modified Cysteine

 <400> 237
 Tyr Arg Asn Val Ile Ala His Thr Leu Asp Glu Asn Glu Xaa Ala Pro
 1 5 10 15
 Val Pro Pro Ala Val Arg
 20

<210> 238
 <211> 13
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

<400> 238
 Gly His Asn Ile Pro Xaa Thr Ser Thr Ile Ser Gly Arg
 1 5 10

<210> 239
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Modified Cysteine

<400> 239
 Val His Ala Xaa Ile Gly Gly Thr Ser Phe Val Glu Asp Ala Glu Gly
 1 5 10 15
 Leu Arg

<210> 240
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 19
 <223> Xaa = Modified Cysteine

<400> 240
 Asp Leu Pro Ser Ser Ile Ala Thr Asn Gln Glu Val Phe Asp Phe Leu
 1 5 10 15
 Glu Ser Xaa Ala Lys
 20

<210> 241
 <211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 25
 <223> Xaa = Modified Cysteine

<400> 241
 Glu Ile Ile Ala Asp Ser Phe Glu Thr Ile Met Met Ala Gln His Tyr
 1 5 10 15
 Asp Ala Asn Ile Ala Ile Pro Ser Xaa Asp Lys
 20 25

<210> 242
 <211> 13
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 242
 Leu Val Ser Asn Ala Ser Asn Gly Xaa Val Leu Asp Ala
 1 5 10

<210> 243
 <211> 22
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 243
 His Leu Gly Val Ile Gly Glu Xaa Asn Val Gln Tyr Ala Leu Gln Pro
 1 5 10 15
 Asp Gly Leu Asp Tyr Arg
 20

<210> 244

<211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 244
 Ile Xaa Leu Pro Thr Phe Asp Pro Glu Glu Leu Ile Thr Leu Ile Gly
 1 5 10 15
 Lys

<210> 245
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 245
 Leu Gly Ala Asn Tyr Ala Pro Xaa Val Leu Pro Gln Leu Gln Ala Ala
 1 5 10 15
 Ser Arg

<210> 246
 <211> 9
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 7
 <223> Xaa = Modified Cysteine

<400> 246
 Trp Ala Ala Ala Ala Val Xaa Glu Lys
 1 5

<210> 247
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 247

Met Leu Asp Leu Ser Glu Glu Thr Asp Glu Glu Asn Ile Ser Thr Xaa
1 5 10 15

Val Lys

<210> 248

<211> 19

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 17

<223> Xaa = Modified Cysteine

<400> 248

Ser Ile Ala Pro Ala Tyr Gly Ile Pro Val Val Leu His Ser Asp His
1 5 10 15

Xaa Ala Lys

<210> 249

<211> 16

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 7

<223> Xaa = Modified Cysteine

<400> 249

Val Asn Leu Asp Thr Asp Xaa Gln Tyr Ala Tyr Leu Thr Gly Ile Arg
1 5 10 15

<210> 250

<211> 17

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 4

<223> Xaa = Modified Cysteine

<400> 250

Gly Tyr Thr Xaa Gln Phe Val Asp Met Val Leu Pro Asn Thr Ala Leu
1 5 10 15

Lys

<210> 251
 <211> 14
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 251
 Thr Xaa Ile Leu His Gly Pro Val Ala Ala Gln Phe Thr Lys
 1 5 10

<210> 252
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 252
 Asp Ala Phe Glu His Leu Leu Xaa Gly Ala Ser Met Leu Gln Ile Gly
 1 5 10 15
 Thr Glu Leu Gln Lys
 20

<210> 253
 <211> 33
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 253
 Ile Gln Asp Ser Glu Phe Asn Gly Ile Thr Glu Leu Asn Leu Ser Xaa
 1 5 10 15
 Pro Asn Val Pro Gly Lys Pro Gln Val Ala Tyr Asp Phe Asp Leu Thr
 20 25 30
 Lys

<210> 254
 <211> 20
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT
 <222> 13
 <223> Xaa = Modified Cysteine

 <400> 254
 Leu Pro Asp Ser Ala Leu Asp Leu Val Asp Ile Ser Xaa Ala Gly Val
 1 5 10 15
 Ala Val Ala Arg
 20

 <210> 255
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

 <400> 255
 Leu Ser Thr Val Ser Pro Val Phe Val Xaa Gln Ser Phe Ala Lys
 1 5 10 15

 <210> 256
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

 <400> 256
 Asn Pro Val Ile Leu Ala Asp Ala Cys Xaa Ser Arg
 1 5 10

 <210> 257
 <211> 8
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Oxidized Methionine

 <221> VARIANT
 <222> 5
 <223> Xaa = Modified Cysteine

 <400> 257
 Xaa Glu Ile Leu Xaa Gln Gln Arg

1 5

<210> 258
 <211> 9
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Modified Cysteine

<400> 258
 Met Leu Ser Xaa Ala Gly Ala Asp Arg
 1 5

<210> 259
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 259
 Phe Gln Tyr Ile Ala Ile Ser Gln Ser Asp Ala Asp Ser Glu Ser Xaa
 1 5 10 15
 Lys

<210> 260
 <211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 260
 Thr Tyr Leu Pro Pro Val Ser Xaa Asp Ala Glu Asp Pro Leu Phe Leu
 1 5 10 15
 Leu Tyr Thr Ser Gly Ser Thr Gly Ser Pro Lys
 20 25

<210> 261
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

 <400> 261
 Ala Ile Ala Asn Gly Gln Val Asp Gly Phe Pro Thr Gln Glu Glu Xaa
 1 5 10 15
 Arg

<210> 262
 <211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

 <400> 262
 Phe Ile Pro Ser Leu Ile Gln Xaa Ile Ala Asp Pro Thr Glu Val Pro
 1 5 10 15
 Glu Thr Val His Leu Leu Gly Ala Thr Thr Phe
 20 25

<210> 263
 <211> 29
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 23
 <223> Xaa = Modified Cysteine

 <400> 263
 Ile Ala Asn Gln Ser Asn Leu Ser Pro Ser Val Glu Pro Tyr Ile Val
 1 5 10 15
 Gln Leu Val Pro Ala Ile Xaa Thr Asn Ala Gly Asn Lys
 20 25

<210> 264
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 7
 <223> Xaa = Modified Cysteine

 <400> 264

Lys Glu Ile Glu Glu His Xaa Ser Met Leu Gly Leu Asp Pro Glu Ile
 1 5 10 15
 Val Ser His Ser Arg
 20

<210> 265
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 7
 <223> Xaa = Modified Cysteine

<400> 265
 Asn Thr Tyr Glu Tyr Glu Xaa Ser Phe Leu Leu Gly Glu Asn Ile Gly
 1 5 10 15
 Met Lys

<210> 266
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 266
 Pro Gln Ile Thr Asp Ile Asn Phe Gln Xaa Ser Leu Ser Ser Arg
 1 5 10 15

<210> 267
 <211> 25
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 24
 <223> Xaa = Modified Cysteine

<400> 267
 Ser Thr Leu Ile Asn Val Leu Thr Gly Glu Leu Leu Pro Thr Ser Gly
 1 5 10 15
 Glu Val Tyr Thr His Glu Asn Xaa Arg
 20 25

<210> 268
 <211> 28

<212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 23
 <223> Xaa = Modified Cysteine

<400> 268
 Val Thr Asn Met Glu Phe Gln Tyr Pro Gly Thr Ser Lys Pro Gln Ile
 1 5 10 15
 Thr Asp Ile Asn Phe Gln Xaa Ser Leu Ser Ser Arg
 20 25

<210> 269
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 6, 9
 <223> Xaa = Modified Cysteine

<221> VARIANT
 <222> 9
 <223> Xaa = Oxidized Methionine

<400> 269
 Asn Val Ala Ala Gly Xaa Asn Pro Xaa Asp Leu Arg
 1 5 10

<210> 270
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

<400> 270
 Asn Val Ala Ala Gly Xaa Asn Pro Met Asp Leu Arg
 1 5 10

<210> 271
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 7

<223> Xaa = Modified Cysteine

<400> 271

Val Gly Leu Ile Gly Ser Xaa Thr Asn Ser Ser Tyr Glu Asp Met Ser
 1 5 10 15
 Arg

<210> 272

<211> 15

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 10

<223> Xaa = Modified Cysteine

<400> 272

Tyr Gly Met Asp Tyr Met Tyr Asp Ala Xaa Ser Thr Thr Ala Arg
 1 5 10 15

<210> 273

<211> 18

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine

<400> 273

Val Val Glu Val Xaa Leu Ala Asp Leu Gln Gly Ser Glu Asp His Ser
 1 5 10 15
 Phe Arg

<210> 274

<211> 14

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 8

<223> Xaa = Modified Cysteine

<400> 274

Asn Ile Thr Trp Ile Ala Glu Xaa Ile Ala Gln Asn Gln Arg
 1 5 10

<210> 275

<211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

 <400> 275
 Glu Phe Xaa Ser Lys Met Asn Gln Val Cys Gly Thr Arg Gln Cys Pro
 1 5 10 15
 Ile Pro Lys Lys Pro Ile Ser Ala Leu Asp Lys
 20 25

<210> 276
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

 <220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Modified Cysteine

<400> 276
 Gly Asp Leu Val Leu Asp Val Gly Xaa Gly Val Gly Gly Pro Ala Arg
 1 5 10 15

<210> 277
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 277
 Val Tyr Ala Ile Glu Ala Thr Xaa His Ala Pro Lys
 1 5 10

<210> 278
 <211> 34
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 17
 <223> Xaa = Modified Cysteine

<400> 278

Leu Val Glu Ala Phe Gln Trp Thr Asp Lys Asn Gly Thr Val Leu Pro
 1 5 10 15
 Xaa Asn Trp Thr Pro Gly Ala Ala Thr Ile Lys Pro Thr Val Glu Asp
 20 25 30
 Ser Lys

<210> 279
 <211> 24
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 7
 <223> Xaa = Modified Cysteine

<400> 279
 Asn Gly Thr Val Leu Pro Xaa Asn Trp Thr Pro Gly Ala Ala Thr Ile
 1 5 10 15
 Lys Pro Thr Val Glu Asp Ser Lys
 20

<210> 280
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Modified Cysteine

<400> 280
 Ile Gly Ile Xaa Tyr Glu Pro Pro Thr Ala Thr Pro Asn Ser Gln Leu
 1 5 10 15
 Ala Thr Val Asp Arg
 20

<210> 281
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 17
 <223> Xaa = Modified Cysteine

<400> 281
 Val Gly Leu Phe Ser Tyr Gly Ser Gly Leu Ala Ala Ser Leu Tyr Ser
 1 5 10 15
 Xaa Lys

<210> 282
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 282
 Ala Ala Gly His Leu Val Glu Thr Ser Xaa Thr Ile Met Asp Leu Lys
 1 5 10 15

<210> 283
 <211> 16
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 283
 Xaa Leu Ala Thr Leu Leu Gly His Asn Asp Trp Val Ser Gln Val Arg
 1 5 10 15

<210> 284
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

<400> 284
 Gly Gln Xaa Leu Ala Thr Leu Leu Gly His Asn Asp Trp Val Ser Gln
 1 5 10 15
 Val Arg

<210> 285
 <211> 11
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8

<223> Xaa = Modified Cysteine.

<400> 285

Tyr Thr Gln Ser Asn Ser Val Xaa Tyr Ala Arg
1 5 10

<210> 286

<211> 17

<212> PRT

<213> *Saccharomyces cerevisiae*.

<220>

<221> VARIANT

<222> 1

<223> Xaa = Modified Cysteine

<400> 286

Xaa Pro His Leu Glu Ile Val Asn Leu Ser Asp Asn Ala Phe Gly Leu
1 5 10 15
Arg

<210> 287

<211> 11

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine

<400> 287

Val Glu Ala Ser Xaa Phe Asp Gly Asn Lys Arg
1 5 10

<210> 288

<211> 22

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 20

<223> Xaa = Modified Cysteine

<400> 288

Ile Ala Glu Ser Thr Pro Leu Pro Val Gly Val Ala Glu Asn Trp Leu
1 5 10 15
Tyr Leu Pro Xaa Ile Lys
20

<210> 289

<211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 289
 Gly Xaa Gly Val Ala Ala Thr Glu Leu Gly Met Leu Ala Gly Ala Asp
 1 5 10 15
 Arg

<210> 290
 <211> 18
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 290
 Ile Gly Pro Gln Gly Ala Leu Leu Gly Xaa Asp Ala Ala Gly Gln Ile
 1 5 10 15
 Val Lys

<210> 291
 <211> 9
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 2
 <223> Xaa = Modified Cysteine

<400> 291
 Gly Xaa Glu Val Val Val Ser Gly Lys
 1 5

<210> 292
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 292

Xaa Ala Gly Gly Asn Asn Ala Gly His Thr Ile Val Val Asp Gly Val
1 5 10 15

Lys

<210> 293

<211> 10

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 1

<223> Xaa = Modified Cysteine

<400> 293

Xaa Gly Trp Leu Asp Leu Val Val Leu Lys
1 5 10

<210> 294

<211> 13

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 2

<223> Xaa = Modified Cysteine

<400> 294

Val Xaa Glu Phe Met Ile Ser Gln Leu Gly Leu Gln Lys
1 5 10

<210> 295

<211> 14

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>

<221> VARIANT

<222> 5

<223> Xaa = Modified Cysteine

<400> 295

Ala Gly Gly Glu Xaa Ile Thr Leu Asp Gln Leu Ala Val Arg
1 5 10

<210> 296

<211> 17

<212> PRT

<213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

 <400> 296
 Xaa Gly Gly Leu Pro Ala Pro Glu Asp Ser Asp Asn Pro Leu Gly Tyr
 1 5 10 15
 Lys

<210> 297
 <211> 10
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 297
 Gly Asn Ala Leu Asp Thr Leu Xaa Ala Arg
 1 5 10

<210> 298
 <211> 20
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 4
 <223> Xaa = Modified Cysteine

<400> 298
 Leu Ser Tyr Xaa Gly Gly Leu Pro Ala Pro Glu Asp Ser Asp Asn Pro
 1 5 10 15
 Leu Gly Tyr Lys
 20

<210> 299
 <211> 22
 <212> PRT
 <213> Saccharomyces cerevisiae

<220>
 <221> VARIANT
 <222> 6
 <223> Xaa = Modified Cysteine

<400> 299
 Ser Phe Leu Ser Tyr Xaa Gly Gly Leu Pro Ala Pro Glu Asp Ser Asp

1 5 10 15
 Asn Pro Leu Gly Tyr Lys
 20

<210> 300
 <211> 32
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 25
 <223> Xaa = Modified Cysteine

<400> 300
 Ala Thr Ala Asp Ala Val Gln Ala Ala His Ile Pro Gln Gly Thr Asp
 1 5 10 15
 Leu Ala Gln Val Ala Pro Ile Leu Xaa Ala Gly Ile Thr Val Tyr Lys
 20 25 30

<210> 301
 <211> 21
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 12
 <223> Xaa = Modified Cysteine

<400> 301
 Val Asp Met Pro Val Ile Phe Gly Leu Leu Thr Xaa Met Thr Glu Glu
 1 5 10 15
 Gln Ala Leu Ala Arg
 20

<210> 302
 <211> 25
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 302
 Glu Ile Ser Glu Asp Gly Ala Asp Ser Leu Asn Val Ala Met Asp Xaa
 1 5 10 15
 Ile Ser Glu Ala Phe Gly Phe Glu Arg
 20 25

<210> 303

<211> 10
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = Modified Cysteine

<400> 303
 His Asp Ala Glu Gly Val Val Xaa Val Arg
 1 5 10

<210> 304
 <211> 27
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 22
 <223> Xaa = Modified Cysteine

<400> 304
 Glu Leu Leu Asn Glu Tyr Gly Phe Asp Gly Asp Asn Ala Pro Ile Ile
 1 5 10 15
 Met Gly Ser Ala Leu Xaa Ala Leu Glu Gly Arg
 20 25

<210> 305
 <211> 12
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 5
 <223> Xaa = Modified Cysteine

<400> 305
 Asp Leu Met Ala Xaa Ala Gln Thr Gly Ser Gly Lys
 1 5 10

<210> 306
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 10
 <223> Xaa = Modified Cysteine

<400> 306

Phe Phe Asn Asn His Leu Phe Ala Ser Xaa Ser Asp Asp Asn Ile Leu
 1 5 10 15
 Arg

<210> 307
 <211> 15
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Modified Cysteine

<400> 307
 Xaa Val Gly Val Ile Leu Gly Asp Ala Asn Ser Ser Thr Ile Arg
 1 5 10 15

<210> 308
 <211> 20
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

<400> 308
 Val Asn Val Tyr Gly Gly Ala Val Ala Leu Gly His Pro Leu Gly Xaa
 1 5 10 15
 Ser Gly Ala Arg
 20

<210> 309
 <211> 14
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 11
 <223> Xaa = Modified Cysteine

<400> 309
 Ile Ala Pro Ala Leu Ala Met Gly Asn Val Xaa Ile Leu Lys
 1 5 10

<210> 310
 <211> 17
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 16
 <223> Xaa = Modified Cysteine

 <400> 310
 Pro Ala Ala Val Thr Pro Leu Asn Ala Leu Tyr Phe Ala Ser Leu Xaa
 1 5 10 15
 Lys

<210> 311
 <211> 24
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<220>
 <221> VARIANT
 <222> 3
 <223> Xaa = Modified Cysteine

 <400> 311
 Ile Ile Xaa Glu Asn Tyr Leu Phe Asn Trp Trp Glu Gln Leu Asp Asp
 1 5 10 15
 Leu Ser Glu Val Glu Asn Asp Arg
 20

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT



(10) International Publication Number
WO 2004/013636 A3

- (51) International Patent Classification⁷: **G01N 33/68**, C07K 1/107, 14/085
- (74) Agent: E. BLUM & CO.; Vorderberg 11, CH-8044 Zürich (CH).
- (21) International Application Number: PCT/IB2003/003863
- (22) International Filing Date: 28 July 2003 (28.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10/212,628 1 August 2002 (01.08.2002) US
- (71) Applicant: SYNGENTA PARTICIPATIONS AG [CH/CH]; Scharzwaldallee 215, CH-4058 Basel (CH).
- (72) Inventors: HAYNES, Paul; 902 Birchview Drive, Encinitas, CA 92024 (US). WEI, Jing; 8537 Donaker St., San Diego, CA 92129 (CN). YATES, John; 5049 Seashell Place, San Diego, CA 92130 (US). ANDON, Nancy; 1543 Kings Cross Drive, Cardiff-By-The-Sea, CA 92007 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report

[Continued on next page]

(54) Title: DIFFERENTIAL LABELING FOR QUANTITATIVE ANALYSIS OF COMPLEX PROTEIN MIXTURES BY TRI-FUNCTIONAL SYNTHETIC PEPTIDE BASED REAGENTS WITH IODOACETAMIDO GROUPS

PETag Sequencing by MS/MS



(57) Abstract: The present invention relates to a method of simultaneously identifying and determining the levels of expression of cysteine-containing proteins in normal and perturbed cells, a method for proteomic analysis, a process for preparing fusion proteins, and compounds and reagents related thereto.

WO 2004/013636 A3



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:
20 January 2005

INTERNATIONAL SEARCH REPORT

International Application No

P IB 03/03863

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 C07K1/107 C07K14/085

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/35887 A (AMRAD OPERATIONS PTY LTD ;KOENTGEN FRANK (AU); SUESS GABRIELE MARI) 2 October 1997 (1997-10-02) the whole document	1,3-9, 11-17
A	----- WO 00/11208 A (UNIV WASHINGTON) 2 March 2000 (2000-03-02) the whole document	1,3-9, 11-17
A	----- WO 01/96539 A (DOUDNA JENNIFER A ;UNIV YALE (US); BATEY ROBERT T (US); LUCAST LOU) 20 December 2001 (2001-12-20) the whole document	1,3-9, 11-17
	----- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 January 2004

Date of mailing of the international search report

16. 11. 04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lüdemann, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/03863

C/(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WETZEL R ET AL: "A general method for highly selective cross-linking of unprotected polypeptides via pH-controlled modification of N-terminal alpha-amino groups." BIOCONJUGATE CHEMISTRY. UNITED STATES 1990 MAR-APR, vol. 1, no. 2, March 1990 (1990-03), pages 114-122, XP002267733 ISSN: 1043-1802 the whole document -----	1,3-9
P,X	WO 02/059144 A (SYNGENTA PARTICIPATION AG) 1 August 2002 (2002-08-01) the whole document -----	1,3-9, 11-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 03/03863

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 (partially), 3-9 (partially), 11-17 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (partially), 3-9 (partially), 11-17 (partially)

A compound of formula II, comprising an N-terminal Acyl-group, a protease cleavage site with an amino acid sequence of seq. id no.1 and a link selected from the group consisting of Lys-epsilon-iodoacetamide, Arg-delta-iodoacetamide and Orn-delta-iodoacetamide. Besides these essential features, all other components, i.e epitope tag site, Y and Z are optional.

2. claims: 1 (partially), 3-9 (partially), 11-17 (partially)

Compound of formula III, comprising an N-terminal acyl-group, an O-Phe-group in the middle of the compound and a link defined as in claim 1, i.e. as Lys-epsilon-iodoacetamide, Arg-delta-iodoacetamide and Orn-delta-iodoacetamide. All other components, i.e. X, alk and Z are optional.

3. claim: 2

Compounds of claim 2 (although defined as dependent on claim 1, NOT falling under claim 1) with the common formula: Acyl-NH-CAS-ENLYFQG-(P)-K/Orn-(CH₂)(3-4)-NH-C(=O)-CH₂I, where CAS is assumed to be X and/or (epitope tag site), ENLYFQG-(P)-K/orn is assumed to be the protease cleavage site, (CH₂)(3-4)-NH-CO is assumed to be Z and CH₂I, is assumed to be the link as defined according to the description on p.5, lines 5-6.

(The applicant is informed that in view of the definitions given in the description on p. 24-25, it cannot be assumed that claim 2 relates to compounds where link is selected from K-iodoacetamine or Orn-iodoacetamine. Furthermore, the fourth compound on claim 2 cannot be an Orn-delta-iodoacetamid.

It also appears that the protease cleavage site sequence does not fall under the scope of protection of claim 1, where said sequence is defined as seq. id. no. 1.)

4. claim: 10

Compound of claim 10 (although defined as dependent on claim 1, NOT falling under claim 1) with the common formula Acyl-(CH₂)₃-O-Ph-CH₂-aa-NH-C(=O)-CH₂-I, i.e. formula III with link defined as CH₂I (according to p.5, lines 5-6 of the description). Thus, in contrast to claim 1, link is not defined as Lys-epsilon-iodoacetamide, Arg-delta-iodoacetamide and Orn-delta-iodoacetamide. "aa" is defined as G, A, V or gamma-aminobutyric acid.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. claims: 18-23

a method for proteomics comprising steps a) to j) with a reagent having the structure Acyl-NH-X[Epitope Tag Site]A-Y-[Protease Cleavage Site]-Z-Link, with X,Y and Z being optional and the sequences of epitope tag site and protease cleavage site not being structurally defined.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 03/03863

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9735887	A	02-10-1997	AU 731580 B2	05-04-2001
			AU 2143497 A	17-10-1997
			WO 9735887 A1	02-10-1997
			CA 2249455 A1	02-10-1997
			EP 0935612 A1	18-08-1999
			GB 2326643 A ,B	30-12-1998
			JP 2000507105 T	13-06-2000
			US 6326179 B1	04-12-2001
			US 6521741 B1	18-02-2003
			US 6043069 A	28-03-2000
			ZA 9702620 A	20-11-1997

WO 0011208	A	02-03-2000	AT 253126 T	15-11-2003
			AU 755334 B2	12-12-2002
			AU 5691399 A	14-03-2000
			DE 69912444 D1	04-12-2003
			DE 69912444 T2	22-07-2004
			EP 1329513 A1	23-07-2003
			EP 1105517 A1	13-06-2001
			JP 3345401 B2	18-11-2002
			JP 2002523058 T	30-07-2002
			JP 2003107066 A	09-04-2003
			WO 0011208 A1	02-03-2000
			US 6670194 B1	30-12-2003
			US 2002076739 A1	20-06-2002

WO 0196539	A	20-12-2001	AU 6827301 A	24-12-2001
			CA 2435381 A1	20-12-2001
			WO 0196539 A2	20-12-2001

WO 02059144	A	01-08-2002	WO 02059144 A2	01-08-2002
			US 2003082522 A1	01-05-2003
			US 2003087329 A1	08-05-2003
